ЗАБОЛЯЕМОСТ ОТ РАК В БЪЛГАРИЯ, 2009 CANCER …€¦ · Head of BNCR Maria S. Danova Minka M. Nenova Tinka P. Kuneva Iovka K. Petkova Minka R. Yordanova Lilyana

НАЦИОНАЛНА БОЛНИЦА ПО ОНКОЛОГИЯ NATIONAL ONCOLOGICAL HOSPITAL

БЪЛГАРСКИ НАЦИОНАЛЕН РАКОВ РЕГИСТЪР BULGARIAN NATIONAL CANCER REGISTRY

ЗАБОЛЯЕМОСТ ОТ РАК В БЪЛГАРИЯ, 2009 CANCER INCIDENCE IN BULGARIA 2009

Том XXVolume XX

2011

РедакториНадя Димитрова

Mирчо Вуков Здрaвка Валерианова

EditorsNadya DimitrovaMircho VukovZdravka Valerianova

Издателство “АВИС-24” ООД Publisher “AVIS-24” Ltd.

БЪЛГАРСКИ НАЦИОНАЛЕН РАКОВ РЕГИСТЪР

ПЕРСОНАЛд-р Надя Е. Димитрова ръководител регистърМария С. ДановаМинка М. НеноваТинка П. КуневаЙовка К. ПетковаМинка Р. ЙордановаЛиляна Н. УзуноваТеодора Й. ГрозеваТраян Й. Атанасов

ЗА ИНФОРМАЦИЯНадя Е. Димитрова

БЪЛГАРСКИ НАЦИОНАЛЕН РАКОВ РЕГИСТЪР„Пловдивско поле“ 61756 СОФИЯ, БЪЛГАРИЯтел/факс: 02/ 8706258, тел: 8076 335факс: 02/ 8720651е-mail: [email protected] web site: http://www.sbaloncology.bg

ПРИНОС ЗА ИЗГОТВЯНЕ НА НАСТОЯЩOТО ИЗДАНИЕ ИМА ПЕРСОНАЛЪТ НА РЕГИОНАЛНИТЕ РАКОВИ РЕГИСТРИ, КАКТО СЛЕДВА:БЛАГОЕВГРАДБУРГАСВАРНАВЕЛИКО ТЪРНОВОВРАЦАПЛЕВЕНПЛОВДИВРУСЕСОФИЯ-ГРАДСОФИЯ ОБЛАСТСТАРА ЗАГОРАХАСКОВОШУМЕН

BULGARIAN NATIONAL CANCER REGISTRY

STAFFNadya Е. Dimitrova, MDHead of BNCRMaria S. DanovaMinka M. NenovaTinka P. KunevaIovka K. PetkovaMinka R. YordanovaLilyana N. UzunovaTeodora Y. GrozevaTrayan Y. Atanasov

FOR INFORMATIONNadya Е. Dimitrova

BULGARIAN NATIONAL CANCER REGISTRY6, Plovdivsko pole Str.1756 SOFIA, BULGARIAtel/fax: +359 2/ 8706258, 8076 335fax: +359 2/ 8720651е-mail: [email protected] web site: http://www.sbaloncology.bg

ACKNOWLEDGEMENT TO THE STAFF OF THE REGIONAL CANCER REGISTRIES AS FOLLOW:

BLAGOEVGRADBOURGASVARNAVELIKO TURNOVOVRATSAPLEVENPLOVDIVROUSSESOFIA SITYSOFIA DISTRICTSTARA ZAGORAHASKOVOSHOUMEN

ЗАБОЛЯЕМОСТ ОТ РАК В БЪЛГАРИЯ, 2009CANCER INCIDENCE IN BULGARIA 2009

Tom XXVolume XX

2011С Ъ Д Ъ Р Ж А Н И Е

Български национален раков регистър (БНРР) ..................................................5

Средногодишно население на България по възрастови групи и пол, 1989......9

Средногодишно население на България по възрастови групи и пол, 2009......9

Средногодишно население на България по пол и области, 2009 .....................9

Възрастова структура на населението на България, 1989 ..............................10

Възрастова структура на населението на България, 2009 ..............................10

Сравнение между структурите на българскатаи световната стандартна популация ..................................................................10

Населението на България ..................................................................................10

Заболяемост от злокачествени новообразувания в България за 2009 г. Разпределение на новите случаи по локализации и пол ............................................................................11

Процентно разпределение на морфологично доказаните и регистрираните по смъртен акт нови случаи от злокачествени новообразувания по локализации в България, 2009 г. .....................................12

Общ брой нови случаи от всички злокачествени новообразувания по години ..........................................13

Общ брой нови случаи от всички злокачествениновообразувания в България и годишен прираст за периода 1993–2009 г. ................................................... 13

Процентно разпределение на броя нови случаи при най-честите локализации от злокачествени новообразувания в България, 2009 г. – мъже ............................................................................... 14

Процентно разпределение на броя нови случаи при най-честите локализации от злокачествени новообразувания в България, 2009 г. – жени ................................................................................ 14

Процентно разпределение на починалите при най-честите локализации от злокачествени новообразувания в България, 2009 г. – мъже ............................................................................... 14

Процентно разпределение на починалите при най-честите локализации от злокачествени новообразувания в България, 2009 г. – жени ................................................................................ 14

Възрастово-специфична заболяемост от всички злокачествени новообразувания на 100 000 при мъжете в България, 1981 и 2009 г. ........... 15

Възрастово-специфична заболяемост от всички злокачествени новообразувания на 100 000 при жените в България, 1981 и 2009 г. ............ 15

Стандартизирана заболяемост и смъртност (световен стандарт) от всички злокачествени новообразувания на 100 000 при мъжете в България, 1981–2009 г. ............................................ 16

Стандартизирана заболяемост и смъртност (световен стандарт) от всички злокачествени новообразувания на 100 000 при жените в България, 1981–2009 г. ............................................ 16

Стандартизирана заболяемост (световен стандарт) на 100 000 при най-честите локализации в България 1981–2009 г. – мъже ...17

Стандартизирана заболяемост (световен стандарт) на 100 000 при най-честите локализации в България 1981–2009 г. – жени ...17

Брой нови случаи от злокачествени новообразувания по локализации и възрастови групи в България за 2009 г. – мъже .................18

Брой нови случаи от злокачествени новообразувания по локализации и възрастови групи в България за 2009 г. – жени .................28

Заболяемост от злокачествени новообразувания на 100 000 по локализации и възрастови групи в България за 2009 г. – мъже ............................................................................ 38

Заболяемост от злокачествени новообразувания на 100 000 по локализации и възрастови групи в България за 2009 г. – жени ............................................................................. 48

C O N T E N T S

Bulgarian National Cancer Registry (BNCR) ...........................................................5

The mean population of Bulgaria by age and sex 1989 ..........................................9

The mean population of Bulgaria by age and sex 2009 ..........................................9

The mean population of Bulgaria by sex and districts 2009 ....................................9

Age structure of the Bulgarian population, 1989 ...................................................10

Age structure of the Bulgarian population, 2009 ...................................................10

Comparison of population structures .........................................................................................10

The population of Bulgaria .....................................................................................10

Cancer incidence in Bulgaria 2009.Distribution of the new cases by primary sites and sex ........................................................................................11

Percentage distribution of morphologically verifi ed (MV) and death certifi cate only (DCO) new cancer cases by primary sites in Bulgaria 2009 .............................................12

Total number of new cases from all cancer sites by years ........................................................................................13

Total number of new cancer cases and growth rates for all cancer sites in Bulgaria for the period 1993–2009 ......................................................................................13

Percentage distribution of the most common new cancer cases in males, Bulgaria 2009 .........................................................................................14

Percentage distribution of the most common new cancer cases in females, Bulgaria 2009 ......................................................................................14

Percentage distribution of the most common cancer deaths in males, Bulgaria 2009 .........................................................................................14

Percentage distribution of the most common cancer deaths in females, Bulgaria 2009 ......................................................................................14

Age-specifi c incidence rates per 100 000 for all cancers in males, Bulgaria, 1981 and 2009 .................................................15

Age-specifi c incidence rates per 100 000 for all cancers in females, Bulgaria, 1981 and 2009 ..............................................15

Age-standardized (world standard) incidence and mortality rates per 100 000 of all cancers in males, Bulgaria 1981-2009 ..........................................................16

Age-standardized (world standard)incidence and mortality rates per 100 000 of all cancers in females, Bulgaria 1981–2009 ......................................................16

Age-standardized (world standard) incidence rates per 100 000 of the most common cancers in males, Bulgaria 1981–2009 ............17

Age-standardized (world standard) incidence rates per 100 000 of the most common cancers in females, Bulgaria 1981–2009 .............................17

Number of new cancer cases by primary sites and age at diagnosis in Bulgaria 2009 – males .......................................................................................18

Number of new cancer cases by primary sites and age at diagnosis in Bulgaria 2009 – females ....................................................................................28

Cancer incidence rates per 100 000 by primary sites and age at diagnosis in Bulgaria 2009 – males .......................................................................................38

Cancer incidence rates per 100 000 by primary sites and age at diagnosisin Bulgaria 2009 – females ....................................................................................48

4

Стандартизирана заболяемост (световен стандарт) от злокачествени новообразувания на 100 000 по локализации в България за периода 1981 – 2009 г. – мъже..................................................58

Стандартизирана заболяемост (световен стандарт) от злокачествени новообразувания на 100 000 по локализации в България за периода 1981 – 2009 г. – жени .....60

Разпределение на новите случаи от злокачествени новообразувания на стомаха по хистологичен вид и пол в България, 2009 г. ............................................................................................. 62

Разпределение на новите случаи от злокачествени новообразувания на дебелото черво по хистологичен вид и пол в България, 2009 г. ................................................ 63

Разпределение на новите случаи от злокачествениновообразувания на маточната шийка по хистологичен вид в България, 2009 г. .............................................................................................63

Разпределение на новите случаи от злокачествениновообразувания на правото черво и ануса по хистологичен вид и пол в България, 2009 г. ................................................ 64

Разпределение на новите случаи от злокачествени новообразувания на простатата по хистологичен вид в България, 2009 г. ....64

Разпределение на новите случаи от злокачествени новообразувания на белия дроб (вкл. трахея и бронхи) по хистологичен вид и пол в България, 2009 г. ..........65

Разпределение на новите случаи от злокачествени новообразувания на млечната жлеза по хистологичен вид и пол в България, 2009 г. ...............................................66

Разпределение на новите случаи от злокачествени новообразувания на яйчниците по хистологичен вид в България, 2009 г. .....67

Брой нови случаи от злокачествени новообразувания по локализации и области в България, 2009 г. – мъже ....................................68

Брой нови случаи от злокачествени новообразувания по локализации и области в България, 2009 г. – жени .....................................72

Стандартизирана заболяемост (световен стандарт) от злокачествени новообразувания на 100 000 по локализации и области в България, 2009 г. – мъже .................................................................................76

Стандартизирана заболяемост (световен стандарт) от злокачествени новообразувания на 100 000 по локализации и области в България, 2009 г. – жени ..................80

Разпределение на новодиагностицираните случаи от злокачествени новообразувания по локализации и стадии в България, 2009 г. .....................84

Разпределение на новодиагностицираните случаи от злокачествени новообразувания при избрани локализации по стадии и области в България, 2009 г. ..............................................................................................85

Смъртност от злокачествени новообразувания в България за 2009 г. Разпределение на смъртните случаи по локализации и пол..........86

Стандартизирана смъртност (световен стандарт)от злокачествени новообразувания на 100 000 по локализации в България за периода 1980 – 2009 г. – мъже...................................................87

Стандартизирана смъртност (световен стандарт)от злокачествени новообразувания на 100 000 по локализациив България за периода 1980 – 2009 г. – жени ...................................................89

Болестност от злокачествени новообразуванияв България за 2009 г. Разпределение по локализации и пол ..........................91

Краткосрочни прогнози на броя заболявания от злокачествени новообразувания в България ...............................................92

Брой наблюдавани и очаквани нови случаи от злокачествени новообразувания при избрани локализации за 2009 г. с 95% доверителен интервал .............................................................................95

Очакван брой нови случаи от злокачествени новообразувания по локализации за 2012 г. с 95% доверителен интервал .................................96

Age-adjusted (world standard) incidence rates per 100 000 by primary cancer sites and year of diagnosisin Bulgaria 1981–2009, males ...............................................................................58

Age-adjusted (world standard) incidence rates per 100 000 by primary cancer sites and year of diagnosis in Bulgaria 1981 – 2009, females ..........................................................................60

Number and percentage of new stomach cancer cases by histological types and sex in Bulgaria 2009 .....................................................................................................62

Number and percentage of new colon cancer cases by histological types and sex in Bulgaria 2009 .....................................................................................................63

Number and percentage of new cervix uteri cancer cases by histological types in Bulgaria 2009 .....................................................................................................63

Number and percentage of new rectum and anus cancer cases by histological types and sex in Bulgaria 2009 .....................................................................................................64

Number and percentage of new prostate cancer cases by histological types in Bulgaria 2009 ...................................................................64

Number and percentage of new lung (incl. trachea and bronchus) cancer cases by histological types and sex in Bulgaria 2009 .....................................................................................................65

Number and percentage of new breast cancer casesby histological types and sexin Bulgaria 2009 .....................................................................................................66

Number and percentage of new ovary cancer cases by histological types in Bulgaria 2009 ...................................................................67

Number of new cancer cases by primary sites and districts in Bulgaria 2009 – males .......................................................................................68

Number of new cancer cases by primary sites and districts in Bulgaria 2009 – females ....................................................................................72

Age-adjusted (world standard) incidence rates of cancer per 100 000 by primary sites and districts in Bulgaria 2009 – males .......................................................................................76

Age-adjusted (world standard) incidence rates of cancerper 100 000 by primary sites and districts in Bulgaria 2009 – females ....................................................................................80

Distribution of the newly diagnosed cancer cases by primary sites and stages in Bulgaria 2009 ..................................................................................84

Distribution of the newly diagnosed cancer cases by selected primary sites, stages and districts in Bulgaria 2009 .....................................................................................................85

Cancer mortality in Bulgaria 2009. Distribution of deaths by primary sites and sex .....................................................86

Age-adjusted (world standard) mortality rates per 100 000 by primary cancer sites and year of diagnosisin Bulgaria 1980 – 2009, males .............................................................................87

Age-adjusted (world standard) mortality ratesper 100 000 by primary cancer sites and year of diagnosisin Bulgaria 1980 – 2009, females ..........................................................................89

Cancer prevalence in Bulgaria 2009.Distribution by primary sites and sex .....................................................................91

Short-term estimates of new cancer cases in Bulgaria ..............................................................................................................92

Number of observed and expected new cases of selected cancer sites for 2009 with 95% confi dence interval .................................................................................95

Expected number of new cancer cases by primary sites for 2012 with 95% confi dence interval ...................................................................96

5

БЪЛГАРСКИ НАЦИОНАЛЕН РАКОВ РЕГИСТЪР (БНРР)

Регистрация на злокачествените новообразувания и из-точници на данниОт 1952 г. в България съществува специализирана онколо-гична мрежа, състояща се от 13 диспансера за онкологични заболявания и Национална специализирана болница за активно лечение по онкология– ЕАД, София. Регионалните ракови регистри са част от структурата на всеки диспансер, а Националният раков регистър – от Националната онколо-гична болница. В страната е въведена задължителна регистрация на зло-качествените новообразувания, регламентирана с Инструк-ция на МЗ № 858/ 05.03.1964 г., Заповед на МЗ № РД-09-451/ 29.06.1990 г. и Наредба на МЗ №34 от 2005 г. Според тези нормативни документи медицински работник, установил пръв контакт с всеки заболял, съмнителен или починал от злокачествено заболяване, се задължава да изпрати „Бързо известие“ до онкологичния диспансер по постоянно местожи-телство на пациента. От 1975 г. информация се изпраща и за всеки заболял от ca in situ. Служителите от регионалните ракови регистри посещават периодично лечебните заведения в региона, който обслуж-ват, и активно издирват всички случаи със злокачествени но-вообразувания и ca in situ, които са неизвестни на съответния регистър. Информацията за онкологично болните се получа-ва и допълва периодично и от свидетелствата за смърт. В Националния раков регистър се получава информация за злокачествените новообразувания от регионалните регистри в страната. Информацията се проверява за обхват и пълнота на данните, дубликати, съвпадение на клинична и морфоло-гична диагноза и др.От 1992 г. е въведен подобрен вариант на бързото извес-тие (Номенклатура №2 за медицински формуляри, пореден №120А на МЗ), включващ допълнителна информация. От 1993 г. болните се проследяват по видове лечение, като се прави съпоставка между топографска и морфологична ди-агноза. От м. януари 2005 г. в България е въведена Между-народната класификация на болестите (МКБ), 10-та ревизия, издание от 1992 г.Това наложи всички случаи със злокачествени новообразува-ния от 1993 г. насам (годината, от която има идентификация на случаите по лица) да се прекодират, съгласно изисквания-та на новата класификация. Локализацията се кодира по че-тиризначната рубрика за всички злокачествени заболявания (С00 – С97), ca in situ (D00 – D09), както и за следните ново-образувания с неопределен или неизвестен характер, които според Международната класификация на болестите за он-кология, 3-то издание от 2000 г., се считат за злокачествени: D 39.0; D 42; D 43; D 45; D 46; D 47.1; D 47.3.

BULGARIAN NATIONAL CANCER REGISTRY (BNCR)

Registration of cancer cases at the Registry and data sources A specialized cancer network was founded in Bulgaria in 1952. It consists of 13 Regional Oncological Centers (dispensaries) and a National Oncological Hospital in Sofia. The Regional Cancer Registries are part of the structure of each Regional Oncological Center, and the Bulgarian National Cancer Registry – of the National Oncological Hospital. In the country exists a compulsory registration of malignant neoplasm, regulated by a Ministry of Health Instruction № 858/ 05.03.1964, a Ministry of Health Order № RD-09-451/ 29.06.1990 and a Ministry of Health Regulation № 34/ 2005.According tо the legislation every physician/medical worker is required to send a “rapid notification” to the Regional Oncological Center for each newly diagnosed cancer case, for a person suspected of having cancer or for those dying from a malignant neoplasm, and since 1975 for carcinoma in situ, as well, by the patient’s permanent residence.The BNCR uses active and passive methods of data collection. The personnel of the Regional Cancer Registries periodically visits the regional health facilities, which provide service, as well as actively seek all cases of malignant neoplasm and carcinoma in situ, unknown to the certain registry. Another main source of information on cancer patients are death certificates. The BNCR receives information from all Regional Cancer Registries around the country. The data are verified for range and completeness, duplication, and consistency between clinical and morphological diagnosis. The most recent update of the rapid notification was introduced in 1992 (Nomenclature № 2 concerning medical forms, serial № 120А of the Ministry of Health). For 1993 the cancer patients have been following up by type of treatment and date of death, as well. In January 2005 the Xth revision of the International Classification of Diseases (ICD), 1992 was introduced in Bulgaria. All cases of malignant neoplasm dated after 1993 (the initial year of cases identification by person) had to be recoded, according to the new classification requirements. The localization is coded according to the four-digit rubrics for all malignant neoplasm (С00 - С97), carcinoma in situ (D00 - D09) and for D39.0, D42, D43, D45, D46, D47.1, D47.3 which are changed from Borderline to Malignant according to ICD-O, Third edition, 2000. A software product “Oncology - 2005”, has been

6

За нуждите на регистрацията на злокачествените новообра-зувания е разработен програмен продукт „Онкология – 2005“, въведен от началото на 2005 г. във всички онкологични дис-пансери в страната. Той е съобразен с изискванията за ко-диране на отделните променливи, залегнали в „Standards and Guidelines for Cancer Registration in Europe“, IARC Technical Publication No.40, 2003. Програмният продукт позволява да се събира допълнителна информация за локализация на метас-тазите; Clark и Breslow за кожния малигнен меланом; естроген и прогестерон рецепторите за рак на млечната жлеза; вида на лечебното заведение, където е проведено лечението през първата година от диагностициране на заболяването, и т.н.В приложените таблици и графики са представени данни по локализации, пол и административни единици (области) за абсолютния брой нови случаи и умирания, фактическа и стандартизирана заболяемост и смъртност от злокачествени заболявания в България за 2009 г. Приложени са: абсолютният брой нови случаи по 5-годишни възрастови групи и изчислените възрастово-специфични показатели; тенденциите на стандартизираната заболяемост и смъртност от 1981 до 2009 г.;броят и процентното разпределение на новодиагностицира-ните случаи по морфологичен вид за най-честите локализа-ции на рака; разпределението на новите случаи по стадии; болестността от злокачествени заболявания по локализации и пол. В настоящото издание се представят данни за разпределе-нието на новите случаи по морфологичен вид при локализа-циите рак на белия дроб, млечната жлеза, стомаха, колона и ректума при мъжете и жените, а също така и при рак на прос-татата и рак на маточната шийка и яйчниците. За първична локализация (първичен тумор) се приема топо-графската локализация, от която той произхожда. Ако има 2 и повече тумора с различна хистология и/или локализация, те се приемат за 2 (или повече) отделни случая. При опреде-ляне на първичната множественост при злокачествените но-вообразувания се спазват правилата на Европейската мрежа на раковите регистри (ENCR) – „Recommendations for coding Multiple Primаries“, 2000.Във връзка с подобряване на системата за регистрация на злокачествените новообразувания, съгласно изискванията на IACR, се прави проверка в службите „ГРАО“ за всички починали от тези заболявания от 1993 г. насам.Данните за населението и смъртните случаи, публикувани в настоящото издание, са обработени и предоставени от Наци-оналния статистически институт. Цялата документация се съхранява съгласно Закона за държавния архивен фонд от 1974 г. и Закона за здравето от 2004 г.Данните за разпространението на злокачествените ново-образувания се използват за епидемиологични проучвания, за вземане на управленчески решения и др. Информацията е достъпна за всички заинтересовани лица и институции.

developed to serve the needs of registration of cancer cases and was implemented throughout the country in all Regional Oncological Centers at the beginning of 2005. The software meets all requirements of “Standards and Guidelines for Cancer Registration in Europe”, IARC Technical Publication № 40, 2003, for coding of certain variables. It also allows additional information for cancer cases to be collected, for example: information for metastases localization; Clark and Breslow for the malignant melanoma of skin; estrogen and progesterone receptors of breast cancer; new information about the type of medical facility, where the initial treatment happened during the first year after cancer diagnoses, etc.The data on the enclosed tables and graphics are presented by sites, age, stage, administrative units (districts), etc. Cancer incidence, mortality and prevalence in Bulgaria for 2009 are presented as both absolute number and rates (crude, age-specific and age-adjusted). In this issue are presented data about the distribution of the new cancer cases of lung, breast, colon, rectum, stomach, cervix uteri, ovary and prostate by morphological type. Primary site is the topographic site, where the tumour originated. If there are two or more tumors of different histological types and/or localization, they are considered as two cases. When determining the multiple primary cancers the rules of the European Network of Cancer Registries (ENCR) “Recommendations for coding Multiple Primaries”, 2000 are followed.A check of the Unified System for Civil Registration and Administrative Services to the Population – ESGRAON was made for all cancer cases died since 1993 in order to improve the malignant neoplasm registration system in accordance with IARC requirements. The National Statistical Institute provides population and mortality data, published in the current issue.All records are kept stored according to The Archives Law from 1974 and The Health Law from 2004.The data on cancer incidence, as well as the included additional data, is used for epidemiological studies, for public health administering, etc. This information is available to all individuals and institutions interested according to the legislation of the country for data confidentiality.

Quality of the Registry’s dataThe quality of the Registry’s data is assessed in terms of comparability, completeness and accuracy. To evaluate the comparability of the data with other populations and periods of time, an analysis of the extent to which the register conforms with international guidelines and standards for cancer registration with regard to the

7

coding of the site and morphology of primary tumours, incidence date, multiple primaries, etc. is performed. The applied indicators for accuracy are as follows – the percentage of all registered cancer cases in 2009 that have been morphologically verified (MV %), and the percentage of death certificate only registrations (DCO%).

Statistical methodsCrude ratesThe main rates used in this report to describe the burden of cancer of the Bulgarian population are incidence, mortality and prevalence.Incidence is the number of new cancer cases in a defined population within a specific period of time. Mortality is the number of cancer deaths that have occurred in a defined population within a specific period of time. Both measures in this report are calculated as the absolute number of new cancer cases or deaths, respectively, in 2009 is divided by the mean population at risk per 100 000.Prevalence is the proportion of the population that has cancer at a specific point in time. In the current edition of the Registry, the prevalence has been calculated as of 31.12.2009 per 100 000.

Age-specific ratesWhen calculating crude rates, distribution by age groups is ignored. In order to determine the cancer rate for a specific age group the age-specific rates have been calculated. In the current edition the different age groups are presented by five-year intervals (0-4, 5-9, 10-14 … 85+ years old). Age-specific incidence is calculated as the number of new cases within a given age group during 2009 divided by the mean population of the age-group multiplied by 100 000.

Age-standardised (age-adjusted) ratesThe adjusting for age is especially important when examining cancer rates since cancer is generally a disease of older people. For the calculation of the age-adjusted rates for Bulgaria, the world standard population (Segi, 1960) and the direct method of standardisation are used. The age-specifi c rates (a) are multiplied by their corresponding weights (k) of the world standard population. The weights represent the number of the population in each age group. The standardised incidence and mortality rates (ASR) are calculated using the following formula:

ASR = (Σa x k) / 100000The structure of the Bulgarian population for 2009 differs from that of the world standard population (the weights of the different age groups). The comparison

Предоставянето на медико-статистическа информация за онкологично болните се осъществява при спазване на необ-ходимите изисквания за конфиденциалност на данните, съо-бразно нормативната уредба на страната – Наредба на МЗ №10/ 05.07.2000 г. за предоставяне на медико-статистическа информация и информация за извършваната медицинска дейност от лечебните заведения, Закон за достъп до общест-вена информация от 2000 г., Закон за защита на личните дан-ни от 2002 г. и Закон за защита на класифицираната инфор-мация от 2002 г.

Качество на данните в раковия регистърКачеството на данните в БНРР е оценено по отношение на сравнимост (съпоставимост), пълнота и изчерпателност (точност). За оценка на сравнимостта на данните с други популации и периоди от време е направен анализ на степента, до която в регистъра се прилагат международните правила и стандарти за регистрация на рака относно кодиране на локализацията и морфологията на тумора, датата на заболяване, първична множественост и др. За оценка на пълнота и изчерпателност на данните са използвани показателите „Процент на морфологично доказани случаи на рак от всички регистрирани през 2009 г.“ (MV %) и „Процент на регистрираните само по смъртен акт от всички регистрирани през 2009 г.“ (DCO %).

Статистически методи за оценка Фактически показатели (crude rates)Основните показатели, чрез които е направена оценка на за-сягането от рак на населението в страната, са заболяемост, смъртност и болестност. Заболяемостта се дефинира като брой нови случаи от злокачествени новообразувания в дадено население за определен период от време. Смъртността представлява броя на починалите от злокачествени новообразувания в дадено население за определен период от време. В настоящото издание и двата показателя са изчислени, като броят на новозаболелите, респективно на починалите през 2009 г., е разделен на средногодишния брой на населението в риск по 100 000. Болестността е показател, който представлява дела на бол-ните от злокачествени заболявания към населението за даден период от време. В настоящото издание болестността е изчислена към 31.12.2009 г. на 100 000.

Възрастово-специфични показатели (age-specifi c rates).При изчисляването на фактическите показатели се игнорира разпределението по възрастови групи. За да може да се определи засягането от злокачествени заболявания в дадена възрастова група са изчислени възрастово-специфичните показатели. В настоящото издание възрастовите групи са представени през 5-годишни интервали (0-4, 5-9, 10-14 ... 85+

8

години). Възрастово-специфичната заболяемост е изчислена като брой нови случаи в дадена възрастова група през 2009 г., разделена на средногодишното население в същата възрастова група, умножено по 100 000.

Стандартизирани показатели (age-standardized or age-adjusted rates).Чрез тези показатели се премахва влиянието на фактора възраст, който е най-важният рисков фактор за появата на рака. При изчисляването на стандартизираните показатели за България са използвани световният стандарт за попула-ция (Segi, 1960) и директният метод на стандартизация, при който възрастово-специфичните показатели (а) се умножават по съответните им тегла (k) от световната стандартна попула-ция. Теглата представляват броя на населението в отделните възрастови групи. Стандартизираните заболяемост и смърт-ност (ASR) са изчислени по следната формула:

ASR = (Σa x k) / 100 000Структурата на българското население за 2009 г. се различава от световната стандартна популация (теглата на отделните възрастови групи). Сравнението между двете популации е представено на графиката на стр. 10. Стандартизацията дава възможност показателите заболяемост и смъртност да се съпоставят за различни по структура популации и периоди от време.Обясненията за структурата на населението в България и направените прогнози за очаквания брой нови случаи от рак по локализации за 2012 г. са представени съответно на стр. 10 и стр. 96.

between the two is shown on the graphic on page 10. The standartization method allows comparisons of the incidence and mortality rates for time periods and populations with different age stuctures.Details on the structure of the population of Bulgaria and the estimated number of new cases by primary cancer site for 2012 are given on pages 10 and 96, respectively.

9

THE MEAN POPULATION OF BULGARIA BY AGE AND SEX 1989AGE MALES FEMALES TOTAL

00-04 296928 282729 57965705-09 305981 289341 59532210-14 343382 326619 67000115-19 328259 312659 64091820-24 293554 283388 57694225-29 301872 295374 59724630-34 311592 309565 62115735-39 323002 324018 64702040-44 311191 314848 62603945-49 262137 267695 52983550-54 266567 276321 54288855-59 279185 294905 57409060-64 258986 284783 54376965-69 218668 258963 47763170-74 105780 129836 23561675-79 101313 133282 23459580-84 52846 76555 12940185+ 21786 35865 57651ALL AGES 4383029 4496746 8879775

THE MEAN POPULATION OF BULGARIA BY AGE AND SEX 2009AGE MALES FEMALES TOTAL

00-04 187710 177604 36531405-09 172949 163244 33619310-14 165317 157074 32239115-19 221204 209765 43096920-24 266324 253740 52006425-29 278811 263966 54277730-34 297129 284269 58139835-39 281240 272488 55372840-44 258311 255406 51371745-49 260175 263412 52358750-54 258798 273649 53244755-59 254082 282833 53691560-64 228684 272079 50076365-69 171279 220485 39176470-74 145893 204208 35010175-79 119212 179621 29883380-84 69538 117201 18673985+ 33640 63791 97431ALL AGES 3670296 3914835 7585131

THE MEAN POPULATION OF BULGARIA BY SEX AND DISTRICTS 2009DISTRICT MALES FEMALES TOTAL

BLAGOEVGRAD 160433 167901 328334BOURGAS 205387 216193 421580YAMBOL 68039 71510 139549VARNA 226184 238178 461362DOBRICH 97855 102747 200602VELIKO TURNOVO 132460 143998 276458GABROVO 63128 67828 130956VRATSA 96124 102141 198265VIDIN 52621 56567 109188MONTANA 75777 81318 157095PLEVEN 142256 150177 292433LOVECH 74329 77984 152313PLOVDIV 338140 364731 702871PAZARDJIK 142617 148957 291574SMOLYAN 60736 64930 125666ROUSSE 121277 128913 250190RAZGRAD 64873 68740 133613SILISTRA 63114 65276 128390SOFIA CITY 563647 654782 1248429SOFIA DISTRICT 123826 129789 253615KYUSTENDIL 71094 75460 146554PERNIK 65996 70853 136849STARA ZAGORA 171011 181198 352209SLIVEN 99948 105778 205726HASKOVO 125097 132611 257708KURDJALI 76381 78982 155363SHOUMEN 94456 100329 194785TURGOVISHTE 63490 66964 130454

10

COMPARISON OF POPULATION STRUCTURES

age (years)85+

80-8475-7970-7465-6960-6455-5950-5445-4940-4435-3930-3425-2920-2415-1910-1405-0900-04

0246810percent

0 2 4 6 8 10

males females

AGE STRUCTURE OF THE BULGARIAN POPULATION, 1989

age (years)85+

80-8475-7970-7465-6960-6455-5950-5445-4940-4435-3930-3425-2920-2415-1910-1405-0900-04

0246810percent

0 2 4 6 8 10

males females

AGE STRUCTURE OF THE BULGARIAN POPULATION, 2009

85+80-8475-7970-7465-6960-6455-5950-5445-4940-4435-3930-3425-2920-2415-1910-1405-09 00-04

02468101214

percent

0 2 4 6 8 10 12 14

World standard populationBulgarian population 2009

age (years)

НАСЕЛЕНИЕТО НА БЪЛГАРИЯПрез последните 20 години се наблюдава трайна тенденция за намаляване броя на населението в Р. България. Намаляването на населението се дължи на засилената емиграция, намалената раждаемост и бавното, но устойчиво нарастване на смъртността. След политическите промени от 1989 г. в страната се развива силна икономическа емиграция. През послед-ните години емиграцията е главно от млади хора . От 1989 г. досега приблизително 1 000 000 души са напус-нали страната, а живеещите в чужбина към 2007 г. са около 750 000 души. Емиграцията е един от главните фактори за намаляване на българското население. Формиралите се негативни тенденции в развитието на демографските процеси водят до значими промени във възрастовата структура на населението и до за-дълбочаване процеса на неговото остаряване. По данни на Националния статистически институт средногодишното население на страната за 2009 г. е 7 585 131 души, от които 51,6% са жени. В сравнение с 1989 г., когато населението е било 8 879 775 души, през 2009 г. то е с 1 294 644 души по-малко. Променена е и възрастовата му структура, като е увеличено населението над 60 години, а е намалено във възрастовите групи до 19 години и при двата пола. Увеличението на относителния дял на лицата над 60-годишна възраст през 2009 г. спрямо 1989 г. е с 5.2%. Средната възраст на населението общо за страната е 41.8 години. Процесът на остаряване се проявява както в селата, така и в градовете, като в селата средната възраст на населението е по-висока в сравнение с тази в градовете - съответно 45.5 и 40.3 години. Страната е разделена административно на 28 области, като 71,1% от населението живее в градовете.Според преброяването от 2001 г. 83,9% от население-то е българско, като двата най-големи други етносa са тези на турците (9,4%) и на ромите (4,7%). Останалите 2% са арменци, руснаци, евреи и др. Източноправославна религия се изповядва от 82,6% от населението, мюсюлманите са 12,2%, католиците са 1%, другите религии са 0,3% и атеистите са 3,9%.

THE POPULATION OF BULGARIAOver the last 20 years there has been a consistent tenden-cy toward a decline in the population of Bulgaria. The de-cline is due to increasing emigration, lower birth rates and a slow but steady increase in mortality rates. Since the political changes of 1989, there has been a strong tenden-cy towards economic emigration. Over the last few years the majority of emigrants has consisted mainly of young people. Since 1989 nearly 1 000 000 people have left the country, and the number of people living abroad in 2007 was about 750 000. Emigration is one of the main factors for the decline in the Bulgarian population. The negative tendencies in the development of the demographic pro-cesses lead to considerable changes in the age structure of the population and intensify the process of its aging. According to the National Statistical Institute the average annual population of the country in 2009 was 7 585 131 people, 51.6% of whom were women. Compared to 1989, when the population was 8 879 775 people, in 2009 it was 1 294 644 less. Its age structure has also changed with an increase in the population over 60 years and a decrease in the age groups up to 19 years for both sexes. The in-crease in percentage of people over 60 in 2009 compared to 1989 is 5.2%. The average age of the Bulgarian popula-tion is 41.8 years. The process of aging is evident both in the villages and in the cities. However the average age of the population in the villages is higher that this in the cities – 44.5 and 40.3 years accordingly. The country is administratively divided into 28 districts, with 71.1% of the population living in the urban areas.According to the census of 2001 83.9% of the population is Bulgarian and the two other largest ethnic groups are Turkish (9.4%) and Roma (4.7%). The other 2% are Arme-nian, Russian, Jewish, etc. 82.6% of the population is East-Orthodox, 12.2% are Muslim, 1% are Catholic, 0.3% belong to other religious groups and 3.9% are atheists.

11

CANCER INCIDENCE IN BULGARIA 2009 DISTRIBUTION OF THE NEW CASES BY PRIMARY SITES AND SEX

CODEICD-10 SITE

MALES FEMALES TOTAL

NUMBERCRUDE

DATA 100 000

% NUMBERCRUDE

DATA 100 000

% NUMBER %

C00-97 ALL SITES 18158 494.7 100.0 16554 422.9 100.0 34712 100.0C00-97 BUT C44 ALL SITES BUT NON-MELANOMA SKIN 15927 433.9 87.7 14480 369.9 87.5 30407 87.6C00 LIP 152 4.1 0.8 62 1.6 0.4 214 0.6C01-02 TONGUE 113 3.1 0.6 29 0.7 0.2 142 0.4C03-06 MOUTH 114 3.1 0.6 24 0.6 0.1 138 0.4C07-08 SALIVARY GLANDS 45 1.2 0.2 32 0.8 0.2 77 0.2C09 TONSIL 81 2.2 0.4 11 0.3 0.1 92 0.3C10 OTHER OROPHARYNX 33 0.9 0.2 10 0.3 0.1 43 0.1C11 NASOPHARYNX 62 1.7 0.3 26 0.7 0.2 88 0.3C12-13 HYPOPHARYNX 83 2.3 0.5 8 0.2 0.0 91 0.3C14 PHARYNX UNSPECIFIED 22 0.6 0.1 4 0.1 0.0 26 0.1C15 OESOPHAGUS 166 4.5 0.9 50 1.3 0.3 216 0.6C16 STOMACH 1027 28.0 5.7 605 15.5 3.7 1632 4.7C17 SMALL INTESTINE 27 0.7 0.1 17 0.4 0.1 44 0.1C18 COLON 1483 40.4 8.2 1259 32.2 7.6 2742 7.9C19-21 RECTUM AND ANUS 1121 30.5 6.2 772 19.7 4.7 1893 5.5C22 LIVER 421 11.5 2.3 194 5.0 1.2 615 1.8C23-24 GALLBLADDER AND EXTRAHEPATIC

BILE DUCTS 115 3.1 0.6 180 4.6 1.1 295 0.8C25 PANCREAS 660 18.0 3.6 485 12.4 2.9 1145 3.3C30-31 NOSE, SINUSES 47 1.3 0.3 19 0.5 0.1 66 0.2C32 LARYNX 616 16.8 3.4 37 0.9 0.2 653 1.9C33-34 TRACHEA, BRONCHUS, LUNG 3267 89.0 18.0 663 16.9 4.0 3930 11.3C37-38 OTHER THORACIC ORGANS 36 1.0 0.2 22 0.6 0.1 58 0.2C40-41 BONE 43 1.2 0.2 38 1.0 0.2 81 0.2C43 MELANOMA OF SKIN 242 6.6 1.3 194 5.0 1.2 436 1.3C44 OTHER SKIN 2231 60.8 12.3 2074 53.0 12.5 4305 12.4C45 MESOTHELIOMA 32 0.9 0.2 22 0.6 0.1 54 0.2C46 KAPOSI’S SARCOMA 7 0.2 0.0 2. 0.1 0.0 9 0.0C47,C49 CONNECTIVE AND SOFT TISSUE 94 2.6 0.5 78 2.0 0.5 172 0.5C50 BREAST 50 1.4 0.3 3809 97.3 23.0 3859 11.1C51 VULVA - - - 117 3.0 0.7 117 0.3C52 VAGINA - - - 25 0.6 0.2 25 0.1C53 CERVIX UTERI - - - 1072 27.4 6.5 1072 3.1C54 CORPUS UTERI - - - 1278 32.6 7.7 1278 3.7C55 UTERUS UNSPECIFIED - - - 47 1.2 0.3 47 0.1C56 OVARY - - - 862 22.0 5.2 862 2.5C57 OTHER FEMALE GENITAL ORGANS - - - 15 0.4 0.1 15 0.0C58 PLACENTA - - - 2 0.1 0.0 2 0.0C60 PENIS 48 1.3 0.3 - - - 48 0.1C61 PROSTATE 1666 45.4 9.2 - - - 1666 4.8C62 TESTIS 235 6.4 1.3 - - - 235 0.7C63 OTHER MALE GENITAL ORGANS 5 0.1 0.0 - - - 5 0.0C64 KIDNEY 455 12.4 2.5 218 5.6 1.3 673 1.9C65 RENAL PELVIS 47 1.3 0.3 25 0.6 0.2 72 0.2C66 URETER 15 0.4 0.1 8 0.2 0.0 23 0.1C67 BLADDER 1175 32.0 6.5 327 8.4 2.0 1502 4.3C68 OTHER URINARY ORGANS 3 0.1 0.0 7 0.2 0.0 10 0.0C69 EYE 29 0.8 0.2 21 0.5 0.1 50 0.1C70-72 BRAIN, NERVOUS SYSTEM 342 9.3 1.9 335 8.6 2.0 677 2.0C73 THYROID GLAND 66 1.8 0.4 250 6.4 1.5 316 0.9C74 ADRENAL GLAND 12 0.3 0.1 6 0.2 0.0 18 0.1C75 OTHER ENDOCRINE GLANDS 2 0.1 0.0 2 0.1 0.0 4 0.0C81 HODGKIN DISEASE 86 2.3 0.5 67 1.7 0.4 153 0.4C82-85, C96 NON-HODGKIN LYMPHOMA 265 7.2 1.5 230 5.9 1.4 495 1.4C88 IMMUNOPROLIFERATIVE DISEASES 1 0.0 0.0 1 0.0 0.0 2 0.0C90 MULTIPLE MYELOMA 96 2.6 0.5 86 2.2 0.5 182 0.5C91 LYMPHOID LEUKAEMIA 164 4.5 0.9 129 3.3 0.8 293 0.8C92 MYELOID LEUKAEMIA 97 2.6 0.5 93 2.4 0.6 190 0.5C93 MONOCYTIC LEUKAEMIA 7 0.2 0.0 7 0.2 0.0 14 0.0C94 OTHER LEUKAEMIAS 31 0.8 0.2 20 0.5 0.1 51 0.1C95 LEUKAEMIA UNSPECIFIED 26 0.7 0.1 21 0.5 0.1 47 0.1C26,C39, C48, C76, C80 OTHERS AND UNSPECIFIED SITES 895 24.4 4.9 557 14.2 3.4 1452 4.2D06 NOT INCLUDED ABOVE CA IN SITU

OF CERVIX UTERI - - - 296 7.6 - - -

12

PERCENTAGE DISTRIBUTION OF MORPHOLOGICALLY VERIFIED (MV) AND DEATH CERTIFICATE ONLY (DCO) NEW CANCER CASES BY PRIMARY SITES IN BULGARIA 2009

CODEICD-10 SITE NUMBER MORPHOLOGICALLY

VERIFIED, (MV)%DEATH CERTIFICATE

ONLY, (DCO)%

C00-97 ALL SITES 34712 86.4 5,8C00-97 BUT C44 ALL SITES BUT NON-MELANOMA SKIN 30407 84.5 6,6C00 LIP 214 99.5 0.5C01-02 TONGUE 142 92.3 7.7C03-06 MOUTH 138 95.7 1.4C07-08 SALIVARY GLANDS 77 92.2 5.2C09 TONSIL 92 95.7 3.3C10 OTHER OROPHARYNX 43 100.0 0.0C11 NASOPHARYNX 88 97.7 1.1C12-13 HYPOPHARYNX 91 91.2 7.7C14 PHARYNX UNSPECIFIED 26 84.6 15.4C15 OESOPHAGUS 216 69.4 19.9C16 STOMACH 1632 79.9 10.2C17 SMALL INTESTINE 44 81.8 15.9C18 COLON 2742 88.3 6.9C19-21 RECTUM AND ANUS 1893 92.5 4.2C22 LIVER 615 43.6 33.3C23-24 GALLBLADDER AND EXTRAHEPATIC BILE DUCTS 295 79.0 9.8C25 PANCREAS 1145 54.1 12.9C30-31 NOSE, SINUSES 66 93.9 4.5C32 LARYNX 653 93.7 4.3C33-34 TRACHEA, BRONCHUS, LUNG 3930 75.7 8.4C37-38 OTHER THORACIC ORGANS 58 65.5 17.2C40-41 BONE 81 81.5 14.8C43 MELANOMA OF SKIN 436 97.5 2.5C44 OTHER SKIN 4305 99.7 0.2C45 MESOTHELIOMA 54 98.1 1.9C46 KAPOSI’S SARCOMA 9 100.0 0.0C47,C49 CONNECTIVE AND SOFT TISSUE 172 98.3 1.2C50 BREAST 3859 96.3 1.7C51 VULVA 117 98.3 0.9C52 VAGINA 25 96.0 4.0C53 CERVIX UTERI 1072 98.6 0.9C54 CORPUS UTERI 1278 98.8 0.8C55 UTERUS UNSPECIFIED 47 68.1 27.7C56 OVARY 862 90.7 3.2C57 OTHER FEMALE GENITAL ORGANS 15 86.7 0.0C58 PLACENTA 2 50.0 0.0C60 PENIS 48 93.8 2.1C61 PROSTATE 1666 90.3 5.2C62 TESTIS 235 98.3 0.9C63 OTHER MALE GENITAL ORGANS 5 80.0 20.0C64 KIDNEY 673 79.5 5.8C65 RENAL PELVIS 72 93.1 1.4C66 URETER 23 73.9 21.7C67 BLADDER 1502 94.8 3.0C68 OTHER URINARY ORGANS 10 100.0 0.0C69 EYE 50 96.0 2.0C70-72 BRAIN, NERVOUS SYSTEM 677 65.7 23.3C73 THYROID GLAND 316 97.2 1.9C74 ADRENAL GLAND 18 66.7 5.6C75 OTHER ENDOCRINE GLANDS 4 75.0 25.0C81 HODGKIN DISEASE 153 98.7 1.3C82-85, C96 NON-HODGKIN LYMPHOMA 495 96.2 3.8C88 IMMUNOPROLIFERATIVE DISEASES 2 50.0 50.0C90 MULTIPLE MYELOMA 182 98.4 1.6C91 LYMPHOID LEUKAEMIA 293 96.6 3.4C92 MYELOID LEUKAEMIA 190 82.6 17.4C93 MONOCYTIC LEUKAEMIA 14 85.7 14.3C94 OTHER LEUKAEMIAS 51 84.3 15.7C95 LEUKAEMIA UNSPECIFIED 47 44.7 55.3C26,C39, C48, C76, C80

OTHERS AND UNSPECIFIED SITES1452 44.2 8.3

D06 NOT INCLUDED ABOVE CA IN SITU OF CERVIX UTERI 296 100.0 0.0

13

TOTAL NUMBER OF NEW CASES FROM ALL CANCER SITES BY YEARS

0

5000

10000

15000

20000

25000

30000

35000

40000

19931994199519961997199819992000200120022003200420052006200720082009

Year of diagnosis

New

cancercases

TOTAL NUMBER OF NEW CANCER CASES AND GROWTH RATES FOR ALL CANCER SITES IN BULGARIA FOR THE PERIOD 1993-2009

YEAR NEW CANCER CASES GROWTH RATE ON BASE 19931993 23528 1.0

1994 23711 1.0

1995 24071 1.0

1996 25598 1.1

1997 24575 1.0

1998 29271 1.2

1999 29069 1.2

2000 28960 1.2

2001 29070 1.2

2002 29718 1.3

2003 30630 1.3

2004 31980 1.4

2005 32343 1.4

2006 32761 1.4

2007 33760 1.4

2008 34576 1.5

2009 34712 1.5

На графиката са представени новите случаи от всички злокачествени заболявания (С00-С97, МКБ10) в България от 1993 до 2009 г.(към 30.06.2011 г.) Наблюдава се тенденция за нарастване на новите случаи от рак. На последващата таблица са дадени коефициентите на нарастване на новите случаи, като за база са взети новозаболелите през 1993 г. През 2009 г. коефициентът на нарастване е 1.5, което означава, че броят на новодиагностицираните случаи от рак през тази година се е увеличил 1.5 пъти спрямо 1993 г., взета за база.

The graph shows all new cancer cases (C00-C97, ICD10) in Bulgaria from 1993 to 2009, as of 30.06.2011. There is a tendency towards an increase of the new cancer cases. The next table shows the growth rates of new cancer cases based on the number from 1993. In 2009, the growth rate is 1.5, which means that the total number of newly diagnosed cancer cases in that year has increased 1.5 times compared to 1993.

14

PERCENTAGE DISTRIBUTION OF THE MOST COMMON NEW CANCER CASES

IN MALES, BULGARIA 2009

PERCENTAGE DISTRIBUTION OF THE MOST COMMON NEW CANCER CASES

IN FEMALES, BULGARIA 2009

PERCENTAGE DISTRIBUTION OF THE MOST COMMON CANCER DEATHS IN MALES, BULGARIA 2009

PERCENTAGE DISTRIBUTION OF THE MOST COMMON CANCER DEATHS

IN FEMALES, BULGARIA 200917,6%

10,1%

8,3%

7,0%

6,2%

5,6%

5,3%

5,1%

4,1%

4,0%

26,7%

BREAST

COLON

LUNG,TRACHEA

STOMACH

PANCREAS

OVARY ETC.

RECTUMAND ANUS

CERVIX UTERI

LIVER

BRAIN,NERVOUS

SYSTEM

OTHER

23,0%

12,5%

7,7%

7,6%

6,5%

5,2%

4,7%

4,0%

3,7%

2,9%

22,2%

BREAST

OTHER SKIN

CORPUS UTERI

COLON

CERVIX UTERI

OVARY ETC.

RECTUMAND ANUS

LUNG,TRACHEA

STOMACH

PANCREAS

OTHER

18,0%

12,3%

9,2%

8,2%

6,5%

6,2%

5,7%

3,6%

3,4%

2,5%

24,6%

LUNG,TRACHEA

OTHER SKIN

PROSTATE

COLON

BLADDER

RECTUNAND ANUS

STOMACH

PANCREAS

LARYNX

KIDNEY

OTHER

27,0%

8,5%

8,5%

8,2%

5,5%

5,3%

5,1%

3,7%

3,5%

3,4%

21,3%

LUNG,TRACHEA

COLON

STOMACH

PROSTATE

PANCREAS

RECTUMAND ANUS

LIVER

BLADDER

LARYNX

BRAIN,NERVOUS

SYSTEM

OTHER

15

AGE-SPECIFIC INCIDENCE RATES PER 100 000 FOR ALL CANCERS IN MALES BULGARIA, 1981 AND 2009

AGE-SPECIFIC INCIDENCE RATES PER 100 000 FOR ALL CANCERS IN FEMALESBULGARIA, 1981 AND 2009

0-14 15-29 30-39 40-49 50-59 60-69 70+

Age Groups

0

300

600

900

1200

1500

1800

21001981 2009

Rat

e pe

r 100

000

0-14 15-29 30-39 40-49 50-59 60-69 70+

Age Groups

0

300

600

900

1200

1500

1800

21001981 2009

Rat

e pe

r 100

000

16

AGE-STANDARDIZED (WORLD STANDARD) INCIDENCE AND MORTALITY RATES PER 100 000 OF ALL CANCERS IN MALES, BULGARIA 1981-2009

AGE-STANDARDIZED (WORLD STANDARD) INCIDENCE AND MORTALITY RATES PER 100 000 OF ALL CANCERS IN FEMALES, BULGARIA 1981-2009

1981 1985 1990 1995 2000 2005 2009

Year

0

50

100

150

200

250

300

350incidence mortality

Rat

e pe

r 100

000

incidence mortality

1981 1985 1990 1995 2000 2005 2009

Year

0

50

100

150

200

250

300

350

Rat

e pe

r 100

000

17

AGE-STANDARDIZED (WORLD STANDARD) INCIDENCE RATES PER 100 000 OF THE MOST COMMON CANCERS IN MALES, BULGARIA 1981-2009

AGE-STANDARDIZED (WORLD STANDARD) INCIDENCE RATES PER 100 000 OF THE MOST COMMON CANCERS IN FEMALES, BULGARIA 1981-2009

1981 1985 1990 1995 2000 2005 2009Year

0

5

10

15

20

25

30

35

40

45

50

55

prostate colonlarynx

lung and trachea stomachrectum and anus bladder

Rate

per

100

000

breast cervix uteri corpus uteri ovary etc.stomach colon rectum and anus

1981 1985 1990 1995 2000 2005 2009Year

0

5

10

15

20

25

30

35

40

45

50

55

Rate

per

100

000

18

NUMB

ER O

F NE

W C

ANCE

R CA

SES

BY P

RIMA

RY S

ITES

AND

AGE

AT

DIAG

NOSI

S IN

BUL

GARI

A 20

09 –

MALE

SCO

DEIC

D-10

SITE

AG

E AT

DIA

GN

OSI

S

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C00-

97AL

L SI

TES

3718

1441

6010

616

022

934

072

013

8221

3828

1327

8527

8425

5713

7659

818

158

C00

LIP

--

--

-1

1-

-5

1413

2020

2827

1310

152

C00.0

--

--

--

--

--

--

2-

-2

-1

5C0

0.1-

--

--

11

--

514

1318

1927

2512

814

3C0

0.4-

--

--

--

--

--

--

11

-1

14

C01

BASE

OF

TONG

UE-

--

--

--

12

32

1016

6-

33

248

C02

OTHE

R AN

D UN

SPEC

IFIE

D PA

RTS

OF T

ONGU

E-

--

--

--

-3

1020

314

83

31

-65

C02.0

--

--

--

--

--

--

2-

--

--

2C0

2.1-

--

--

--

-1

38

-7

41

-1

-25

C02.2

--

--

--

--

-3

32

-1

-2

--

11C0

2.3-

--

--

--

--

12

--

1-

1-

-5

C02.4

--

--

--

--

-1

--

-1

--

--

2C0

2.8-

--

--

--

--

-2

11

--

--

-4

C02.9

--

--

--

--

22

5-

41

2-

--

16C0

3GU

M-

--

--

1-

11

19

48

52

--

-32

C03.0

--

--

--

--

11

--

1-

1-

--

4C0

3.1-

--

--

1-

1-

-9

35

51

--

-25

C03.9

--

--

--

--

--

-1

2-

--

--

3C0

4FL

OOR

OF M

OUTH

--

--

--

--

13

716

121

42

--

46C0

4.0-

--

--

--

--

22

33

-2

--

-12

C04.1

--

--

--

--

--

22

3-

-1

--

8C0

4.8-

--

--

--

--

--

1-

-1

--

-2

C04.9

--

--

--

--

11

310

61

11

--

24C0

5PA

LATE

--

--

--

--

-1

45

63

2-

--

21C0

5.0-

--

--

--

--

-1

2-

--

--

-3

C05.1

--

--

--

--

--

32

62

2-

--

15C0

5.8-

--

--

--

--

1-

1-

1-

--

-3

C06

OTHE

R AN

D UN

SPEC

IFIE

D PA

RTS

OF M

OUTH

--

--

--

--

--

-4

44

3-

--

15C0

6.0-

--

--

--

--

--

22

22

--

-8

C06.2

--

--

--

--

--

--

1-

--

--

1C0

6.8-

--

--

--

--

--

1-

--

--

-1

C06.9

--

--

--

--

--

-1

12

1-

--

5C0

7PA

ROTI

D GL

AND

--

--

--

-1

--

46

35

36

32

33C0

8OT

HER

AND

UNSP

ECIF

IED

MAJO

R SA

LIVA

RY G

LAND

S-

--

--

--

--

-2

14

21

2-

-12

C08.0

--

--

--

--

--

21

41

12

--

11C0

8.9-

--

--

--

--

--

--

1-

--

-1

C09

TONS

IL-

--

--

-1

44

810

1715

88

41

181

C09.0

--

--

--

--

-1

-1

11

--

--

4

Part

1

19Part

2NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C09.1

--

--

--

-1

12

13

22

--

--

12C0

9.8-

--

--

-1

--

11

43

-2

1-

-13

C09.9

--

--

--

-3

34

89

95

63

11

52C1

0OR

OPHA

RYNX

--

--

--

--

11

212

93

32

--

33C1

0.0-

--

--

--

--

--

21

--

--

-3

C10.1

--

--

--

--

--

1-

--

--

--

1C1

0.2-

--

--

--

--

--

42

-2

--

-8

C10.3

--

--

--

--

--

--

--

-1

--

1C1

0.4-

--

--

--

--

--

--

1-

--

-1

C10.8

--

--

--

--

-1

-1

--

--

--

2C1

0.9-

--

--

--

-1

-1

56

21

1-

-17

C11

NASO

PHAR

YNX

--

-2

-2

2-

47

1316

73

23

1-

62C1

1.0-

--

--

--

--

21

31

1-

1-

-9

C11.1

--

--

--

--

--

2-

-1

11

--

5C1

1.2-

--

--

1-

-1

-2

-2

--

11

-8

C11.3

--

--

--

--

--

-1

--

--

--

1C1

1.8-

--

--

--

--

11

31

11

--

-8

C11.9

--

-2

-1

2-

34

79

3-

--

--

31C1

2PY

RIFO

RM S

INUS

--

--

--

--

-1

24

31

-3

--

14C1

3HY

POPH

ARYN

X-

--

1-

--

-3

89

189

98

4-

-69

C13.0

--

--

--

--

--

-2

--

--

--

2C1

3.1-

--

--

--

--

22

12

4-

1-

-12

C13.2

--

-1

--

--

11

11

21

-2

--

10C1

3.8-

--

--

--

-1

11

42

--

--

-9

C13.9

--

--

--

--

14

510

34

81

--

36C1

4OT

HER

AND

ILL-

DEFI

NED

SITE

S IN

LIP,

ORA

L CA

VITY

AND

PHAR

YNX

--

--

--

--

-4

62

54

--

1-

22C1

4.0-

--

--

--

--

32

1-

1-

--

-7

C14.8

--

--

--

--

-1

41

53

--

1-

15C1

5OE

SOPH

AGUS

--

--

--

-3

311

1326

3236

2110

83

166

C15.0

--

--

--

--

-1

--

12

--

--

4C1

5.1-

--

--

--

-1

-1

41

2-

--

-9

C15.2

--

--

--

--

12

1-

2-

3-

11

11C1

5.3-

--

--

--

1-

2-

23

21

11

-13

C15.4

--

--

--

--

-3

25

45

31

--

23C1

5.5-

--

--

--

1-

-6

612

1010

33

-51

C15.8

--

--

--

--

--

-2

-1

2-

--

5C1

5.9-

--

--

--

11

33

79

142

53

250

C16

STOM

ACH

1-

--

-1

47

2128

6610

014

117

917

916

999

3210

27C1

6.0-

--

--

--

-6

39

1712

2321

1415

512

5

20 Part

3NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C16.1

--

--

--

--

--

-2

52

43

1-

17C1

6.2-

--

--

-1

23

615

1923

3543

3417

320

1C1

6.3-

--

--

-1

16

611

1429

2826

2618

216

8C1

6.4-

--

--

--

--

15

64

57

61

237

C16.5

--

--

-1

-2

11

713

1611

1013

61

82C1

6.6-

--

--

--

-2

-2

34

1410

105

151

C16.8

--

--

--

12

-5

615

1635

2531

97

152

C16.9

1-

--

--

1-

36

1111

3226

3332

2711

194

C17

SMAL

L IN

TEST

INE

--

--

--

21

11

33

-2

76

1-

27C1

7.0-

--

--

--

--

-1

--

-4

2-

-7

C17.1

--

--

--

--

1-

--

-1

--

--

2C1

7.2-

--

--

--

--

-2

1-

--

1-

-4

C17.8

--

--

--

--

--

--

--

1-

--

1C1

7.9-

--

--

-2

1-

1-

2-

12

31

-13

C18

COLO

N-

-1

-1

711

1026

3792

143

225

244

268

231

133

5414

83C1

8.0-

--

--

2-

15

213

1231

2738

2116

317

1C1

8.1-

-1

--

--

1-

--

-1

-1

--

-4

C18.2

--

--

-1

31

42

1328

2728

2938

239

206

C18.3

--

--

--

11

13

78

1411

1419

91

89C1

8.4-

--

-1

-3

25

99

1019

1927

1610

413

4C1

8.5-

--

--

--

12

513

917

1618

85

610

0C1

8.6-

--

--

--

13

37

914

1320

247

310

4C1

8.7-

--

--

42

-6

1030

5886

118

107

7940

1455

4C1

8.8-

--

--

-1

--

--

-4

22

11

-11

C18.9

--

--

--

12

-3

-9

1210

1225

2214

110

C19

RECT

OSIG

MOID

JUNC

TION

--

--

-1

12

29

1013

2132

2929

1611

176

C20

RECT

UM-

--

1-

12

711

2268

106

158

159

174

130

7018

927

C21

ANUS

AND

ANA

L CA

NAL

--

--

--

-1

--

43

15

31

--

18C2

1.0-

--

--

--

1-

-3

2-

22

--

-10

C21.1

--

--

--

--

--

11

1-

-1

--

4C2

1.8-

--

--

--

--

--

--

31

--

-4

C22

LIVE

R AN

D IN

TRAH

EPAT

IC

BILE

DUC

TS1

--

-3

21

712

2339

4665

6855

5633

1042

1C2

2.0-

--

-1

--

26

713

1823

2526

218

215

2C2

2.1-

--

--

--

-1

-2

26

73

12

-24

C22.3

--

--

--

--

--

--

--

--

1-

1C2

2.7-

--

--

--

--

--

46

52

21

-20

C22.9

1-

--

22

15

516

2422

3031

2432

218

224

C23

GALL

BLAD

DER

--

--

--

1-

-4

35

93

816

85

62C2

4OT

HER

AND

UNSP

ECIF

IED

PART

S OF

BIL

IARY

TRA

CT-

--

--

--

-1

15

78

94

125

153

C24.0

--

--

--

--

11

25

42

48

1-

28

21Part

4NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C24.1

--

--

--

--

--

21

26

-4

11

17C2

4.9-

--

--

--

--

-1

12

1-

-3

-8

C25

PANC

REAS

--

-1

--

17

1533

6889

9410

099

9540

1866

0C2

5.0-

--

1-

-1

37

1933

5548

5245

5025

634

5C2

5.1-

--

--

--

-2

17

1010

912

163

272

C25.2

--

--

--

-1

-3

64

76

41

--

32C2

5.8-

--

--

--

22

48

612

68

92

-59

C25.9

--

--

--

-1

46

1414

1727

3019

1010

152

C26

OTHE

R AN

D IL

L-DE

FINE

D DI

GEST

IVE

ORGA

NS-

--

--

--

--

--

1-

-1

11

-4

C26.0

--

--

--

--

--

--

--

1-

1-

2C2

6.9-

--

--

--

--

--

1-

--

1-

-2

C30

NASA

L CA

VITY

AND

MIDD

LE E

AR-

--

--

-1

--

11

32

21

11

114

C30.0

--

--

--

1-

-1

12

22

11

11

13C3

0.1-

--

--

--

--

--

1-

--

--

-1

C31

ACCE

SSOR

Y SI

NUSE

S-

--

--

--

11

34

73

64

13

-33

C31.0

--

--

--

-1

12

27

26

31

--

25C3

1.8-

--

--

--

--

-1

-1

-1

-3

-6

C31.9

--

--

--

--

-1

1-

--

--

--

2C3

2LA

RYNX

--

--

11

-3

1336

9613

212

987

5742

172

616

C32.0

--

--

1-

-1

414

3448

5136

3017

101

247

C32.1

--

--

--

-1

41

911

116

13

--

47C3

2.2-

--

--

--

--

12

11

--

--

-5

C32.8

--

--

-1

-1

214

2742

2926

118

3-

164

C32.9

--

--

--

--

36

2430

3719

1514

41

153

C33

TRAC

HEA

--

--

--

--

--

-1

2-

21

--

6C3

4BR

ONCH

US A

ND L

UNG

--

--

14

1017

4213

932

255

269

157

946

729

610

833

3261

C34.0

--

--

--

11

818

3975

8278

5532

61

396

C34.1

--

--

12

49

1668

152

248

324

255

210

123

4313

1468

C34.2

--

--

-1

-1

49

1750

5947

3032

103

263

C34.3

--

--

-1

14

920

6410

013

511

397

5321

562

3C3

4.8-

--

--

--

-3

35

1118

1014

2-

167

C34.9

--

--

--

42

221

4568

7376

6154

2810

444

C37

THYM

US-

--

--

--

11

3-

1-

1-

-1

-8

C38

HEAR

T, ME

DIAS

TINU

M, A

ND

PLEU

RA-

1-

--

--

1-

15

44

24

31

228

C38.0

--

--

--

--

--

-2

--

1-

1-

4C3

8.1-

1-

--

--

--

-1

11

1-

--

-5

C38.2

--

--

--

--

-1

-1

--

1-

--

3C3

8.3-

--

--

--

--

-4

-3

-1

2-

111

C38.4

--

--

--

--

--

--

--

1-

-1

2

22 Part

5NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C38.8

--

--

--

-1

--

--

-1

-1

--

3C3

9OT

HER

AND

ILL-

DEFI

NED

SITE

S W

ITHI

N RE

SPIR

ATOR

Y SY

STEM

AND

INTR

ATHO

RACI

C OR

GANS

--

--

--

--

--

--

--

--

1-

1C3

9.0-

--

--

--

--

--

--

--

-1

-1

C40

BONE

S, JO

INTS

AND

AR

TICU

LAR

CART

ILAG

E OF

LI

MBS

--

-4

33

1-

-1

23

-3

-2

1-

23C4

0.0-

--

--

2-

--

-1

--

1-

--

-4

C40.2

--

-4

31

1-

--

13

-2

-1

1-

17C4

0.9-

--

--

--

--

1-

--

--

1-

-2

C41

BONE

S, JO

INTS

AND

ART

ICUL

AR

CART

ILAGE

OF O

THER

AND

UN

SPEC

IFIED

SITE

S-

2-

4-

-1

-1

11

13

12

12

-20

C41.0

--

--

--

--

1-

--

-1

1-

--

3C4

1.1-

--

--

--

--

--

1-

--

--

-1

C41.2

--

-1

--

--

--

--

--

--

--

1C4

1.3-

1-

3-

-1

--

--

-2

--

--

-7

C41.4

-1

--

--

--

--

--

1-

1-

1-

4C4

1.8-

--

--

--

--

-1

--

--

--

-1

C41.9

--

--

--

--

-1

--

--

-1

1-

3C4

3ME

LANO

MA O

F SK

IN-

-1

21

29

915

1424

3427

2621

2620

1124

2C4

3.0-

--

--

--

1-

--

--

--

--

-1

C43.1

--

--

--

--

--

--

-1

1-

--

2C4

3.2-

--

--

--

--

--

--

--

2-

-2

C43.3

--

--

--

--

-1

11

21

-2

22

12C4

3.4-

--

--

11

11

14

51

22

73

130

C43.5

--

-1

11

55

87

1317

1615

138

98

127

C43.6

--

--

--

--

12

33

-2

12

4-

18C4

3.7-

-1

1-

-3

13

32

35

42

11

-30

C43.9

--

--

--

-1

2-

15

31

24

1-

20C4

4OT

HER

SKIN

--

-1

33

1219

2752

9516

924

728

438

146

630

117

122

31C4

4.0-

--

--

--

--

-1

36

410

127

144

C44.1

--

--

1-

13

11

818

1813

2112

142

113

C44.2

--

--

--

-1

-1

413

1022

3147

2624

179

C44.3

--

-1

12

37

1234

4582

129

159

205

252

166

9311

91C4

4.4-

--

--

11

2-

-10

1434

3037

4428

1721

8C4

4.5-

--

--

-6

510

919

2634

3252

7237

2232

4C4

4.6-

--

--

-1

13

55

510

1517

1819

610

5C4

4.7-

--

-1

--

-1

23

86

76

84

450

23Part

6NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C44.8

--

--

--

--

--

--

-2

11

--

4C4

4.9-

--

--

--

--

--

--

-1

--

23

C45

MESO

THEL

IOMA

--

--

--

-1

-4

24

43

71

51

32C4

5.0-

--

--

--

1-

42

24

27

-4

127

C45.1

--

--

--

--

--

-2

-1

-1

--

4C4

5.9-

--

--

--

--

--

--

--

-1

-1

C46

KAPO

SI’S

SAR

COMA

--

--

--

--

--

--

11

21

11

7C4

6.0-

--

--

--

--

--

--

11

11

15

C46.9

--

--

--

--

--

--

1-

1-

--

2C4

7PE

RIPH

ERAL

NER

VES A

ND

AUTO

NOMI

C NE

RVOU

S SY

STEM

--

--

--

1-

--

-1

-1

--

--

3C4

7.3-

--

--

-1

--

--

--

1-

--

-2

C47.4

--

--

--

--

--

-1

--

--

--

1C4

8RE

TROP

ERIT

ONEU

M AN

D PE

RITO

NEUM

1-

--

-1

-1

23

58

104

54

21

47C4

8.01

--

--

--

11

14

49

34

32

134

C48.1

--

--

-1

--

-1

--

--

--

--

2C4

8.2-

--

--

--

-1

-1

4-

11

1-

-9

C48.8

--

--

--

--

-1

--

1-

--

--

2C4

9CO

NNEC

TIVE

AND

OTH

ER

SOFT

TIS

SUES

1-

--

32

57

33

89

1010

1012

62

91C4

9.01

--

--

-1

11

21

-2

21

31

-16

C49.1

--

--

--

1-

--

1-

1-

11

-1

6C4

9.2-

--

-1

21

32

-3

46

42

52

136

C49.3

--

--

--

--

--

12

-1

2-

1-

7C4

9.4-

--

-1

-1

--

--

21

-3

1-

-9

C49.5

--

--

--

--

-1

-1

-3

-1

1-

7C4

9.6-

--

--

-1

3-

-1

--

-1

11

-8

C49.9

--

--

1-

--

--

1-

--

--

--

2C5

0BR

EAST

--

--

--

1-

1-

68

77

79

22

50C5

0.0-

--

--

--

--

-1

22

21

21

-11

C50.1

--

--

--

--

--

12

11

12

-1

9C5

0.2-

--

--

-1

--

--

-1

--

1-

14

C50.4

--

--

--

--

1-

32

23

11

1-

14C5

0.5-

--

--

--

--

-1

-1

-1

--

-3

C50.8

--

--

--

--

--

-1

-1

-3

--

5C5

0.9-

--

--

--

--

--

1-

-3

--

-4

C60

PENI

S-

--

--

1-

-1

33

611

76

53

248

C60.0

--

--

--

--

-1

--

21

-1

-1

6C6

0.1-

--

--

--

-1

13

47

55

42

-32

C60.2

--

--

--

--

--

--

1-

--

--

1

24 Part

7NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C60.8

--

--

--

--

-1

-1

--

1-

--

3C6

0.9-

--

--

1-

--

--

11

1-

-1

16

C61

PROS

TATE

GLA

ND-

--

--

--

12

720

7518

826

135

441

524

499

1666

C62

TEST

IS-

-1

821

3940

3926

1711

136

43

33

123

5C6

2.0-

--

--

34

-1

1-

--

--

--

-9

C62.1

--

13

919

1828

127

77

42

22

--

121

C62.9

--

-5

1217

1811

139

46

22

11

31

105

C63

OTHE

R AN

D UN

SPEC

IFIE

D MA

LE G

ENITA

L OR

GANS

--

--

--

--

-1

-2

-1

--

-1

5C6

3.1-

--

--

--

--

--

--

1-

--

-1

C63.2

--

--

--

--

-1

-2

--

--

--

3C6

3.9-

--

--

--

--

--

--

--

--

11

C64

KIDN

EY4

1-

--

44

816

2848

6069

8461

3917

1245

5C6

5RE

NAL

PELV

IS-

--

--

-1

-2

-4

513

39

63

147

C66

URET

ER-

--

--

--

-1

-2

11

51

11

215

C67

BLAD

DER

-1

--

-3

714

2059

6713

319

118

619

018

385

3611

75C6

7.0-

--

--

--

11

42

1013

1312

127

-75

C67.1

--

--

--

--

--

23

52

75

1-

25C6

7.2-

--

--

31

39

1620

5060

6157

6030

1638

6C6

7.3-

--

--

--

23

63

815

1918

136

-93

C67.4

--

--

--

--

-5

211

1515

1416

61

85C6

7.5-

--

--

--

1-

-2

63

65

81

335

C67.6

--

--

--

23

410

1612

2115

1413

51

116

C67.7

--

--

--

--

--

-1

--

--

--

1C6

7.8-

--

--

-1

1-

79

1519

1924

207

112

3C6

7.9-

1-

--

-3

33

1111

1740

3639

3622

1423

6C6

8OT

HER

AND

UNSP

ECIF

IED

URIN

ARY

ORGA

NS-

--

--

--

--

--

1-

--

2-

-3

C68.0

--

--

--

--

--

-1

--

-2

--

3C6

9EY

E AN

D AD

NEXA

3-

--

--

--

23

31

46

12

22

29C6

9.0-

--

--

--

-1

--

--

21

--

26

C69.2

3-

--

--

--

--

--

1-

--

--

4C6

9.3-

--

--

--

--

22

12

1-

2-

-10

C69.4

--

--

--

--

--

--

-2

--

1-

3C6

9.6-

--

--

--

-1

-1

--

1-

-1

-4

C69.9

--

--

--

--

-1

--

1-

--

--

2C7

0ME

NING

ES-

--

--

2-

--

13

28

2-

42

-24

C70.0

--

--

-1

--

-1

-1

31

--

--

7C7

0.1-

--

--

--

--

-1

--

--

--

-1

C70.9

--

--

-1

--

--

21

51

-4

2-

16C7

1BR

AIN

84

-1

410

814

1325

3331

5540

3220

65

309

25Part

8NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C71.0

1-

--

-1

-2

1-

21

11

1-

--

11C7

1.1-

--

-1

13

33

55

18

26

1-

-39

C71.2

--

--

12

--

58

95

139

44

2-

62C7

1.3-

--

--

21

11

33

94

115

31

-44

C71.4

--

--

--

--

-2

13

4-

4-

--

14C7

1.51

1-

--

--

1-

-2

-1

--

--

-6

C71.6

32

-1

--

21

-1

2-

11

1-

--

15C7

1.7-

--

--

--

1-

--

1-

--

--

-2

C71.8

1-

--

-3

23

-5

45

84

22

11

41C7

1.92

1-

-2

1-

23

15

615

129

102

475

C72

SPIN

AL C

ORD,

CRA

NIAL

NE

RVES

, AND

OTH

ER PA

RTS

OF

CENT

RAL N

ERVO

US S

YSTE

M-

1-

--

--

--

11

-2

21

-1

-9

C72.0

-1

--

--

--

-1

1-

11

--

1-

6C7

2.5-

--

--

--

--

--

--

1-

--

-1

C72.9

--

--

--

--

--

--

1-

1-

--

2C7

3TH

YROI

D GL

AND

--

-1

41

26

54

712

98

24

1-

66C7

4AD

RENA

L GL

AND

31

--

1-

--

11

-1

11

11

--

12C7

4.0-

--

--

--

--

--

--

--

1-

-1

C74.1

--

--

1-

--

--

--

-1

--

-2

C74.9

31

--

--

--

11

-1

11

--

--

9C7

5OT

HER

ENDO

CRIN

E GL

ANDS

AN

D RE

LATE

D ST

RUCT

URES

--

--

1-

--

--

1-

--

--

--

2C7

5.1-

--

--

--

--

-1

--

--

--

-1

C75.3

--

--

1-

--

--

--

--

--

--

1C7

6OT

HER

AND

ILL-

DEFI

NED

SITE

S1

--

1-

1-

--

11

-1

-2

--

-8

C76.0

--

--

--

--

--

--

1-

--

--

1C7

6.1-

--

--

--

--

--

--

-1

--

-1

C76.2

1-

-1

--

--

-1

1-

--

--

--

4C7

6.3-

--

--

--

--

--

--

-1

--

-1

C76.7

--

--

-1

--

--

--

--

--

--

1C8

0MA

LIGN

ANT

NEOP

LASM

W

ITHO

UT S

PECI

FICA

TION

OF

SIT

E1

--

1-

44

613

3775

112

124

142

134

103

5623

835

C81

HODG

KIN

DISE

ASE

2-

42

45

1311

37

66

72

66

-2

86C8

1.01

-1

-1

-1

1-

-1

--

--

1-

-7

C81.1

--

2-

22

95

15

32

41

22

--

40C8

1.2-

-1

11

23

51

12

33

11

1-

127

C81.3

--

--

--

--

-1

--

--

--

--

1C8

1.91

--

1-

1-

-1

--

1-

-3

2-

111

26 Part

9NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C82

FOLL

ICUL

AR N

ON-H

ODGK

IN

LYMP

HOMA

--

-1

1-

-1

-1

28

43

33

2-

29C8

2.0-

--

--

--

--

--

1-

--

--

-1

C82.2

--

--

1-

--

--

-1

32

2-

--

9C8

2.7-

--

--

--

--

--

--

-1

-1

-2

C82.9

--

-1

--

-1

-1

26

11

-3

1-

17C8

3DI

FFUS

E NO

N-HO

DGKI

N LY

MPHO

MA-

12

23

12

85

1110

1124

1521

199

314

7C8

3.0-

--

--

--

33

23

16

35

51

-32

C83.1

--

--

--

--

--

--

1-

--

--

1C8

3.2-

--

--

--

--

--

--

--

1-

-1

C83.3

--

1-

21

14

17

66

158

1211

21

78C8

3.5-

-1

21

-1

-1

--

--

1-

-1

-8

C83.7

-1

--

--

--

--

--

--

--

--

1C8

3.8-

--

--

--

1-

11

22

11

13

114

C83.9

--

--

--

--

-1

-2

-2

31

21

12C8

4PE

RIPH

ERAL

AND

CUT

ANEO

US

T-CE

LL LY

MPHO

MAS

--

--

--

1-

15

-1

12

23

21

19C8

4.0-

--

--

--

-1

2-

1-

-2

12

110

C84.4

--

--

--

--

-3

--

12

-2

--

8C8

4.5-

--

--

-1

--

--

--

--

--

-1

C85

OTHE

R AN

D UN

SPEC

IFIE

D TY

PES

OF N

ON-H

ODGK

INS

LYMP

HOMA

-

11

21

-1

22

23

99

1111

63

367

C85.0

--

--

--

-1

--

--

--

--

--

1C8

5.1-

--

--

--

-1

-1

21

12

--

-8

C85.7

--

--

--

1-

--

1-

--

23

--

7C8

5.9-

11

21

--

11

21

78

107

33

351

C88

MALI

GNAN

T IM

MUNO

PROL

IFER

ATIV

E DI

SEAS

ES-

--

--

--

--

--

--

-1

--

-1

C88.9

--

--

--

--

--

--

--

1-

--

1C9

0MU

LTIP

LE M

YELO

MA A

ND

MALI

GNAN

T PL

ASMA

CEL

L NE

OPLA

SMS

--

--

--

-2

16

1310

2314

128

43

96C9

0.0-

--

--

--

1-

511

920

1312

74

284

C90.2

--

--

--

-1

11

21

31

-1

-1

12C9

1LY

MPHO

ID L

EUKA

EMIA

95

45

23

11

38

715

1423

2427

94

164

C91.0

95

45

22

1-

11

14

22

32

--

44C9

1.1-

--

--

1-

12

42

610

1721

218

396

27Part

10NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C91.4

--

--

--

--

-2

43

-2

-2

-1

14C9

1.5-

--

--

--

--

1-

2-

--

--

-3

C91.9

--

--

--

--

--

--

22

-2

1-

7C9

2MY

ELOI

D LE

UKAE

MIA

1-

-1

2-

53

26

106

1318

913

71

97C9

2.01

--

11

-1

-1

11

15

63

53

-30

C92.1

--

--

1-

32

11

65

56

34

11

39C9

2.2-

--

--

--

--

--

--

-1

--

-1

C92.5

--

--

--

11

-1

--

-2

12

1-

9C9

2.7-

--

--

--

--

1-

--

1-

-1

-3

C92.9

--

--

--

--

-2

3-

33

12

1-

15C9

3MO

NOCY

TIC

LEUK

AEMI

A-

--

--

--

1-

-1

3-

-1

-1

-7

C93.0

--

--

--

-1

--

-2

--

1-

1-

5C9

3.1-

--

--

--

--

--

1-

--

--

-1

C93.9

--

--

--

--

--

1-

--

--

--

1C9

4OT

HER

LEUK

AEMI

AS O

F SP

ECIF

IED

CELL

TYP

E-

--

--

-3

-2

24

23

77

-1

-31

C94.0

--

--

--

2-

--

--

2-

--

--

4C9

4.1-

--

--

-1

-2

22

11

64

-1

-20

C94.3

--

--

--

--

--

1-

--

--

--

1C9

4.4-

--

--

--

--

--

--

1-

--

-1

C94.5

--

--

--

--

--

-1

--

1-

--

2C9

4.7-

--

--

--

--

-1

--

-2

--

-3

C95

LEUK

AEMI

A, U

NSPE

CIFI

ED

CELL

TYP

E-

--

--

--

-2

21

13

25

34

326

C95.0

--

--

--

--

1-

--

3-

22

--

8C9

5.1-

--

--

--

--

--

--

1-

--

-1

C95.9

--

--

--

--

12

11

-1

31

43

17C9

6OT

HER

AND

UNSP

ECIF

IED

NEOP

LASM

S OF

LYMP

HOID

, BL

OOD

FORM

ING

AND

RELA

TED

TISS

UES

1-

--

--

--

--

-1

--

--

1-

3C9

6.11

--

--

--

--

--

1-

--

-1

-3

28

NUMB

ER O

F NE

W C

ANCE

R CA

SES

BY P

RIMA

RY S

ITES

AND

AGE

AT

DIAG

NOSI

S IN

BUL

GARI

A 20

09 –

FEMA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C00-

97AL

L SI

TES

2520

1928

5810

926

145

164

710

1613

5218

1522

4420

2622

7721

5713

4970

016

554

C00

LIP

--

--

--

1-

--

2-

39

1320

59

62C0

0.0-

--

--

--

--

--

--

2-

21

-5

C00.1

--

--

--

1-

--

2-

37

1318

49

57C0

1BA

SE O

F TO

NGUE

--

--

-1

-1

--

-1

11

11

3-

10C0

2OT

HER

AND

UNSP

ECIF

IED

PART

S OF

TON

GUE

--

--

--

-2

12

23

22

2-

12

19C0

2.1-

--

--

--

11

-2

21

11

--

110

C02.2

--

--

--

-1

--

--

--

--

--

1C0

2.3-

--

--

--

--

1-

-1

--

--

-2

C02.8

--

--

--

--

--

-1

--

--

--

1C0

2.9-

--

--

--

--

1-

--

11

-1

15

C03

GUM

--

--

--

--

--

11

1-

13

12

10C0

3.0-

--

--

--

--

--

11

-1

11

-5

C03.1

--

--

--

--

--

1-

--

-2

-2

5C0

4FL

OOR

OF M

OUTH

--

--

--

--

--

-1

-1

1-

--

3C0

4.0-

--

--

--

--

--

--

1-

--

-1

C04.8

--

--

--

--

--

--

--

1-

--

1C0

4.9-

--

--

--

--

--

1-

--

--

-1

C05

PALA

TE-

--

--

--

--

-1

11

-1

11

-6

C05.0

--

--

--

--

--

11

1-

--

1-

4C0

5.1-

--

--

--

--

--

--

-1

--

-1

C05.8

--

--

--

--

--

--

--

-1

--

1C0

6OT

HER

AND

UNSP

ECIF

IED

PART

S OF

MOU

TH-

--

--

--

-1

11

-1

-1

--

-5

C06.0

--

--

--

--

11

1-

1-

--

--

4C0

6.9-

--

--

--

--

--

--

-1

--

-1

C07

PARO

TID

GLAN

D-

--

--

1-

-2

--

2-

36

41

120

C08

OTHE

R AN

D UN

SPEC

IFIE

D MA

JOR

SALI

VARY

GLA

NDS

--

--

--

--

11

13

21

-2

1-

12C0

8.0-

--

--

--

-1

11

21

--

11

-8

C08.9

--

--

--

--

--

-1

11

-1

--

4C0

9TO

NSIL

--

--

--

-2

2-

2-

11

1-

11

11C0

9.0-

--

--

--

-1

--

--

--

--

-1

C09.1

--

--

--

-1

--

--

--

--

--

1C0

9.9-

--

--

--

11

-2

-1

11

-1

19

C10

OROP

HARY

NX-

--

--

-1

-1

11

--

5-

-1

-10

C10.1

--

--

--

--

--

--

-1

--

--

1C1

0.2-

--

--

--

--

--

--

2-

-1

-3

C10.4

--

--

--

--

--

--

-1

--

--

1C1

0.8-

--

--

--

-1

-1

--

1-

--

-3

Part

1

29Part

2NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C10.9

--

--

--

1-

-1

--

--

--

--

2C1

1NA

SOPH

ARYN

X-

--

11

12

31

46

3-

-2

11

-26

C11.0

--

-1

--

-1

--

21

--

--

1-

6C1

1.1-

--

--

--

--

--

1-

--

--

-1

C11.2

--

--

--

1-

11

--

--

-1

--

4C1

1.3-

--

-1

--

--

--

--

--

--

-1

C11.8

--

--

--

11

-2

1-

--

--

--

5C1

1.9-

--

--

1-

1-

13

1-

-2

--

-9

C12

PYRI

FORM

SIN

US-

--

--

--

--

--

--

--

--

11

C13

HYPO

PHAR

YNX

--

--

--

--

1-

22

-1

-1

--

7C1

3.1-

--

--

--

-1

--

--

1-

--

-2

C13.2

--

--

--

--

--

1-

--

--

--

1C1

3.9-

--

--

--

--

-1

2-

--

1-

-4

C14

OTHE

R AN

D IL

L-DE

FINE

D SI

TES

IN L

IP, O

RAL

CAVI

TY A

ND

PHAR

YNX

--

--

--

--

1-

--

1-

-1

-1

4C1

4.0-

--

--

--

--

--

-1

--

1-

13

C14.8

--

--

--

--

1-

--

--

--

--

1C1

5OE

SOPH

AGUS

--

--

--

-1

12

45

134

67

34

50C1

5.0-

--

--

--

--

--

-1

--

--

-1

C15.1

--

--

--

--

--

-1

--

--

--

1C1

5.2-

--

--

--

--

--

-2

--

--

-2

C15.3

--

--

--

-1

-1

--

--

1-

--

3C1

5.4-

--

--

--

-1

12

1-

2-

--

-7

C15.5

--

--

--

--

--

-1

7-

11

12

13C1

5.8-

--

--

--

--

-1

--

--

--

-1

C15.9

--

--

--

--

--

12

32

46

22

22C1

6ST

OMAC

H-

--

-1

14

1214

1226

4057

8611

712

375

3760

5C1

6.0-

--

--

1-

--

34

56

1311

810

263

C16.1

--

--

--

--

1-

-1

11

-2

-1

7C1

6.2-

--

-1

-1

1-

15

812

1736

2812

612

8C1

6.3-

--

--

-2

26

17

710

1720

1810

310

3C1

6.4-

--

--

--

11

--

12

25

61

-19

C16.5

--

--

--

--

21

25

37

86

33

40C1

6.6-

--

--

-1

-1

--

23

21

83

-21

C16.8

--

--

--

-5

23

25

1116

1319

86

90C1

6.9-

--

--

--

31

36

69

1123

2828

1613

4C1

7SM

ALL

INTE

STIN

E-

--

-1

--

1-

2-

11

22

23

217

C17.0

--

--

--

-1

--

--

1-

11

1-

5C1

7.1-

--

-1

--

--

--

1-

--

--

24

30 Part

3NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C17.2

--

--

--

--

-1

--

--

--

--

1C1

7.9-

--

--

--

--

1-

--

21

12

-7

C18

COLO

N-

--

--

17

1218

3110

010

416

818

221

020

015

472

1259

C18.0

--

--

-1

13

16

1214

1828

2934

2510

182

C18.1

--

--

--

2-

1-

-1

-2

--

1-

7C1

8.2-

--

--

-2

15

210

1423

2840

3825

519

3C1

8.3-

--

--

-1

-1

35

513

619

107

373

C18.4

--

--

--

-1

13

1411

1611

2118

137

116

C18.5

--

--

--

--

11

106

813

124

73

65C1

8.6-

--

--

--

21

313

512

915

138

485

C18.7

--

--

--

15

712

3146

7375

5467

4214

427

C18.8

--

--

--

--

--

11

1-

1-

1-

5C1

8.9-

--

--

--

--

14

14

1019

1625

2610

6C1

9RE

CTOS

IGMO

ID JU

NCTI

ON-

--

--

--

21

310

916

1429

2811

913

2C2

0RE

CTUM

--

--

-1

11

1223

4176

8082

9211

657

2560

7C2

1AN

US A

ND A

NAL

CANA

L-

--

--

--

-2

25

42

36

45

-33

C21.0

--

--

--

--

22

23

22

41

2-

20C2

1.1-

--

--

--

--

-2

1-

11

2-

-7

C21.8

--

--

--

--

--

1-

--

11

3-

6C2

2LI

VER

AND

INTR

AHEP

ATIC

BIL

E DU

CTS

--

--

--

11

59

914

1218

3051

2420

194

C22.0

--

--

--

--

33

55

66

517

34

57C2

2.1-

--

--

--

--

2-

2-

24

63

-19

C22.7

--

--

--

--

--

1-

21

31

--

8C2

2.9-

--

--

-1

12

43

74

918

2718

1611

0C2

3GA

LLBL

ADDE

R-

--

--

--

--

25

814

3027

3113

813

8C2

4OT

HER

AND

UNSP

ECIF

IED

PART

S OF

BIL

IARY

TRA

CT-

--

--

--

--

-1

75

312

85

142

C24.0

--

--

--

--

--

16

32

74

2-

25C2

4.1-

--

--

--

--

--

1-

13

3-

-8

C24.9

--

--

--

--

--

--

2-

21

31

9C2

5PA

NCRE

AS-

--

--

1-

42

918

4568

6989

9164

2548

5C2

5.0-

--

--

1-

31

610

2743

3948

4330

1226

3C2

5.1-

--

--

--

1-

21

45

510

104

345

C25.2

--

--

--

--

-1

-2

23

13

41

17C2

5.8-

--

--

--

--

-4

97

1110

137

-61

C25.9

--

--

--

--

1-

33

1111

2022

199

99C2

6OT

HER

AND

ILL-

DEFI

NED

DIGE

STIV

E OR

GANS

--

--

--

--

1-

2-

-2

24

52

18C2

6.0-

--

--

--

--

-1

--

--

21

15

31Part

4NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C26.9

--

--

--

--

1-

1-

-2

22

41

13C3

0NA

SAL

CAVI

TY

AND

MIDD

LE E

AR-

--

--

--

-1

--

--

2-

2-

16

C30.0

--

--

--

--

--

--

-2

-2

-1

5C3

0.1-

--

--

--

-1

--

--

--

--

-1

C31

ACCE

SSOR

Y SI

NUSE

S-

--

--

-1

1-

--

33

-1

11

213

C31.0

--

--

--

-1

--

-2

3-

-1

12

10C3

1.3-

--

--

-1

--

--

--

--

--

-1

C31.8

--

--

--

--

--

-1

--

1-

--

2C3

2LA

RYNX

--

--

--

-1

21

57

74

41

23

37C3

2.0-

--

--

--

11

--

35

22

--

317

C32.1

--

--

--

--

-1

11

11

-1

--

6C3

2.8-

--

--

--

-1

-1

11

1-

--

-5

C32.9

--

--

--

--

--

32

--

2-

2-

9C3

3TR

ACHE

A-

--

--

--

--

--

11

-1

--

-3

C34

BRON

CHUS

AND

LUN

G-

--

--

14

1117

4262

7911

186

102

7350

2266

0C3

4.0-

--

--

--

23

66

811

313

94

166

C34.1

--

--

--

23

815

3135

4741

3725

108

262

C34.2

--

--

--

1-

-5

49

95

95

43

54C3

4.3-

--

--

11

41

1012

1025

2221

1911

-13

7C3

4.8-

--

--

--

--

21

24

4-

13

-17

C34.9

--

--

--

-2

54

815

1511

2214

1810

124

C37

THYM

US-

--

--

--

--

-1

11

1-

1-

-5

C38

HEAR

T, ME

DIAS

TINU

M, A

ND

PLEU

RA

-1

--

--

11

-1

1-

22

32

3-

17C3

8.1-

--

--

-1

1-

--

--

--

-1

-3

C38.2

-1

--

--

--

--

--

--

1-

--

2C3

8.3-

--

--

--

--

11

-2

12

--

-7

C38.4

--

--

--

--

--

--

-1

-2

2-

5C3

9OT

HER

AND

ILL-

DEFI

NED

SITE

S W

ITHI

N RE

SPIR

ATOR

Y SY

STEM

AN

D IN

TRAT

HORA

CIC

ORGA

NS-

--

--

--

--

1-

--

--

--

-1

C39.9

--

--

--

--

-1

--

--

--

--

1C4

0BO

NES,

JOIN

TS A

ND

ARTI

CULA

R CA

RTIL

AGE

OF

LIMB

S-

-3

-3

--

-1

2-

-2

-2

12

-16

C40.0

--

--

1-

--

--

--

--

11

--

3C4

0.1-

--

--

--

--

--

--

-1

--

-1

C40.2

--

3-

1-

--

12

--

1-

--

1-

9C4

0.3-

--

-1

--

--

--

--

--

--

-1

32 Part

5NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C40.9

--

--

--

--

--

--

1-

--

1-

2C4

1BO

NES,

JOIN

TS A

ND A

RTIC

ULAR

CA

RTILA

GE O

F OTH

ER A

ND

UNSP

ECIFI

ED S

ITES

-1

21

11

2-

-1

22

2-

-4

3-

22C4

1.0-

--

-1

--

--

--

-1

--

3-

-5

C41.2

--

--

--

1-

--

--

--

--

--

1C4

1.3-

1-

1-

-1

--

11

-1

--

--

-6

C41.4

--

1-

-1

--

--

12

--

--

--

5C4

1.9-

-1

--

--

--

--

--

--

13

-5

C43

MELA

NOMA

OF

SKIN

--

-1

15

1011

1311

1417

3122

1923

88

194

C43.0

--

--

--

--

1-

--

--

--

--

1C4

3.1-

--

--

--

--

--

--

--

-1

-1

C43.2

--

--

--

--

--

--

1-

--

--

1C4

3.3-

--

--

--

--

--

42

12

31

-13

C43.4

--

--

11

--

4-

--

-1

1-

--

8C4

3.5-

--

--

25

43

45

37

93

32

252

C43.6

--

-1

-1

-1

22

32

81

54

21

33C4

3.7-

--

--

15

32

43

711

107

91

366

C43.8

--

--

--

--

-1

--

--

--

--

1C4

3.9-

--

--

--

31

-3

12

-1

41

218

C44

OTHE

R SK

IN-

--

-3

112

2340

5672

135

225

238

369

429

278

193

2074

C44.0

--

--

--

--

-1

22

45

106

85

43C4

4.1-

--

-1

--

-5

48

1519

1329

2211

1113

8C4

4.2-

--

--

--

-1

-1

23

57

916

1054

C44.3

--

--

-1

67

1225

3572

139

142

236

305

188

130

1298

C44.4

--

--

--

32

13

56

1923

2429

156

136

C44.5

--

--

2-

310

1712

1827

2627

3027

149

222

C44.6

--

--

--

-2

16

37

814

1716

1514

103

C44.7

--

--

--

-2

33

-3

77

1511

105

66C4

4.8-

--

--

--

--

--

1-

21

4-

-8

C44.9

--

--

--

--

-2

--

--

--

13

6C4

5ME

SOTH

ELIO

MA-

--

--

--

--

4-

44

73

--

-22

C45.0

--

--

--

--

-4

-3

45

3-

--

19C4

5.1-

--

--

--

--

--

1-

1-

--

-2

C45.7

--

--

--

--

--

--

-1

--

--

1C4

6KA

POSI

’S S

ARCO

MA-

--

--

--

--

-1

--

--

-1

-2

C46.0

--

--

--

--

--

1-

--

--

--

1C4

6.1-

--

--

--

--

--

--

--

-1

-1

33Part

6NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C47

PERI

PHER

AL N

ERVE

S AN

D AU

TONO

MIC

NERV

OUS

SYST

EM-

--

--

--

--

--

-1

-1

1-

14

C47.1

--

--

--

--

--

--

1-

--

--

1C4

7.3-

--

--

--

--

--

--

--

1-

-1

C47.4

--

--

--

--

--

--

--

1-

--

1C4

7.9-

--

--

--

--

--

--

--

--

11

C48

RETR

OPER

ITON

EUM

AND

PERI

TONE

UM2

--

--

11

41

27

84

54

43

349

C48.0

2-

--

-1

14

11

57

44

33

23

41C4

8.1-

--

--

--

--

11

--

11

--

-4

C48.2

--

--

--

--

--

11

--

-1

1-

4C4

9CO

NNEC

TIVE

AND

OTH

ER

SOFT

TIS

SUES

1-

-1

13

46

39

47

76

106

51

74C4

9.0-

--

--

--

--

--

-1

1-

2-

-4

C49.1

--

--

--

--

1-

11

2-

11

1-

8C4

9.2-

--

11

12

4-

22

43

44

22

-32

C49.3

--

--

--

--

11

-1

-1

1-

1-

6C4

9.4-

--

--

--

11

1-

--

-2

-1

-6

C49.5

1-

--

-1

11

-5

1-

--

-1

-1

12C4

9.6-

--

--

1-

--

--

11

--

--

-3

C49.8

--

--

--

1-

--

--

--

--

--

1C4

9.9-

--

--

--

--

--

--

-2

--

-2

C50

BREA

ST-

--

-4

1881

140

216

353

385

495

594

456

419

342

207

9938

09C5

0.0-

--

--

14

108

1420

2728

2522

196

518

9C5

0.1-

--

--

25

1022

3535

4263

2942

2920

1134

5C5

0.2-

--

-2

59

624

1939

3559

4141

3517

433

6C5

0.3-

--

--

-2

65

1522

2922

2716

1911

117

5C5

0.4-

--

-1

843

7111

417

219

423

726

021

317

314

287

3417

49C5

0.5-

--

-1

16

1313

2424

3739

3537

2714

427

5C5

0.6-

--

--

-1

-1

21

24

-2

-1

115

C50.8

--

--

-1

620

2654

3763

9369

5947

3322

530

C50.9

--

--

--

54

318

1323

2617

2724

1817

195

C51

VULV

A-

--

--

1-

--

33

1014

1021

2719

911

7C5

1.0-

--

--

--

--

-1

45

511

139

755

C51.1

--

--

--

--

-1

-3

41

-1

11

12C5

1.2-

--

--

--

--

--

1-

-2

-1

-4

C51.8

--

--

--

--

-1

-1

1-

11

31

9C5

1.9-

--

--

1-

--

12

14

47

125

-37

C52

VAGI

NA-

--

1-

--

--

32

33

55

21

-25

C53

CERV

IX U

TERI

--

-2

218

7010

711

914

211

414

512

779

6448

278

1072

34 Part

7NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C53.0

--

--

27

2231

3447

3647

3929

2515

32

339

C53.1

--

-2

-7

3355

5861

5162

4933

2517

184

475

C53.8

--

--

--

12

87

22

22

21

--

29C5

3.9-

--

--

414

1919

2725

3437

1512

156

222

9C5

4CO

RPUS

UTE

RI-

--

-1

41

1137

7514

720

022

019

917

913

255

1712

78C5

4.0-

--

--

--

--

-2

1-

-1

--

-4

C54.1

--

--

12

111

2969

137

186

200

184

165

120

4915

1169

C54.2

--

--

-2

--

53

-9

63

53

11

38C5

4.3-

--

--

--

--

--

-2

2-

--

-4

C54.8

--

--

--

--

11

13

65

43

3-

27C5

4.9-

--

--

--

-2

27

16

54

62

136

C55

UTER

US, N

OS-

--

--

--

2-

26

79

43

66

247

C56

OVAR

Y-

-1

37

1220

3246

7611

412

113

070

9375

4418

862

C57

OTHE

R AN

D UN

SPEC

IFIE

D FE

MALE

GEN

ITAL

ORGA

NS-

--

--

--

-1

22

33

1-

2-

115

C57.0

--

--

--

--

11

23

31

-2

--

13C5

7.2-

--

--

--

--

1-

--

--

--

-1

C57.9

--

--

--

--

--

--

--

--

-1

1C5

8PL

ACEN

TA-

--

--

1-

-1

--

--

--

--

-2

C64

KIDN

EY5

--

--

-5

57

1613

3225

3331

2119

621

8C6

5RE

NAL

PELV

IS-

--

--

--

2-

-1

21

63

54

125

C66

URET

ER-

--

--

--

--

--

1-

13

21

-8

C67

BLAD

DER

--

--

-1

35

119

1727

4252

4561

3618

327

C67.0

--

--

--

-1

1-

41

-9

3-

41

24C6

7.1-

--

--

-1

--

--

11

3-

-1

-7

C67.2

--

--

--

-1

32

38

179

1423

115

96C6

7.3-

--

--

-1

-1

-1

11

35

42

120

C67.4

--

--

--

--

1-

34

46

411

12

36C6

7.5-

--

--

--

--

--

-2

1-

1-

15

C67.6

--

--

--

--

-1

15

57

56

41

35C6

7.8-

--

--

--

-1

42

45

36

55

439

C67.9

--

--

-1

13

42

33

711

811

83

65C6

8OT

HER

AND

UNSP

ECIF

IED

URIN

ARY

ORGA

NS-

--

--

-1

--

--

-1

11

--

37

C68.0

--

--

--

1-

--

--

11

--

-3

6C6

8.9-

--

--

--

--

--

--

-1

--

-1

C69

EYE

AND

ADNE

XA-

--

--

--

--

-3

14

45

-4

-21

C69.0

--

--

--

--

--

--

-1

2-

--

3C6

9.1-

--

--

--

--

--

--

-1

--

-1

C69.3

--

--

--

--

--

1-

32

1-

3-

10

35Part

8NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C69.4

--

--

--

--

--

1-

--

--

--

1C6

9.5-

--

--

--

--

--

--

1-

--

-1

C69.6

--

--

--

--

--

11

1-

--

--

3C6

9.9-

--

--

--

--

--

--

-1

-1

-2

C70

MENI

NGES

--

--

--

--

-2

21

47

44

42

30C7

0.0-

--

--

--

--

22

13

52

1-

-16

C70.9

--

--

--

--

--

--

12

23

42

14C7

1BR

AIN

26

54

35

39

719

2336

3538

3334

2215

299

C71.0

--

--

--

1-

--

1-

11

-4

1-

9C7

1.1-

1-

--

--

42

2-

55

62

32

133

C71.2

--

1-

1-

-3

23

66

1111

55

1-

55C7

1.3-

1-

--

11

11

55

62

53

4-

237

C71.4

--

11

--

--

--

--

-1

31

1-

8C7

1.5-

-1

--

1-

-1

--

--

--

--

-3

C71.6

21

1-

-2

--

-1

1-

12

--

1-

12C7

1.7-

1-

-1

--

--

22

1-

--

--

-7

C71.8

--

11

11

1-

15

69

75

51

11

46C7

1.9-

2-

2-

--

1-

12

98

715

1615

1189

C72

SPIN

AL C

ORD,

CRA

NIAL

NE

RVES

, AND

OTH

ER PA

RTS

OF

CENT

RAL N

ERVO

US S

YSTE

M-

--

--

3-

--

11

1-

--

--

-6

C72.0

--

--

-3

--

--

11

--

--

--

5C7

2.1-

--

--

--

--

1-

--

--

--

-1

C73

THYR

OID

GLAN

D-

--

211

1213

1926

2633

3135

1510

115

125

0C7

4AD

RENA

L GL

AND

--

-1

--

--

1-

-1

21

--

--

6C7

4.1-

--

--

--

--

--

11

--

--

-2

C74.9

--

-1

--

--

1-

--

11

--

--

4C7

5OT

HER

ENDO

CRIN

E GL

ANDS

AN

D RE

LATE

D ST

RUCT

URES

--

--

--

--

1-

-1

--

--

--

2C7

5.0-

--

--

--

-1

--

1-

--

--

-2

C76

OTHE

R AN

D IL

L-DE

FINE

D SI

TES

4-

1-

--

--

-1

--

11

41

21

16C7

6.01

--

--

--

--

--

--

-1

--

-2

C76.1

--

--

--

--

--

--

-1

--

--

1C7

6.23

--

--

--

--

1-

-1

-2

12

111

C76.5

--

1-

--

--

--

--

--

--

--

1C7

6.7-

--

--

--

--

--

--

-1

--

-1

C80

MALI

GNAN

T NE

OPLA

SM

WIT

HOUT

SPE

CIFI

CATI

ON O

F SI

TE-

--

-1

12

46

1825

4362

6391

5969

2947

3C8

1HO

DGKI

N DI

SEAS

E-

21

66

65

62

-4

83

58

4-

167

36 Part

9NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C81.0

--

1-

--

1-

--

--

-1

1-

--

4C8

1.1-

1-

55

42

21

-1

33

12

1-

-31

C81.2

--

-1

12

24

1-

14

-1

33

--

23C8

1.3-

--

--

--

--

-1

--

--

--

-1

C81.9

-1

--

--

--

--

11

-2

2-

-1

8C8

2FO

LLIC

ULAR

NON

-HOD

GKIN

LY

MPHO

MA-

--

--

--

13

23

14

23

51

227

C82.0

--

--

--

--

--

1-

1-

--

--

2C8

2.1-

--

--

--

--

1-

--

-1

1-

-3

C82.2

--

--

--

--

--

2-

21

11

-1

8C8

2.7-

--

--

--

--

--

--

--

-1

-1

C82.9

--

--

--

-1

31

-1

11

13

-1

13C8

3DI

FFUS

E NO

N-HO

DGKI

N LY

MPHO

MA1

1-

-3

41

48

710

1611

2621

117

213

3C8

3.0-

--

--

-1

--

13

52

92

3-

127

C83.1

--

--

--

--

--

-1

-2

2-

--

5C8

3.3-

--

-2

4-

45

65

58

811

62

167

C83.4

--

--

--

--

--

--

-1

2-

--

3C8

3.5-

1-

-1

--

-1

--

-1

11

--

-6

C83.6

--

--

--

--

--

--

--

-1

--

1C8

3.7-

--

--

--

--

--

--

-1

--

-1

C83.8

--

--

--

--

2-

14

-2

2-

5-

16C8

3.91

--

--

--

--

-1

1-

3-

1-

-7

C84

PERI

PHER

AL A

ND C

UTAN

EOUS

T-

CELL

LYMP

HOMA

S-

--

--

--

--

15

--

31

4-

-14

C84.0

--

--

--

--

-1

2-

-1

-1

--

5C8

4.3-

--

--

--

--

--

--

1-

--

-1

C84.4

--

--

--

--

--

3-

-1

13

--

8C8

5OT

HER

AND

UNSP

ECIF

IED

TYPE

S OF

NON

-HOD

GKIN

LY

MPHO

MA-

--

-2

-1

11

55

25

612

84

-52

C85.1

--

--

1-

--

-1

1-

--

15

--

9C8

5.7-

--

--

--

--

-1

1-

1-

1-

-4

C85.9

--

--

1-

11

14

31

55

112

4-

39C8

8MA

LIGN

ANT

IMMU

NOPR

OLIF

ERAT

IVE

DISE

ASES

--

--

--

--

--

--

-1

--

--

1C8

8.9-

--

--

--

--

--

--

1-

--

-1

C90

MULT

IPLE

MYE

LOMA

AND

MA

LIGN

ANT

PLAS

MA C

ELL

NEOP

LASM

S1

--

--

--

-2

49

918

1313

132

286

37Part

10NU

MBER

OF

NEW

CAN

CER

CASE

S BY

PRI

MARY

SIT

ES A

ND A

GE A

T DI

AGNO

SIS

IN B

ULGA

RIA

2009

– FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C90.0

--

--

--

--

22

88

1511

1312

12

74C9

0.11

--

--

--

--

--

--

--

--

-1

C90.2

--

--

--

--

-2

11

32

-1

1-

11C9

1LY

MPHO

ID L

EUKA

EMIA

88

33

2-

-1

15

812

1912

2214

83

129

C91.0

88

33

2-

--

-1

21

11

-1

2-

33C9

1.1-

--

--

--

11

45

915

1019

95

381

C91.3

--

--

--

--

--

--

1-

-2

--

3C9

1.4-

--

--

--

--

--

11

13

--

-6

C91.5

--

--

--

--

--

11

--

-1

--

3C9

1.9-

--

--

--

--

--

-1

--

11

-3

C92

MYEL

OID

LEUK

AEMI

A1

13

13

22

25

62

816

167

115

293

C92.0

11

11

11

1-

31

-4

102

14

21

35C9

2.1-

-1

-1

--

11

3-

34

94

43

-34

C92.4

--

--

--

--

--

--

1-

--

--

1C9

2.5-

--

-1

1-

-1

-2

--

11

--

-7

C92.9

--

1-

--

11

-2

-1

14

13

-1

16C9

3MO

NOCY

TIC

LEUK

AEMI

A-

--

--

--

--

1-

11

-3

1-

-7

C93.0

--

--

--

--

-1

-1

1-

-1

--

4C9

3.1-

--

--

--

--

--

--

-1

--

-1

C93.9

--

--

--

--

--

--

--

2-

--

2C9

4OT

HER

LEUK

AEMI

AS O

F SP

ECIF

IED

CELL

TYP

E-

--

1-

11

--

13

14

22

31

-20

C94.0

--

--

--

--

--

--

-1

-1

--

2C9

4.1-

--

--

11

--

12

-2

12

11

-12

C94.5

--

--

--

--

--

11

1-

--

--

3C9

4.7-

--

1-

--

--

--

-1

--

1-

-3

C95

LEUK

AEMI

A, U

NSPE

CIFI

ED

CELL

TYP

E-

--

-1

--

-1

22

21

11

45

121

C95.0

--

--

1-

--

-2

2-

1-

-2

1-

9C9

5.9-

--

--

--

-1

--

2-

11

24

112

C96

OTHE

R AN

D UN

SPEC

IFIE

D NE

OPLA

SMS

OF LY

MPHO

ID,

BLOO

D FO

RMIN

G AN

D RE

LATE

D TI

SSUE

S-

--

--

1-

--

-1

--

1-

--

14

C96.1

--

--

-1

--

--

--

-1

--

--

2C9

6.2-

--

--

--

--

-1

--

--

--

12

D06

CARC

INOM

A IN

SIT

U OF

CE

RVIX

UTE

RI-

--

38

3151

6451

4022

106

81

-1

-29

6

38

CANC

ER IN

CIDE

NCE

RATE

S PE

R 10

0 000

BY

PRIM

ARY

SITE

S AN

D AG

E AT

DIA

GNOS

IS IN

BUL

GARI

A 20

09 -

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ES

C00-

97AL

L SI

TES

19.7

10.4

8.5

18.5

22.5

38.0

53.8

81.4

131.

627

6.7

534.

084

1.5

1230

.116

26.0

1908

.221

44.9

1978

.817

77.6

494.

728

0.0

C00

LIP

--

--

-0.

40.

3-

-1.

95.

45.

18.

811

.719

.222

.618

.729

.74.

12.

2C0

0.0-

--

--

--

--

--

-0.

9-

-1.

7-

3.0

0.1

0.1

C00.1

--

--

-0.

40.

3-

-1.

95.

45.

17.

911

.118

.521

.017

.323

.83.

92.

1C0

0.4-

--

--

--

--

--

--

0.6

0.7

-1.

43.

00.

10.

1C0

1BA

SE O

F TO

NGUE

--

--

--

-0.

40.

81.

20.

83.

97.

03.

5-

2.5

4.3

6.0

1.3

0.8

C02

OTHE

R AN

D UN

SPEC

IFIE

D PA

RTS

OF T

ONGU

E-

--

--

--

-1.

23.

87.

71.

26.

14.

72.

12.

51.

4-

1.8

1.2

C02.0

--

--

--

--

--

--

0.9

--

--

-0.

10.

0C0

2.1-

--

--

--

-0.

41.

23.

1-

3.1

2.3

0.7

-1.

4-

0.7

0.5

C02.2

--

--

--

--

-1.

21.

20.

8-

0.6

-1.

7-

-0.

30.

2C0

2.3-

--

--

--

--

0.4

0.8

--

0.6

-0.

8-

-0.

10.

1C0

2.4-

--

--

--

--

0.4

--

-0.

6-

--

-0.

10.

0C0

2.8-

--

--

--

--

-0.

80.

40.

4-

--

--

0.1

0.1

C02.9

--

--

--

--

0.8

0.8

1.9

-1.

80.

61.

4-

--

0.4

0.3

C03

GUM

--

--

-0.

4-

0.4

0.4

0.4

3.5

1.6

3.5

2.9

1.4

--

-0.

90.

6C0

3.0-

--

--

--

-0.

40.

4-

-0.

4-

0.7

--

-0.

10.

1C0

3.1-

--

--

0.4

-0.

4-

-3.

51.

22.

22.

90.

7-

--

0.7

0.5

C03.9

--

--

--

--

--

-0.

40.

9-

--

--

0.1

0.1

C04

FLOO

R OF

MOU

TH-

--

--

--

-0.

41.

22.

76.

35.

20.

62.

71.

7-

-1.

20.

8C0

4.0-

--

--

--

--

0.8

0.8

1.2

1.3

-1.

4-

--

0.3

0.2

C04.1

--

--

--

--

--

0.8

0.8

1.3

--

0.8

--

0.2

0.1

C04.8

--

--

--

--

--

-0.

4-

-0.

7-

--

0.1

0.0

C04.9

--

--

--

--

0.4

0.4

1.2

3.9

2.6

0.6

0.7

0.8

--

0.6

0.4

C05

PALA

TE-

--

--

--

--

0.4

1.6

2.0

2.6

1.8

1.4

--

-0.

60.

4C0

5.0-

--

--

--

--

-0.

40.

8-

--

--

-0.

10.

1C0

5.1-

--

--

--

--

-1.

20.

82.

61.

21.

4-

--

0.4

0.3

C05.8

--

--

--

--

-0.

4-

0.4

-0.

6-

--

-0.

10.

1C0

6OT

HER

AND

UNSP

ECIF

IED

PART

S OF

MOU

TH-

--

--

--

--

--

1.6

1.8

2.3

2.1

--

-0.

40.

2C0

6.0-

--

--

--

--

--

0.8

0.9

1.2

1.4

--

-0.

20.

1C0

6.2-

--

--

--

--

--

-0.

4-

--

--

0.0

0.0

C06.8

--

--

--

--

--

-0.

4-

--

--

-0.

00.

0C0

6.9-

--

--

--

--

--

0.4

0.4

1.2

0.7

--

-0.

10.

1C0

7PA

ROTI

D GL

AND

--

--

--

-0.

4-

-1.

62.

41.

32.

92.

15.

04.

36.

00.

90.

5C0

8OT

HER

AND

UNSP

ECIF

IED

MAJO

R SA

LIVA

RY G

LAND

S-

--

--

--

--

-0.

80.

41.

81.

20.

71.

7-

-0.

30.

2C0

8.0-

--

--

--

--

-0.

80.

41.

80.

60.

71.

7-

-0.

30.

2C0

8.9-

--

--

--

--

--

--

0.6

--

--

0.0

0.0

C09

TONS

IL-

--

--

-0.

31.

41.

63.

13.

96.

76.

64.

75.

53.

41.

43.

02.

21.

4C0

9.0-

--

--

--

--

0.4

-0.

40.

40.

6-

--

-0.

10.

1

Part

1

39Part

2CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ESC0

9.1-

--

--

--

0.4

0.4

0.8

0.4

1.2

0.9

1.2

--

--

0.3

0.2

C09.8

--

--

--

0.3

--

0.4

0.4

1.6

1.3

-1.

40.

8-

-0.

40.

2C0

9.9-

--

--

--

1.1

1.2

1.5

3.1

3.5

3.9

2.9

4.1

2.5

1.4

3.0

1.4

0.9

C10

OROP

HARY

NX-

--

--

--

-0.

40.

40.

84.

73.

91.

82.

11.

7-

-0.

90.

5C1

0.0-

--

--

--

--

--

0.8

0.4

--

--

-0.

10.

1C1

0.1-

--

--

--

--

-0.

4-

--

--

--

0.0

0.0

C10.2

--

--

--

--

--

-1.

60.

9-

1.4

--

-0.

20.

1C1

0.3-

--

--

--

--

--

--

--

0.8

--

0.0

0.0

C10.4

--

--

--

--

--

--

-0.

6-

--

-0.

00.

0C1

0.8-

--

--

--

--

0.4

-0.

4-

--

--

-0.

10.

0C1

0.9-

--

--

--

-0.

4-

0.4

2.0

2.6

1.2

0.7

0.8

--

0.5

0.3

C11

NASO

PHAR

YNX

--

-0.

9-

0.7

0.7

-1.

62.

75.

06.

33.

11.

81.

42.

51.

4-

1.7

1.2

C11.0

--

--

--

--

-0.

80.

41.

20.

40.

6-

0.8

--

0.2

0.2

C11.1

--

--

--

--

--

0.8

--

0.6

0.7

0.8

--

0.1

0.1

C11.2

--

--

-0.

4-

-0.

4-

0.8

-0.

9-

-0.

81.

4-

0.2

0.1

C11.3

--

--

--

--

--

-0.

4-

--

--

-0.

00.

0C1

1.8-

--

--

--

--

0.4

0.4

1.2

0.4

0.6

0.7

--

-0.

20.

1C1

1.9-

--

0.9

-0.

40.

7-

1.2

1.5

2.7

3.5

1.3

--

--

-0.

80.

6C1

2PY

RIFO

RM S

INUS

--

--

--

--

-0.

40.

81.

61.

30.

6-

2.5

--

0.4

0.2

C13

HYPO

PHAR

YNX

--

-0.

4-

--

-1.

23.

13.

57.

13.

95.

25.

53.

4-

-1.

91.

2C1

3.0-

--

--

--

--

--

0.8

--

--

--

0.1

0.0

C13.1

--

--

--

--

-0.

80.

80.

40.

92.

3-

0.8

--

0.3

0.2

C13.2

--

-0.

4-

--

-0.

40.

40.

40.

40.

90.

6-

1.7

--

0.3

0.2

C13.8

--

--

--

--

0.4

0.4

0.4

1.6

0.9

--

--

-0.

20.

2C1

3.9-

--

--

--

-0.

41.

51.

93.

91.

32.

35.

50.

8-

-1.

00.

6C1

4OT

HER

AND

ILL-

DEFI

NED

SITE

S IN

LIP,

ORA

L CA

VITY

AN

D PH

ARYN

X-

--

--

--

--

1.5

2.3

0.8

2.2

2.3

--

1.4

-0.

60.

4C1

4.0-

--

--

--

--

1.2

0.8

0.4

-0.

6-

--

-0.

20.

1C1

4.8-

--

--

--

--

0.4

1.6

0.4

2.2

1.8

--

1.4

-0.

40.

3C1

5OE

SOPH

AGUS

--

--

--

-1.

11.

24.

25.

010

.214

.021

.014

.48.

411

.58.

94.

52.

7C1

5.0-

--

--

--

--

0.4

--

0.4

1.2

--

--

0.1

0.1

C15.1

--

--

--

--

0.4

-0.

41.

60.

41.

2-

--

-0.

20.

2C1

5.2-

--

--

--

-0.

40.

80.

4-

0.9

-2.

1-

1.4

3.0

0.3

0.2

C15.3

--

--

--

-0.

4-

0.8

-0.

81.

31.

20.

70.

81.

4-

0.4

0.2

C15.4

--

--

--

--

-1.

20.

82.

01.

82.

92.

10.

8-

-0.

60.

4C1

5.5-

--

--

--

0.4

--

2.3

2.4

5.2

5.8

6.8

2.5

4.3

-1.

40.

8C1

5.8-

--

--

--

--

--

0.8

-0.

61.

4-

--

0.1

0.1

C15.9

--

--

--

-0.

40.

41.

21.

22.

83.

98.

21.

44.

24.

36.

01.

40.

8C1

6ST

OMAC

H0.

5-

--

-0.

41.

42.

58.

110

.825

.539

.461

.710

4.5

122.

714

1.8

142.

495

.128

.015

.0C1

6.0-

--

--

--

-2.

31.

23.

56.

75.

213

.414

.411

.721

.614

.93.

41.

8

40 Part

3CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ESC1

6.1-

--

--

--

--

--

0.8

2.2

1.2

2.7

2.5

1.4

-0.

50.

2C1

6.2-

--

--

-0.

30.

71.

22.

35.

87.

510

.120

.429

.528

.524

.48.

95.

52.

9C1

6.3-

--

--

-0.

30.

42.

32.

34.

25.

512

.716

.417

.821

.825

.96.

04.

62.

5C1

6.4-

--

--

--

--

0.4

1.9

2.4

1.8

2.9

4.8

5.0

1.4

6.0

1.0

0.6

C16.5

--

--

-0.

4-

0.7

0.4

0.4

2.7

5.1

7.0

6.4

6.8

10.9

8.6

3.0

2.2

1.2

C16.6

--

--

--

--

0.8

-0.

81.

21.

88.

26.

88.

47.

23.

01.

40.

7C1

6.8-

--

--

-0.

30.

7-

1.9

2.3

5.9

7.0

20.4

17.1

26.0

12.9

20.8

4.1

2.2

C16.9

0.5

--

--

-0.

3-

1.2

2.3

4.2

4.3

14.0

15.2

22.6

26.8

38.8

32.7

5.3

2.8

C17

SMAL

L IN

TEST

INE

--

--

--

0.7

0.4

0.4

0.4

1.2

1.2

-1.

24.

85.

01.

4-

0.7

0.4

C17.0

--

--

--

--

--

0.4

--

-2.

71.

7-

-0.

20.

1C1

7.1-

--

--

--

-0.

4-

--

-0.

6-

--

-0.

10.

0C1

7.2-

--

--

--

--

-0.

80.

4-

--

0.8

--

0.1

0.1

C17.8

--

--

--

--

--

--

--

0.7

--

-0.

00.

0C1

7.9-

--

--

-0.

70.

4-

0.4

-0.

8-

0.6

1.4

2.5

1.4

-0.

40.

2C1

8CO

LON

--

0.6

-0.

42.

53.

73.

610

.114

.235

.656

.398

.414

2.5

183.

719

3.8

191.

316

0.5

40.4

21.8

C18.0

--

--

-0.

7-

0.4

1.9

0.8

5.0

4.7

13.6

15.8

26.0

17.6

23.0

8.9

4.7

2.6

C18.1

--

0.6

--

--

0.4

--

--

0.4

-0.

7-

--

0.1

0.1

C18.2

--

--

-0.

41.

00.

41.

60.

85.

011

.011

.816

.419

.931

.933

.126

.85.

62.

9C1

8.3-

--

--

-0.

30.

40.

41.

22.

73.

26.

16.

49.

615

.912

.93.

02.

41.

3C1

8.4-

--

-0.

4-

1.0

0.7

1.9

3.5

3.5

3.9

8.3

11.1

18.5

13.4

14.4

11.9

3.6

2.1

C18.5

--

--

--

-0.

40.

81.

95.

03.

57.

49.

312

.36.

77.

217

.82.

71.

6C1

8.6-

--

--

--

0.4

1.2

1.2

2.7

3.5

6.1

7.6

13.7

20.1

10.1

8.9

2.8

1.5

C18.7

--

--

-1.

40.

7-

2.3

3.8

11.6

22.8

37.6

68.9

73.3

66.3

57.5

41.6

15.1

8.2

C18.8

--

--

--

0.3

--

--

-1.

81.

21.

40.

81.

4-

0.3

0.2

C18.9

--

--

--

0.3

0.7

-1.

2-

3.5

5.2

5.8

8.2

21.0

31.6

41.6

3.0

1.4

C19

RECT

OSIG

MOID

JUNC

TION

--

--

-0.

40.

30.

70.

83.

53.

95.

19.

218

.719

.924

.323

.032

.74.

82.

6C2

0RE

CTUM

--

-0.

4-

0.4

0.7

2.5

4.3

8.5

26.3

41.7

69.1

92.8

119.

310

9.0

100.

753

.525

.313

.8C2

1AN

US A

ND A

NAL

CANA

L-

--

--

--

0.4

--

1.6

1.2

0.4

2.9

2.1

0.8

--

0.5

0.3

C21.0

--

--

--

-0.

4-

-1.

20.

8-

1.2

1.4

--

-0.

30.

2C2

1.1-

--

--

--

--

-0.

40.

40.

4-

-0.

8-

-0.

10.

1C2

1.8-

--

--

--

--

--

--

1.8

0.7

--

-0.

10.

1C2

2LI

VER

AND

INTR

AHEP

ATIC

BI

LE D

UCTS

0.5

--

-1.

10.

70.

32.

54.

68.

815

.118

.128

.439

.737

.747

.047

.529

.711

.56.

6C2

2.0-

--

-0.

4-

-0.

72.

32.

75.

07.

110

.114

.617

.817

.611

.56.

04.

12.

4C2

2.1-

--

--

--

-0.

4-

0.8

0.8

2.6

4.1

2.1

0.8

2.9

-0.

60.

4C2

2.3-

--

--

--

--

--

--

--

-1.

4-

0.0

0.0

C22.7

--

--

--

--

--

-1.

62.

62.

91.

41.

71.

4-

0.5

0.3

C22.9

0.5

--

-0.

80.

70.

31.

81.

96.

29.

38.

713

.118

.116

.426

.830

.223

.86.

13.

5C2

3GA

LLBL

ADDE

R-

--

--

-0.

3-

-1.

51.

22.

03.

91.

85.

513

.411

.514

.91.

70.

8C2

4OT

HER

AND

UNSP

ECIF

IED

PART

S OF

BIL

IARY

TRA

CT-

--

--

--

-0.

40.

41.

92.

83.

55.

22.

710

.17.

23.

01.

40.

8C2

4.0-

--

--

--

-0.

40.

40.

82.

01.

81.

22.

76.

71.

4-

0.8

0.4

41Part

4CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ESC2

4.1-

--

--

--

--

-0.

80.

40.

93.

5-

3.4

1.4

3.0

0.5

0.2

C24.9

--

--

--

--

--

0.4

0.4

0.9

0.6

--

4.3

-0.

20.

1C2

5PA

NCRE

AS-

--

0.4

--

0.3

2.5

5.8

12.7

26.3

35.0

41.1

58.4

67.9

79.7

57.5

53.5

18.0

10.1

C25.0

--

-0.

4-

-0.

31.

12.

77.

312

.821

.621

.030

.430

.841

.936

.017

.89.

45.

3C2

5.1-

--

--

--

-0.

80.

42.

73.

94.

45.

28.

213

.44.

36.

02.

01.

0C2

5.2-

--

--

--

0.4

-1.

22.

31.

63.

13.

52.

70.

8-

-0.

90.

6C2

5.8-

--

--

--

0.7

0.8

1.5

3.1

2.4

5.2

3.5

5.5

7.6

2.9

-1.

60.

9C2

5.9-

--

--

--

0.4

1.6

2.3

5.4

5.5

7.4

15.8

20.6

15.9

14.4

29.7

4.1

2.3

C26

OTHE

R AN

D IL

L-DE

FINE

D DI

GEST

IVE

ORGA

NS-

--

--

--

--

--

0.4

--

0.7

0.8

1.4

-0.

10.

1C2

6.0-

--

--

--

--

--

--

-0.

7-

1.4

-0.

10.

0C2

6.9-

--

--

--

--

--

0.4

--

-0.

8-

-0.

10.

0C3

0NA

SAL

CAVI

TY

AND

MIDD

LE E

AR-

--

--

-0.

3-

-0.

40.

41.

20.

91.

20.

70.

81.

43.

00.

40.

2C3

0.0-

--

--

-0.

3-

-0.

40.

40.

80.

91.

20.

70.

81.

43.

00.

40.

2C3

0.1-

--

--

--

--

--

0.4

--

--

--

0.0

0.0

C31

ACCE

SSOR

Y SI

NUSE

S-

--

--

--

0.4

0.4

1.2

1.6

2.8

1.3

3.5

2.7

0.8

4.3

-0.

90.

5C3

1.0-

--

--

--

0.4

0.4

0.8

0.8

2.8

0.9

3.5

2.1

0.8

--

0.7

0.4

C31.8

--

--

--

--

--

0.4

-0.

4-

0.7

-4.

3-

0.2

0.1

C31.9

--

--

--

--

-0.

40.

4-

--

--

--

0.1

0.0

C32

LARY

NX-

--

-0.

40.

4-

1.1

5.0

13.8

37.1

52.0

56.4

50.8

39.1

35.2

24.4

6.0

16.8

10.2

C32.0

--

--

0.4

--

0.4

1.6

5.4

13.1

18.9

22.3

21.0

20.6

14.3

14.4

3.0

6.7

4.0

C32.1

--

--

--

-0.

41.

60.

43.

54.

34.

83.

50.

72.

5-

-1.

30.

8C3

2.2-

--

--

--

--

0.4

0.8

0.4

0.4

--

--

-0.

10.

1C3

2.8-

--

--

0.4

-0.

40.

85.

410

.416

.512

.715

.27.

56.

74.

3-

4.5

2.8

C32.9

--

--

--

--

1.2

2.3

9.3

11.8

16.2

11.1

10.3

11.7

5.8

3.0

4.2

2.5

C33

TRAC

HEA

--

--

--

--

--

-0.

40.

9-

1.4

0.8

--

0.2

0.1

C34

BRON

CHUS

AND

LUN

G-

--

-0.

41.

43.

46.

016

.353

.412

4.4

217.

230

2.2

338.

032

0.1

248.

315

5.3

98.1

88.8

52.2

C34.0

--

--

--

0.3

0.4

3.1

6.9

15.1

29.5

35.9

45.5

37.7

26.8

8.6

3.0

10.8

6.5

C34.1

--

--

0.4

0.7

1.4

3.2

6.2

26.1

58.7

97.6

141.

714

8.9

143.

910

3.2

61.8

38.6

40.0

23.7

C34.2

--

--

-0.

4-

0.4

1.6

3.5

6.6

19.7

25.8

27.4

20.6

26.8

14.4

8.9

7.2

4.1

C34.3

--

--

-0.

40.

31.

43.

57.

724

.739

.459

.066

.066

.544

.530

.214

.917

.010

.0C3

4.8-

--

--

--

-1.

21.

21.

94.

37.

95.

89.

61.

7-

3.0

1.8

1.1

C34.9

--

--

--

1.4

0.7

0.8

8.1

17.4

26.8

31.9

44.4

41.8

45.3

40.3

29.7

12.1

6.8

C37

THYM

US-

--

--

--

0.4

0.4

1.2

-0.

4-

0.6

--

1.4

-0.

20.

2C3

8HE

ART,

MEDI

ASTI

NUM,

AND

PL

EURA

-0.

6-

--

--

0.4

-0.

41.

91.

61.

81.

22.

72.

51.

46.

00.

80.

5C3

8.0-

--

--

--

--

--

0.8

--

0.7

-1.

4-

0.1

0.1

C38.1

-0.

6-

--

--

--

-0.

40.

40.

40.

6-

--

-0.

10.

1C3

8.2-

--

--

--

--

0.4

-0.

4-

-0.

7-

--

0.1

0.1

C38.3

--

--

--

--

--

1.6

-1.

3-

0.7

1.7

-3.

00.

30.

2C3

8.4-

--

--

--

--

--

--

-0.

7-

-3.

00.

10.

0

42 Part

5CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ESC3

8.8-

--

--

--

0.4

--

--

-0.

6-

0.8

--

0.1

0.1

C39

OTHE

R AN

D IL

L-DE

FINE

D SI

TES

WIT

HIN

RESP

IRAT

ORY

SYST

EM A

ND IN

TRAT

HORA

CIC

ORGA

NS-

--

--

--

--

--

--

--

-1.

4-

0.0

0.0

C39.0

--

--

--

--

--

--

--

--

1.4

-0.

00.

0C4

0BO

NES,

JOIN

TS A

ND

ARTI

CULA

R CA

RTIL

AGE

OF

LIMB

S-

--

1.8

1.1

1.1

0.3

--

0.4

0.8

1.2

-1.

8-

1.7

1.4

-0.

60.

5C4

0.0-

--

--

0.7

--

--

0.4

--

0.6

--

--

0.1

0.1

C40.2

--

-1.

81.

10.

40.

3-

--

0.4

1.2

-1.

2-

0.8

1.4

-0.

50.

4C4

0.9-

--

--

--

--

0.4

--

--

-0.

8-

-0.

10.

0C4

1BO

NES,

JOIN

TS A

ND A

RTIC

ULAR

CA

RTILA

GE O

F OTH

ER A

ND

UNSP

ECIFI

ED S

ITES

-1.

2-

1.8

--

0.3

-0.

40.

40.

40.

41.

30.

61.

40.

82.

9-

0.5

0.5

C41.0

--

--

--

--

0.4

--

--

0.6

0.7

--

-0.

10.

1C4

1.1-

--

--

--

--

--

0.4

--

--

--

0.0

0.0

C41.2

--

-0.

4-

--

--

--

--

--

--

-0.

00.

0C4

1.3-

0.6

-1.

4-

-0.

3-

--

--

0.9

--

--

-0.

20.

2C4

1.4-

0.6

--

--

--

--

--

0.4

-0.

7-

1.4

-0.

10.

1C4

1.8-

--

--

--

--

-0.

4-

--

--

--

0.0

0.0

C41.9

--

--

--

--

-0.

4-

--

--

0.8

1.4

-0.

10.

0C4

3ME

LANO

MA O

F SK

IN-

-0.

60.

90.

40.

73.

03.

25.

85.

49.

313

.411

.815

.214

.421

.828

.832

.76.

64.

0C4

3.0-

--

--

--

0.4

--

--

--

--

--

0.0

0.0

C43.1

--

--

--

--

--

--

-0.

60.

7-

--

0.1

0.0

C43.2

--

--

--

--

--

--

--

-1.

7-

-0.

10.

0C4

3.3-

--

--

--

--

0.4

0.4

0.4

0.9

0.6

-1.

72.

96.

00.

30.

2C4

3.4-

--

--

0.4

0.3

0.4

0.4

0.4

1.6

2.0

0.4

1.2

1.4

5.9

4.3

3.0

0.8

0.4

C43.5

--

-0.

40.

40.

41.

71.

83.

12.

75.

06.

77.

08.

88.

96.

712

.923

.83.

52.

1C4

3.6-

--

--

--

-0.

40.

81.

21.

2-

1.2

0.7

1.7

5.8

-0.

50.

3C4

3.7-

-0.

60.

4-

-1.

00.

41.

21.

20.

81.

22.

22.

31.

40.

81.

4-

0.8

0.6

C43.9

--

--

--

-0.

40.

8-

0.4

2.0

1.3

0.6

1.4

3.4

1.4

-0.

50.

3C4

4OT

HER

SKIN

--

-0.

41.

11.

14.

06.

810

.420

.036

.766

.510

8.0

165.

826

1.2

390.

943

2.9

508.

360

.830

.3C4

4.0-

--

--

--

--

-0.

41.

22.

62.

36.

810

.110

.13.

01.

20.

5C4

4.1-

--

-0.

4-

0.3

1.1

0.4

0.4

3.1

7.1

7.9

7.6

14.4

10.1

20.1

6.0

3.1

1.7

C44.2

--

--

--

-0.

4-

0.4

1.6

5.1

4.4

12.8

21.2

39.4

37.4

71.3

4.9

2.2

C44.3

--

-0.

40.

40.

71.

02.

54.

613

.117

.432

.356

.492

.814

0.5

211.

423

8.7

276.

532

.416

.1C4

4.4-

--

--

0.4

0.3

0.7

--

3.9

5.5

14.9

17.5

25.4

36.9

40.3

50.5

5.9

3.0

C44.5

--

--

--

2.0

1.8

3.9

3.5

7.3

10.2

14.9

18.7

35.6

60.4

53.2

65.4

8.8

4.5

C44.6

--

--

--

0.3

0.4

1.2

1.9

1.9

2.0

4.4

8.8

11.6

15.1

27.3

17.8

2.9

1.4

C44.7

--

--

0.4

--

-0.

40.

81.

23.

22.

64.

14.

16.

75.

811

.91.

40.

8

43Part

6CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ESC4

4.8-

--

--

--

--

--

--

1.2

0.7

0.8

--

0.1

0.1

C44.9

--

--

--

--

--

--

--

0.7

--

6.0

0.1

0.0

C45

MESO

THEL

IOMA

--

--

--

-0.

4-

1.5

0.8

1.6

1.8

1.8

4.8

0.8

7.2

3.0

0.9

0.5

C45.0

--

--

--

-0.

4-

1.5

0.8

0.8

1.8

1.2

4.8

-5.

83.

00.

70.

4C4

5.1-

--

--

--

--

--

0.8

-0.

6-

0.8

--

0.1

0.1

C45.9

--

--

--

--

--

--

--

--

1.4

-0.

00.

0C4

6KA

POSI

’S S

ARCO

MA-

--

--

--

--

--

-0.

40.

61.

40.

81.

43.

00.

20.

1C4

6.0-

--

--

--

--

--

--

0.6

0.7

0.8

1.4

3.0

0.1

0.1

C46.9

--

--

--

--

--

--

0.4

-0.

7-

--

0.1

0.0

C47

PERI

PHER

AL N

ERVE

S AN

D AU

TONO

MIC

NERV

OUS

SYST

EM-

--

--

-0.

3-

--

-0.

4-

0.6

--

--

0.1

0.1

C47.3

--

--

--

0.3

--

--

--

0.6

--

--

0.1

0.0

C47.4

--

--

--

--

--

-0.

4-

--

--

-0.

00.

0C4

8RE

TROP

ERIT

ONEU

M AN

D PE

RITO

NEUM

0.5

--

--

0.4

-0.

40.

81.

21.

93.

24.

42.

33.

43.

42.

93.

01.

30.

8C4

8.00.

5-

--

--

-0.

40.

40.

41.

61.

63.

91.

82.

72.

52.

93.

00.

90.

6C4

8.1-

--

--

0.4

--

-0.

4-

--

--

--

-0.

10.

1C4

8.2-

--

--

--

-0.

4-

0.4

1.6

-0.

60.

70.

8-

-0.

20.

2C4

8.8-

--

--

--

--

0.4

--

0.4

--

--

-0.

10.

0C4

9CO

NNEC

TIVE

AND

OTH

ER

SOFT

TIS

SUES

0.5

--

-1.

10.

71.

72.

51.

21.

23.

13.

54.

45.

86.

810

.18.

66.

02.

51.

6C4

9.00.

5-

--

--

0.3

0.4

0.4

0.8

0.4

-0.

91.

20.

72.

51.

4-

0.4

0.3

C49.1

--

--

--

0.3

--

-0.

4-

0.4

-0.

70.

8-

3.0

0.2

0.1

C49.2

--

--

0.4

0.7

0.3

1.1

0.8

-1.

21.

62.

62.

31.

44.

22.

93.

01.

00.

6C4

9.3-

--

--

--

--

-0.

40.

8-

0.6

1.4

-1.

4-

0.2

0.1

C49.4

--

--

0.4

-0.

3-

--

-0.

80.

4-

2.1

0.8

--

0.2

0.2

C49.5

--

--

--

--

-0.

4-

0.4

-1.

8-

0.8

1.4

-0.

20.

1C4

9.6-

--

--

-0.

31.

1-

-0.

4-

--

0.7

0.8

1.4

-0.

20.

1C4

9.9-

--

-0.

4-

--

--

0.4

--

--

--

-0.

10.

1C5

0BR

EAST

--

--

--

0.3

-0.

4-

2.3

3.2

3.1

4.1

4.8

7.6

2.9

6.0

1.4

0.8

C50.0

--

--

--

--

--

0.4

0.8

0.9

1.2

0.7

1.7

1.4

-0.

30.

2C5

0.1-

--

--

--

--

-0.

40.

80.

40.

60.

71.

7-

3.0

0.2

0.1

C50.2

--

--

--

0.3

--

--

-0.

4-

-0.

8-

3.0

0.1

0.1

C50.4

--

--

--

--

0.4

-1.

20.

80.

91.

80.

70.

81.

4-

0.4

0.2

C50.5

--

--

--

--

--

0.4

-0.

4-

0.7

--

-0.

10.

1C5

0.8-

--

--

--

--

--

0.4

-0.

6-

2.5

--

0.1

0.1

C50.9

--

--

--

--

--

-0.

4-

-2.

1-

--

0.1

0.1

C60

PENI

S-

--

--

0.4

--

0.4

1.2

1.2

2.4

4.8

4.1

4.1

4.2

4.3

6.0

1.3

0.8

C60.0

--

--

--

--

-0.

4-

-0.

90.

6-

0.8

-3.

00.

20.

1C6

0.1-

--

--

--

-0.

40.

41.

21.

63.

12.

93.

43.

42.

9-

0.9

0.5

C60.2

--

--

--

--

--

--

0.4

--

--

-0.

00.

0

44 Part

7CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ESC6

0.8-

--

--

--

--

0.4

-0.

4-

-0.

7-

--

0.1

0.1

C60.9

--

--

-0.

4-

--

--

0.4

0.4

0.6

--

1.4

3.0

0.2

0.1

C61

PROS

TATE

GLA

ND-

--

--

--

0.4

0.8

2.7

7.7

29.5

82.2

152.

424

2.6

348.

135

0.9

294.

345

.421

.2C6

2TE

STIS

--

0.6

3.6

7.9

14.0

13.5

13.9

10.1

6.5

4.2

5.1

2.6

2.3

2.1

2.5

4.3

3.0

6.4

5.5

C62.0

--

--

-1.

11.

4-

0.4

0.4

--

--

--

--

0.2

0.2

C62.1

--

0.6

1.4

3.4

6.8

6.1

10.0

4.6

2.7

2.7

2.8

1.8

1.2

1.4

1.7

--

3.3

2.8

C62.9

--

-2.

34.

56.

16.

13.

95.

03.

51.

62.

40.

91.

20.

70.

84.

33.

02.

92.

5C6

3OT

HER

AND

UNSP

ECIF

IED

MALE

GEN

ITAL

ORGA

NS-

--

--

--

--

0.4

-0.

8-

0.6

--

-3.

00.

10.

1C6

3.1-

--

--

--

--

--

--

0.6

--

--

0.0

0.0

C63.2

--

--

--

--

-0.

4-

0.8

--

--

--

0.1

0.1

C63.9

--

--

--

--

--

--

--

--

-3.

00.

00.

0C6

4KI

DNEY

2.1

0.6

--

-1.

41.

42.

86.

210

.818

.623

.630

.249

.041

.832

.724

.435

.712

.47.

7C6

5RE

NAL

PELV

IS-

--

--

-0.

3-

0.8

-1.

62.

05.

71.

86.

25.

04.

33.

01.

30.

7C6

6UR

ETER

--

--

--

--

0.4

-0.

80.

40.

42.

90.

70.

81.

46.

00.

40.

2C6

7BL

ADDE

R-

0.6

--

-1.

12.

45.

07.

722

.725

.952

.483

.510

8.6

130.

215

3.5

122.

210

7.0

32.0

17.7

C67.0

--

--

--

-0.

40.

41.

50.

83.

95.

77.

68.

210

.110

.1-

2.0

1.1

C67.1

--

--

--

--

--

0.8

1.2

2.2

1.2

4.8

4.2

1.4

-0.

70.

4C6

7.2-

--

--

1.1

0.3

1.1

3.5

6.2

7.7

19.7

26.2

35.6

39.1

50.3

43.1

47.6

10.5

5.8

C67.3

--

--

--

-0.

71.

22.

31.

23.

26.

611

.112

.310

.98.

6-

2.5

1.4

C67.4

--

--

--

--

-1.

90.

84.

36.

68.

89.

613

.48.

63.

02.

31.

2C6

7.5-

--

--

--

0.4

--

0.8

2.4

1.3

3.5

3.4

6.7

1.4

8.9

1.0

0.5

C67.6

--

--

--

0.7

1.1

1.6

3.8

6.2

4.7

9.2

8.8

9.6

10.9

7.2

3.0

3.2

1.9

C67.7

--

--

--

--

--

-0.

4-

--

--

-0.

00.

0C6

7.8-

--

--

-0.

30.

4-

2.7

3.5

5.9

8.3

11.1

16.4

16.8

10.1

3.0

3.4

1.8

C67.9

-0.

6-

--

-1.

01.

11.

24.

24.

26.

717

.521

.026

.730

.231

.641

.66.

43.

5C6

8OT

HER

AND

UNSP

ECIF

IED

URIN

ARY

ORGA

NS-

--

--

--

--

--

0.4

--

-1.

7-

-0.

10.

0C6

8.0-

--

--

--

--

--

0.4

--

-1.

7-

-0.

10.

0C6

9EY

E AN

D AD

NEXA

1.6

--

--

--

-0.

81.

21.

20.

41.

83.

50.

71.

72.

96.

00.

80.

6C6

9.0-

--

--

--

-0.

4-

--

-1.

20.

7-

-6.

00.

20.

1C6

9.21.

6-

--

--

--

--

--

0.4

--

--

-0.

10.

2C6

9.3-

--

--

--

--

0.8

0.8

0.4

0.9

0.6

-1.

7-

-0.

30.

2C6

9.4-

--

--

--

--

--

--

1.2

--

1.4

-0.

10.

0C6

9.6-

--

--

--

-0.

4-

0.4

--

0.6

--

1.4

-0.

10.

1C6

9.9-

--

--

--

--

0.4

--

0.4

--

--

-0.

10.

0C7

0ME

NING

ES-

--

--

0.7

--

-0.

41.

20.

83.

51.

2-

3.4

2.9

-0.

60.

4C7

0.0-

--

--

0.4

--

-0.

4-

0.4

1.3

0.6

--

--

0.2

0.1

C70.1

--

--

--

--

--

0.4

--

--

--

-0.

00.

0C7

0.9-

--

--

0.4

--

--

0.8

0.4

2.2

0.6

-3.

42.

9-

0.4

0.2

C71

BRAI

N4.

32.

3-

0.4

1.5

3.6

2.7

5.0

5.0

9.6

12.8

12.2

24.0

23.4

21.9

16.8

8.6

14.9

8.4

6.0

45Part

8CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ESC7

1.00.

5-

--

-0.

4-

0.7

0.4

-0.

80.

40.

40.

60.

7-

--

0.3

0.3

C71.1

--

--

0.4

0.4

1.0

1.1

1.2

1.9

1.9

0.4

3.5

1.2

4.1

0.8

--

1.1

0.8

C71.2

--

--

0.4

0.7

--

1.9

3.1

3.5

2.0

5.7

5.2

2.7

3.4

2.9

-1.

71.

1C7

1.3-

--

--

0.7

0.3

0.4

0.4

1.2

1.2

3.5

1.8

6.4

3.4

2.5

1.4

-1.

20.

8C7

1.4-

--

--

--

--

0.8

0.4

1.2

1.8

-2.

7-

--

0.4

0.2

C71.5

0.5

0.6

--

--

-0.

4-

-0.

8-

0.4

--

--

-0.

20.

2C7

1.61.

61.

2-

0.4

--

0.7

0.4

-0.

40.

8-

0.4

0.6

0.7

--

-0.

40.

5C7

1.7-

--

--

--

0.4

--

-0.

4-

--

--

-0.

10.

0C7

1.80.

5-

--

-1.

10.

71.

1-

1.9

1.6

2.0

3.5

2.3

1.4

1.7

1.4

3.0

1.1

0.8

C71.9

1.1

0.6

--

0.8

0.4

-0.

71.

20.

41.

92.

46.

67.

06.

28.

42.

911

.92.

01.

4C7

2SP

INAL

COR

D, C

RANI

AL

NERV

ES, A

ND O

THER

PART

S OF

CE

NTRA

L NER

VOUS

SYS

TEM

-0.

6-

--

--

--

0.4

0.4

-0.

91.

20.

7-

1.4

-0.

20.

2C7

2.0-

0.6

--

--

--

-0.

40.

4-

0.4

0.6

--

1.4

-0.

20.

1C7

2.5-

--

--

--

--

--

--

0.6

--

--

0.0

0.0

C72.9

--

--

--

--

--

--

0.4

-0.

7-

--

0.1

0.0

C73

THYR

OID

GLAN

D-

--

0.4

1.5

0.4

0.7

2.1

1.9

1.5

2.7

4.7

3.9

4.7

1.4

3.4

1.4

-1.

81.

3C7

4AD

RENA

L GL

AND

1.6

0.6

--

0.4

--

-0.

40.

4-

0.4

0.4

0.6

0.7

0.8

--

0.3

0.4

C74.0

--

--

--

--

--

--

--

-0.

8-

-0.

00.

0C7

4.1-

--

-0.

4-

--

--

--

--

0.7

--

-0.

10.

0C7

4.91.

60.

6-

--

--

-0.

40.

4-

0.4

0.4

0.6

--

--

0.2

0.4

C75

OTHE

R EN

DOCR

INE

GLAN

DS

AND

RELA

TED

STRU

CTUR

ES-

--

-0.

4-

--

--

0.4

--

--

--

-0.

10.

1C7

5.1-

--

--

--

--

-0.

4-

--

--

--

0.0

0.0

C75.3

--

--

0.4

--

--

--

--

--

--

-0.

00.

0C7

6OT

HER

AND

ILL-

DEFI

NED

SITE

S0.

5-

-0.

4-

0.4

--

-0.

40.

4-

0.4

-1.

4-

--

0.2

0.2

C76.0

--

--

--

--

--

--

0.4

--

--

-0.

00.

0C7

6.1-

--

--

--

--

--

--

-0.

7-

--

0.0

0.0

C76.2

0.5

--

0.4

--

--

-0.

40.

4-

--

--

--

0.1

0.2

C76.3

--

--

--

--

--

--

--

0.7

--

-0.

00.

0C7

6.7-

--

--

0.4

--

--

--

--

--

--

0.0

0.0

C80

MALI

GNAN

T NE

OPLA

SM

WIT

HOUT

SPE

CIFI

CATI

ON

OF S

ITE

0.5

--

0.4

-1.

41.

42.

15.

014

.229

.044

.154

.282

.991

.886

.480

.568

.422

.812

.9C8

1HO

DGKI

N DI

SEAS

E1.

1-

2.4

0.9

1.5

1.8

4.4

3.9

1.2

2.7

2.3

2.4

3.1

1.2

4.1

5.0

-6.

02.

32.

0C8

1.00.

5-

0.6

-0.

4-

0.3

0..4

--

0.4

--

--

0.8

--

0.2

0.2

C81.1

--

1.2

-0.

80.

73.

01.

80.

41.

91.

20.

81.

80.

61.

41.

7-

-1.

10.

9C8

1.2-

-0.

60.

40.

40.

71.

01.

80.

40.

40.

81.

21.

30.

60.

70.

8-

3.0

0.7

0.6

C81.3

--

--

--

--

-0.

4-

--

--

--

-0.

00.

0C8

1.90.

5-

-0.

4-

0.4

--

0.4

--

0.4

--

2.1

1.7

-3.

00.

30.

2

46 Part

9CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ESC8

2FO

LLIC

ULAR

NON

-HOD

GKIN

LY

MPHO

MA-

--

0.4

0.4

--

0.4

-0.

40.

83.

21.

81.

82.

12.

52.

9-

0.8

0.5

C82.0

--

--

--

--

--

-0.

4-

--

--

-0.

00.

0C8

2.4-

--

-0.

4-

--

--

-0.

41.

31.

21.

4-

--

0.2

0.2

C82.7

--

--

--

--

--

--

--

0.7

-1.

4-

0.1

0.0

C82.9

--

-0.

4-

--

0.4

-0.

40.

82.

40.

40.

6-

2.5

1.4

-0.

50.

3C8

3DI

FFUS

E NO

N-HO

DGKI

N LY

MPHO

MA-

0.6

1.2

0.9

1.1

0.4

0.7

2.8

1.9

4.2

3.9

4.3

10.5

8.8

14.4

15.9

12.9

8.9

4.0

2.6

C83.0

--

--

--

-1.

11.

20.

81.

20.

42.

61.

83.

44.

21.

4-

0.9

0.5

C83.1

--

--

--

--

--

--

0.4

--

--

-0.

00.

0C8

3.2-

--

--

--

--

--

--

--

0.8

--

0.0

0.0

C83.3

--

0.6

-0.

80.

40.

31.

40.

42.

72.

32.

46.

64.

78.

29.

22.

93.

02.

11.

3C8

3.5-

-0.

60.

90.

4-

0.3

-0.

4-

--

-0.

6-

-1.

4-

0.2

0.2

C83.7

-0.

6-

--

--

--

--

--

--

--

-0.

00.

1C8

3.8-

--

--

--

0.4

-0.

40.

40.

80.

90.

60.

70.

84.

33.

00.

40.

2C8

3.9-

--

--

--

--

0.4

-0.

8-

1.2

2.1

0.8

2.9

3.0

0.3

0.2

C84

PERI

PHER

AL A

ND C

UTAN

EOUS

T-

CELL

LYMP

HOMA

S-

--

--

-0.

3-

0.4

1.9

-0.

40.

41.

21.

42.

52.

93.

00.

50.

3C8

4.0-

--

--

--

-0.

40.

8-

0.4

--

1.4

0.8

2.9

3.0

0.3

0.2

C84.2

--

--

--

--

-1.

2-

-0.

41.

2-

1.7

--

0.2

0.1

C84.5

--

--

--

0.3

--

--

--

--

--

-0.

00.

0C8

5OT

HER

AND

UNSP

ECIF

IED

TYPE

S OF

NON

-HOD

GKIN

LY

MPHO

MA-

0.6

0.6

0.9

0.4

-0.

30.

70.

80.

81.

23.

53.

96.

47.

55.

04.

38.

91.

81.

2C8

5.0-

--

--

--

0.4

--

--

--

--

--

0.0

0.0

C85.1

--

--

--

--

0.4

-0.

40.

80.

40.

61.

4-

--

0.2

0.1

C85.7

--

--

--

0.3

--

-0.

4-

--

1.4

2.5

--

0.2

0.1

C85.9

-0.

60.

60.

90.

4-

-0.

40.

40.

80.

42.

83.

55.

84.

82.

54.

38.

91.

41.

0C8

8MA

LIGN

ANT

IMMU

NOPR

OLIF

ERAT

IVE

DISE

ASES

--

--

--

--

--

--

--

0.7

--

-0.

00.

0C8

8.9-

--

--

--

--

--

--

-0.

7-

--

0.0

0.0

C90

MULT

IPLE

MYE

LOMA

AND

MA

LIGN

ANT

PLAS

MA C

ELL

NEOP

LASM

S-

--

--

--

0.7

0.4

2.3

5.0

3.9

10.1

8.2

8.2

6.7

5.8

8.9

2.6

1.6

C90.0

--

--

--

-0.

4-

1.9

4.2

3.5

8.8

7.6

8.2

5.9

5.8

6.0

2.3

1.4

C90.2

--

--

--

-0.

40.

40.

40.

80.

41.

30.

6-

0.8

-3.

00.

30.

2C9

1LY

MPHO

ID L

EUKA

EMIA

4.8

2.9

2.4

2.3

0.8

1.1

0.3

0.4

1.2

3.1

2.7

5.9

6.1

13.4

16.4

22.6

12.9

11.9

4.5

3.4

C91.0

4.8

2.9

2.4

2.3

0.8

0.7

0.3

-0.

40.

40.

41.

60.

91.

22.

11.

7-

-1.

21.

7C9

1.1-

--

--

0.4

-0.

40.

81.

50.

82.

44.

49.

914

.417

.611

.58.

92.

61.

4

47Part

10CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- MA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STAN

D.RA

TE0-

45-

910

-14

15-1

920

-24

25-2

930

-34

35-3

940

-44

45-4

950

-54

55-5

960

-64

65-6

970

-74

75-7

980

-84

85+

ALL

AG

ESC9

1.4-

--

--

--

--

0.8

1.6

1.2

-1.

2-

1.7

-3.

00.

40.

2C9

1.5-

--

--

--

--

0.4

-0.

8-

--

--

-0.

10.

1C9

1.9-

--

--

--

--

--

-0.

91.

2-

1.7

1.4

-0.

20.

1C9

2MY

ELOI

D LE

UKAE

MIA

0.5

--

0.4

0.8

-1.

71.

10.

82.

33.

92.

45.

710

.56.

210

.910

.13.

02.

61.

6C9

2.00.

5-

-0.

40.

4-

0.3

-0.

40.

40.

40.

42.

23.

52.

14.

24.

3-

0.8

0.5

C92.1

--

--

0.4

-1.

00.

70.

40.

42.

32.

02.

23.

52.

13.

41.

43.

01.

10.

7C9

2.2-

--

--

--

--

--

--

-0.

7-

--

0.0

0.0

C92.5

--

--

--

0.3

0.4

-0.

4-

--

1.2

0.7

1.7

1.4

-0.

20.

1C9

2.7-

--

--

--

--

0.4

--

-0.

6-

-1.

4-

0.1

0.1

C92.9

--

--

--

--

-0.

81.

2-

1.3

1.8

0.7

1.7

1.4

-0.

40.

2C9

3MO

NOCY

TIC

LEUK

AEMI

A-

--

--

--

0.4

--

0.4

1.2

--

0.7

-1.

4-

0.2

0.1

C93.0

--

--

--

-0.

4-

--

0.8

--

0.7

-1.

4-

0.1

0.1

C93.1

--

--

--

--

--

-0.

4-

--

--

-0.

00.

0C9

3.9-

--

--

--

--

-0.

4-

--

--

--

0.0

0.0

C94

OTHE

R LE

UKAE

MIAS

OF

SPEC

IFIE

D CE

LL T

YPE

--

--

--

1.0

-0.

80.

81.

60.

81.

34.

14.

8-

1.4

-0.

80.

5C9

4.0-

--

--

-0.

7-

--

--

0.9

--

--

-0.

10.

1C9

4.1-

--

--

-0.

3-

0.8

0.8

0.8

0.4

0.4

3.5

2.7

-1.

4-

0.5

0.4

C94.3

--

--

--

--

--

0.4

--

--

--

-0.

00.

0C9

4.4-

--

--

--

--

--

--

0.6

--

--

0.0

0.0

C94.5

--

--

--

--

--

-0.

4-

-0.

7-

--

0.1

0.0

C94.7

--

--

--

--

--

0.4

--

-1.

4-

--

0.1

0.1

C95

LEUK

AEMI

A, U

NSPE

CIFI

ED

CELL

TYP

E-

--

--

--

-0.

80.

80.

40.

41.

31.

23.

42.

55.

88.

90.

70.

4C9

5.0-

--

--

--

-0.

4-

--

1.3

-1.

41.

7-

-0.

20.

1C9

5.1-

--

--

--

--

--

--

0.6

--

--

0.0

0.0

C95.9

--

--

--

--

0.4

0.8

0.4

0.4

-0.

62.

10.

85.

88.

90.

50.

2C9

6OT

HER

AND

UNSP

ECIF

IED

NEOP

LASM

S OF

LYMP

HOID

, BL

OOD

FORM

ING

AND

RELA

TED

TISS

UES

0.5

--

--

--

--

--

0.4

--

--

1.4

-0.

10.

1C9

6.10.

5-

--

--

--

--

-0.

4-

--

-1.

4-

0.1

0.1

48

CANC

ER IN

CIDE

NCE

RATE

S PE

R 10

0 000

BY

PRIM

ARY

SITE

S AN

D AG

E AT

DIA

GNOS

IS IN

BUL

GARI

A 20

09 -

FEMA

LES

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C00-

97AL

L SI

TES

14.1

12.2

12.1

13.4

22.9

41.3

91.8

165.

525

3.3

385.

749

4.1

641.

782

4.8

918.

911

15.0

1200

.911

51.0

1097

.342

2.8

220.

6C0

0LI

P-

--

--

-0.

4-

--

0.7

-1.

14.

16.

411

.14.

314

.11.

60.

6C0

0.0-

--

--

--

--

--

--

0.9

-1.

10.

8-

0.1

0.0

C00.1

--

--

--

0.4

--

-0.

7-

1.1

3.2

6.4

10.0

3.4

14.1

1.5

0.5

C01

BASE

OF

TONG

UE-

--

--

0.4

-0.

4-

--

0.4

0.4

0.4

0.5

0.6

2.6

-0.

30.

1C0

2OT

HER

AND

UNSP

ECIF

IED

PART

S OF

TON

GUE

--

--

--

-0.

70.

40.

80.

71.

10.

70.

91.

0-

0.8

3.1

0.5

0.3

C02.1

--

--

--

-0.

40.

4-

0.7

0.7

0.4

0.4

0.5

--

1.6

0.3

0.2

C02.2

--

--

--

-0.

4-

--

--

--

--

-0.

00.

0C0

2.3-

--

--

--

--

0.4

--

0.4

--

--

-0.

10.

0C0

2.8-

--

--

--

--

--

0.4

--

--

--

0.0

0.0

C02.9

--

--

--

--

-0.

4-

--

0.4

0.5

-0.

81.

60.

10.

1C0

3GU

M-

--

--

--

--

-0.

40.

40.

4-

0.5

1.7

0.8

3.1

0.3

0.1

C03.0

--

--

--

--

--

-0.

40.

4-

0.5

0.6

0.8

-0.

10.

1C0

3.1-

--

--

--

--

-0.

4-

--

-1.

1-

3.1

0.1

0.1

C04

FLOO

R OF

MOU

TH-

--

--

--

--

--

0.4

-0.

40.

5-

--

0.1

0.0

C04.0

--

--

--

--

--

--

-0.

4-

--

-0.

00.

0C0

4.8-

--

--

--

--

--

--

-0.

5-

--

0.0

0.0

C04.9

--

--

--

--

--

-0.

4-

--

--

-0.

00.

0C0

5PA

LATE

--

--

--

--

--

0.4

0.4

0.4

-0.

50.

60.

8-

0.2

0.1

C05.0

--

--

--

--

--

0.4

0.4

0.4

--

-0.

8-

0.1

0.1

C05.1

--

--

--

--

--

--

--

0.5

--

-0.

00.

0C0

5.8-

--

--

--

--

--

--

--

0.6

--

0.0

0.0

C06

OTHE

R AN

D UN

SPEC

IFIE

D PA

RTS

OF M

OUTH

--

--

--

--

0.4

0.4

0.4

-0.

4-

0.5

--

-0.

10.

1C0

6.0-

--

--

--

-0.

40.

40.

4-

0.4

--

--

-0.

10.

1C0

6.9-

--

--

--

--

--

--

-0.

5-

--

0.0

0.0

C07

PARO

TID

GLAN

D-

--

--

0.4

--

0.8

--

0.7

-1.

42.

92.

20.

81.

60.

50.

2C0

8OT

HER

AND

UNSP

ECIF

IED

MAJO

R SA

LIVA

RY G

LAND

S-

--

--

--

-0.

40.

40.

41.

10.

70.

4-

1.1

0.8

-0.

30.

2C0

8.0-

--

--

--

-0.

40.

40.

40.

70.

4-

-0.

60.

8-

0.2

0.1

C08.9

--

--

--

--

--

-0.

40.

40.

4-

0.6

--

0.1

0.1

C09

TONS

IL-

--

--

--

0.7

0.8

-0.

7-

0.4

0.4

0.5

-0.

81.

60.

30.

2C0

9.0-

--

--

--

-0.

4-

--

--

--

--

0.0

0.0

C09.1

--

--

--

-0.

4-

--

--

--

--

-0.

00.

0C0

9.9-

--

--

--

0.4

0.4

-0.

7-

0.4

0.4

0.5

-0.

81.

60.

20.

1C1

0OR

OPHA

RYNX

--

--

--

0.4

-0.

40.

40.

4-

-2.

3-

-0.

8-

0.3

0.2

C10.1

--

--

--

--

--

--

-0.

4-

--

-0.

00.

0C1

0.2-

--

--

--

--

--

--

0.9

--

0.8

-0.

10.

0C1

0.4-

--

--

--

--

--

--

0.4

--

--

0.0

0.0

C10.8

--

--

--

--

0.4

-0.

4-

-0.

4-

--

-0.

10.

1

Part

1

49Part

2CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C10.9

--

--

--

0.4

--

0.4

--

--

--

--

0.1

0.0

C11

NASO

PHAR

YNX

--

-0.

50.

40.

40.

71.

10.

41.

52.

21.

1-

-1.

00.

60.

8-

0.7

0.5

C11.0

--

-0.

5-

--

0.4

--

0.7

0.4

--

--

0.8

-0.

20.

1C1

1.1-

--

--

--

--

--

0.4

--

--

--

0.0

0.0

C11.2

--

--

--

0.4

-0.

40.

4-

--

--

0.6

--

0.1

0.1

C11.3

--

--

0.4

--

--

--

--

--

--

-0.

00.

0C1

1.8-

--

--

-0.

40.

4-

0.8

0.4

--

--

--

-0.

10.

1C1

1.9-

--

--

0.4

-0.

4-

0.4

1.1

0.4

--

1.0

--

-0.

20.

2C1

2PY

RIFO

RM S

INUS

--

--

--

--

--

--

--

--

-1.

60.

00.

0C1

3HY

POPH

ARYN

X-

--

--

--

-0.

4-

0.7

0.7

-0.

4-

0.6

--

0.2

0.1

C13.1

--

--

--

--

0.4

--

--

0.4

--

--

0.1

0.0

C13.2

--

--

--

--

--

0.4

--

--

--

-0.

00.

0C1

3.9-

--

--

--

--

-0.

40.

7-

--

0.6

--

0.1

0.1

C14

OTHE

R AN

D IL

L-DE

FINE

D SI

TES

IN L

IP, O

RAL

CAVI

TY

AND

PHAR

YNX

--

--

--

--

0.4

--

-0.

4-

-0.

6-

1.6

0.1

0.1

C14.0

--

--

--

--

--

--

0.4

--

0.6

-1.

60.

10.

0C1

4.8-

--

--

--

-0.

4-

--

--

--

--

0.0

0.0

C15

OESO

PHAG

US-

--

--

--

0.4

0.4

0.8

1.5

1.8

4.8

1.8

2.9

3.9

2.6

6.3

1.3

0.6

C15.0

--

--

--

--

--

--

0.4

--

--

-0.

00.

0C1

5.1-

--

--

--

--

--

0.4

--

--

--

0.0

0.0

C15.2

--

--

--

--

--

--

0.7

--

--

-0.

10.

0C1

5.3-

--

--

--

0.4

-0.

4-

--

-0.

5-

--

0.1

0.1

C15.4

--

--

--

--

0.4

0.4

0.7

0.4

-0.

9-

--

-0.

20.

1C1

5.5-

--

--

--

--

--

0.4

2.6

-0.

50.

60.

83.

10.

30.

2C1

5.8-

--

--

--

--

-0.

4-

--

--

--

0.0

0.0

C15.9

--

--

--

--

--

0.4

0.7

1.1

0.9

2.0

3.3

1.7

3.1

0.6

0.2

C16

STOM

ACH

--

--

0.4

0.4

1.4

4.4

5.5

4.6

9.5

14.1

21.0

39.0

57.3

68.5

64.0

58.0

15.4

6.5

C16.0

--

--

-0.

4-

--

1.1

1.5

1.8

2.2

5.9

5.4

4.4

8.5

3.1

1.6

0.7

C16.1

--

--

--

--

0.4

--

0.4

0.4

0.4

-1.

1-

1.6

0.2

0.1

C16.2

--

--

0.4

-0.

40.

4-

0.4

1.8

2.8

4.4

7.7

17.6

15.6

10.2

9.4

3.3

1.3

C16.3

--

--

--

0.7

0.7

2.4

0.4

2.6

2.5

3.7

7.7

9.8

10.0

8.5

4.7

2.6

1.2

C16.4

--

--

--

-0.

40.

4-

-0.

40.

70.

92.

43.

30.

8-

0.5

0.2

C16.5

--

--

--

--

0.8

0.4

0.7

1.8

1.1

3.2

3.9

3.3

2.6

4.7

1.0

0.5

C16.6

--

--

--

0.4

-0.

4-

-0.

71.

10.

90.

54.

42.

6-

0.5

0.2

C16.8

--

--

--

-1.

80.

81.

10.

71.

84.

07.

36.

410

.66.

89.

42.

31.

0C1

6.9-

--

--

--

1.1

0.4

1.1

2.2

2.1

3.3

5.0

11.3

15.6

23.9

25.1

3.4

1.3

C17

SMAL

L IN

TEST

INE

--

--

0.4

--

0.4

-0.

8-

0.4

0.4

0.9

1.0

1.1

2.6

3.1

0.4

0.2

C17.0

--

--

--

-0.

4-

--

-0.

4-

0.5

0.6

0.8

-0.

10.

1C1

7.1-

--

-0.

4-

--

--

-0.

4-

--

--

3.1

0.1

0.1

50 Part

3CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C17.2

--

--

--

--

-0.

4-

--

--

--

-0.

00.

0C1

7.9-

--

--

--

--

0.4

--

-0.

90.

50.

61.

7-

0.2

0.1

C18

COLO

N-

--

--

0.4

2.5

4.4

7.0

11.8

36.5

36.8

61.8

82.6

102.

811

1.4

131.

411

2.9

32.2

14.2

C18.0

--

--

-0.

40.

41.

10.

42.

34.

45.

06.

612

.714

.218

.921

.315

.74.

62.

0C1

8.1-

--

--

-0.

7-

0.4

--

0.4

-0.

9-

-0.

8-

0.2

0.1

C18.2

--

--

--

0.7

0.4

2.0

0.8

3.6

5.0

8.4

12.7

19.6

21.2

21.3

7.8

4.9

2.1

C18.3

--

--

--

0.4

-0.

41.

11.

81.

84.

82.

79.

35.

66.

04.

71.

90.

8C1

8.4-

--

--

--

0.4

0.4

1.1

5.1

3.9

5.9

5.0

10.3

10.0

11.1

11.0

3.0

1.3

C18.5

--

--

--

--

0.4

0.4

3.6

2.1

2.9

5.9

5.9

2.2

6.0

4.7

1.7

0.8

C18.6

--

--

--

-0.

70.

41.

14.

81.

84.

44.

17.

47.

26.

86.

32.

21.

0C1

8.7-

--

--

-0.

41.

82.

74.

611

.316

.326

.834

.026

.437

.335

.822

.010

.95.

1C1

8.8-

--

--

--

--

-0.

40.

40.

4-

0.5

-0.

8-

0.1

0.1

C18.9

--

--

--

--

-0.

41.

50.

41.

54.

59.

38.

921

.340

.82.

70.

9C1

9RE

CTOS

IGMO

ID JU

NCTI

ON-

--

--

--

0.7

0.4

1.1

3.6

3.2

5.9

6.4

14.2

15.6

9.4

14.1

3.4

1.4

C20

RECT

UM-

--

--

0.4

0.4

0.4

4.7

8.7

15.0

26.9

29.4

37.2

45.0

64.6

48.6

39.2

15.5

7.0

C21

ANUS

AND

ANA

L CA

NAL

--

--

--

--

0.8

0.8

1.8

1.4

0.7

1.4

2.9

2.2

4.3

-0.

80.

4C2

1.0-

--

--

--

-0.

80.

80.

71.

10.

70.

92.

00.

61.

7-

0.5

0.3

C21.1

--

--

--

--

--

0.7

0.4

-0.

40.

51.

1-

-0.

20.

1C2

1.8-

--

--

--

--

-0.

4-

--

0.5

0.6

2.6

-0.

20.

1C2

2LI

VER

AND

INTR

AHEP

ATIC

BI

LE D

UCTS

--

--

--

0.4

0.4

2.0

3.4

3.3

5.0

4.4

8.2

14.7

28.4

20.5

31.4

5.0

2.0

C22.0

--

--

--

--

1.2

1.1

1.8

1.8

2.2

2.7

2.4

9.5

2.6

6.3

1.5

0.7

C22.1

--

--

--

--

-0.

8-

0.7

-0.

92.

03.

32.

6-

0.5

0.2

C22.7

--

--

--

--

--

0.4

-0.

70.

41.

50.

6-

-0.

20.

1C2

2.9-

--

--

-0.

40.

40.

81.

51.

12.

51.

54.

18.

815

.015

.425

.12.

81.

0C2

3GA

LLBL

ADDE

R-

--

--

--

--

0.8

1.8

2.8

5.2

13.6

13.2

17.3

11.1

12.5

3.5

1.4

C24

OTHE

R AN

D UN

SPEC

IFIE

D PA

RTS

OF B

ILIA

RY T

RACT

--

--

--

--

--

0.4

2.5

1.8

1.4

5.9

4.4

4.3

1.6

1.1

0.4

C24.0

--

--

--

--

--

0.4

2.1

1.1

0.9

3.4

2.2

1.7

-0.

60.

3C2

4.1-

--

--

--

--

--

0.4

-0.

41.

51.

7-

-0.

20.

1C2

4.9-

--

--

--

--

--

-0.

7-

1.0

0.6

2.6

1.6

0.2

0.1

C25

PANC

REAS

--

--

-0.

4-

1.5

0.8

3.4

6.6

15.9

25.0

31.3

43.6

50.7

54.6

39.2

12.4

5.1

C25.0

--

--

-0.

4-

1.1

0.4

2.3

3.6

9.6

15.8

17.7

23.5

23.9

25.6

18.8

6.7

2.9

C25.1

--

--

--

-0.

4-

0.8

0.4

1.4

1.8

2.3

4.9

5.6

3.4

4.7

1.2

0.5

C25.2

--

--

--

--

-0.

4-

0.7

0.7

1.4

0.5

1.7

3.4

1.6

0.4

0.2

C25.8

--

--

--

--

--

1.5

3.2

2.6

5.0

4.9

7.2

6.0

-1.

60.

6C2

5.9-

--

--

--

-0.

4-

1.1

1.1

4.0

5.0

9.8

12.2

16.2

14.1

2.5

0.9

C26

OTHE

R AN

D IL

L-DE

FINE

D DI

GEST

IVE

ORGA

NS-

--

--

--

-0.

4-

0.7

--

0.9

1.0

2.2

4.3

3.1

0.5

0.2

C26.0

--

--

--

--

--

0.4

--

--

1.1

0.8

1.6

0.1

0.0

51Part

4CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C26.9

--

--

--

--

0.4

-0.

4-

-0.

91.

01.

13.

41.

60.

30.

1C3

0NA

SAL

CAVI

TY A

NDMI

DDLE

EAR

--

--

--

--

0.4

--

--

0.9

-1.

1-

1.6

0.2

0.1

C30.0

--

--

--

--

--

--

-0.

9-

1.1

-1.

60.

10.

1C3

0.1-

--

--

--

-0.

4-

--

--

--

--

0.0

0.0

C31

ACCE

SSOR

Y SI

NUSE

S-

--

--

-0.

40.

4-

--

1.1

1.1

-0.

50.

60.

83.

10.

30.

2C3

1.0-

--

--

--

0.4

--

-0.

71.

1-

-0.

60.

83.

10.

30.

1C3

1.3-

--

--

-0.

4-

--

--

--

--

--

0.0

0.0

C31.8

--

--

--

--

--

-0.

4-

-0.

5-

--

0.1

0.0

C32

LARY

NX-

--

--

--

0.4

0.8

0.4

1.8

2.5

2.6

1.8

2.0

0.6

1.7

4.7

1.0

0.5

C32.0

--

--

--

-0.

40.

4-

-1.

11.

80.

91.

0-

-4.

70.

40.

2C3

2.1-

--

--

--

--

0.4

0.4

0.4

0.4

0.4

-0.

6-

-0.

20.

1C3

2.8-

--

--

--

-0.

4-

0.4

0.4

0.4

0.4

--

--

0.1

0.1

C32.9

--

--

--

--

--

1.1

0.7

--

1.0

-1.

7-

0.2

0.1

C33

TRAC

HEA

--

--

--

--

--

-0.

40.

4-

0.5

--

-0.

10.

0C3

4BR

ONCH

US A

ND L

UNG

--

--

-0.

41.

44.

06.

715

.922

.727

.940

.839

.050

.040

.642

.734

.516

.98.

6C3

4.0-

--

--

--

0.7

1.2

2.3

2.2

2.8

4.0

1.4

6.4

5.0

3.4

1.6

1.7

0.9

C34.1

--

--

--

0.7

1.1

3.1

5.7

11.3

12.4

17.3

18.6

18.1

13.9

8.5

12.5

6.7

3.6

C34.2

--

--

--

0.4

--

1.9

1.5

3.2

3.3

2.3

4.4

2.8

3.4

4.7

1.4

0.7

C34.3

--

--

-0.

40.

41.

50.

43.

84.

43.

59.

210

.010

.310

.69.

4-

3.5

1.8

C34.8

--

--

--

--

-0.

80.

40.

71.

51.

8-

0.6

2.6

-0.

40.

2C3

4.9-

--

--

--

0.7

2.0

1.5

2.9

5.3

5.5

5.0

10.8

7.8

15.4

15.7

3.2

1.4

C37

THYM

US-

--

--

--

--

-0.

40.

40.

40.

4-

0.6

--

0.1

0.1

C38

HEAR

T, ME

DIAS

TINU

M, A

ND

PLEU

RA-

0.6

--

--

0.4

0.4

-0.

40.

4-

0.7

0.9

1.5

1.1

2.6

-0.

40.

3C3

8.1-

--

--

-0.

40.

4-

--

--

--

-0.

8-

0.1

0.1

C38.2

-0.

6-

--

--

--

--

--

-0.

5-

--

0.1

0.1

C38.3

--

--

--

--

-0.

40.

4-

0.7

0.4

1.0

--

-0.

20.

1C3

8.4-

--

--

--

--

--

--

0.4

-1.

11.

7-

0.1

0.0

C39

OTHE

R AN

D IL

L-DE

FINE

D SI

TES

WIT

HIN

RESP

IRAT

ORY

SYST

EM A

ND IN

TRAT

HORA

CIC

ORGA

NS-

--

--

--

--

0.4

--

--

--

--

0.0

0.0

C39.9

--

--

--

--

-0.

4-

--

--

--

-0.

00.

0C4

0BO

NES,

JOIN

TS A

ND

ARTI

CULA

R CA

RTIL

AGE

OF

LIMB

S-

-1.

9-

1.2

--

-0.

40.

8-

-0.

7-

1.0

0.6

1.7

-0.

40.

4C4

0.0-

--

-0.

4-

--

--

--

--

0.5

0.6

--

0.1

0.1

C40.1

--

--

--

--

--

--

--

0.5

--

-0.

00.

0C4

0.2-

-1.

9-

0.4

--

-0.

40.

8-

-0.

4-

--

0.8

-0.

20.

3C4

0.3-

--

-0.

4-

--

--

--

--

--

--

0.0

0.0

52 Part

5CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C40.9

--

--

--

--

--

--

0.4

--

-0.

8-

0.1

0.0

C41

BONE

S, JO

INTS

AND

ART

ICUL

AR

CART

ILAGE

OF O

THER

AND

UN

SPEC

IFIED

SITE

S-

0.6

1.3

0.5

0.4

0.4

0.7

--

0.4

0.7

0.7

0.7

--

2.2

2.6

-0.

60.

5C4

1.0-

--

-0.

4-

--

--

--

0.4

--

1.7

--

0.1

0.1

C41.2

--

--

--

0.4

--

--

--

--

--

-0.

00.

0C4

1.3-

0.6

-0.

5-

-0.

4-

-0.

40.

4-

0.4

--

--

-0.

20.

2C4

1.4-

-0.

6-

-0.

4-

--

-0.

40.

7-

--

--

-0.

10.

1C4

1.9-

-0.

6-

--

--

--

--

--

-0.

62.

6-

0.1

0.1

C43

MELA

NOMA

OF

SKIN

--

-0.

50.

41.

93.

54.

05.

14.

25.

16.

011

.410

.09.

312

.86.

812

.55.

02.

9C4

3.0-

--

--

--

-0.

4-

--

--

--

--

0.0

0.0

C43.1

--

--

--

--

--

--

--

--

0.8

-0.

00.

0C4

3.2-

--

--

--

--

--

-0.

4-

--

--

0.0

0.0

C43.3

--

--

--

--

--

-1.

40.

70.

41.

01.

70.

8-

0.3

0.1

C43.4

--

--

0.4

0.4

--

1.6

--

--

0.4

0.5

--

-0.

20.

2C4

3.5-

--

--

0.8

1.8

1.5

1.2

1.5

1.8

1.1

2.6

4.1

1.5

1.7

1.7

3.1

1.3

0.8

C43.6

--

-0.

5-

0.4

-0.

40.

80.

81.

10.

72.

90.

42.

42.

21.

71.

60.

80.

5C4

3.7-

--

--

0.4

1.8

1.1

0.8

1.5

1.1

2.5

4.0

4.5

3.4

5.0

0.8

4.7

1.7

0.9

C43.8

--

--

--

--

-0.

4-

--

--

--

-0.

00.

0C4

3.9-

--

--

--

1.1

0.4

-1.

10.

40.

7-

0.5

2.2

0.8

3.1

0.5

0.2

C44

OTHE

R SK

IN-

--

-1.

20.

44.

28.

415

.721

.326

.347

.782

.710

7.9

180.

723

8.8

237.

230

2.6

53.0

21.6

C44.0

--

--

--

--

-0.

40.

70.

71.

52.

34.

93.

36.

87.

81.

10.

4C4

4.1-

--

-0.

4-

--

2.0

1.5

2.9

5.3

7.0

5.9

14.2

12.2

9.4

17.2

3.5

1.6

C44.2

--

--

--

--

0.4

-0.

40.

71.

12.

33.

45.

013

.615

.71.

40.

4C4

4.3-

--

--

0.4

2.1

2.6

4.7

9.5

12.8

25.5

51.1

64.4

115.

616

9.8

160.

420

3.8

33.2

12.6

C44.4

--

--

--

1.1

0.7

0.4

1.1

1.8

2.1

7.0

10.4

11.8

16.2

12.8

9.4

3.5

1.5

C44.5

--

--

0.8

-1.

13.

76.

74.

66.

69.

69.

612

.214

.715

.012

.014

.15.

73.

0C4

4.6-

--

--

--

0.7

0.4

2.3

1.1

2.5

2.9

6.4

8.3

8.9

12.8

22.0

2.6

1.1

C44.7

--

--

--

-0.

71.

21.

1-

1.1

2.6

3.2

7.4

6.1

8.5

7.8

1.7

0.7

C44.8

--

--

--

--

--

-0.

4-

0.9

0.5

2.2

--

0.2

0.1

C44.9

--

--

--

--

-0.

8-

--

--

-0.

84.

70.

20.

1C4

5ME

SOTH

ELIO

MA-

--

--

--

--

1.5

-1.

41.

53.

21.

5-

--

0.6

0.3

C45.0

--

--

--

--

-1.

5-

1.1

1.5

2.3

1.5

--

-0.

50.

3C4

5.1-

--

--

--

--

--

0.4

-0.

4-

--

-0.

10.

0C4

5.7-

--

--

--

--

--

--

0.4

--

--

0.0

0.0

C46

KAPO

SI S

ARCO

MA-

--

--

--

--

-0.

4-

--

--

0.8

-0.

10.

0C4

6.0-

--

--

--

--

-0.

4-

--

--

--

0.0

0.0

C46.1

--

--

--

--

--

--

--

--

0.8

-0.

00.

0

53Part

6CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C47

PERI

PHER

AL N

ERVE

S AN

D AU

TONO

MIC

NERV

OUS

SYST

EM-

--

--

--

--

--

-0.

4-

0.5

0.6

-1.

60.

10.

0C4

7.1-

--

--

--

--

--

-0.

4-

--

--

0.0

0.0

C47.3

--

--

--

--

--

--

--

-0.

6-

-0.

00.

0C4

7.4-

--

--

--

--

--

--

-0.

5-

--

0.0

0.0

C47.9

--

--

--

--

--

--

--

--

-1.

60.

00.

0C4

8RE

TROP

ERIT

ONEU

M AN

D PE

RITO

NEUM

1.1

--

--

0.4

0.4

1.5

0.4

0.8

2.6

2.8

1.5

2.3

2.0

2.2

2.6

4.7

1.2

0.8

C48.0

1.1

--

--

0.4

0.4

1.5

0.4

0.4

1.8

2.5

1.5

1.8

1.5

1.7

1.7

4.7

1.0

0.7

C48.1

--

--

--

--

-0.

40.

4-

-0.

40.

5-

--

0.1

0.1

C48.2

--

--

--

--

--

0.4

0.4

--

-0.

60.

8-

0.1

0.0

C49

CONN

ECTI

VE A

ND O

THER

SO

FT T

ISSU

ES0.

6-

-0.

50.

41.

11.

42.

21.

23.

41.

52.

52.

62.

74.

93.

34.

31.

61.

91.

2C4

9.0-

--

--

--

--

--

-0.

40.

4-

1.1

--

0.1

0.0

C49.1

--

--

--

--

0.4

-0.

40.

40.

7-

0.5

0.6

0.8

-0.

20.

1C4

9.2-

--

0.5

0.4

0.4

0.7

1.5

-0.

80.

71.

41.

11.

82.

01.

11.

7-

0.8

0.5

C49.3

--

--

--

--

0.4

0.4

-0.

4-

0.4

0.5

-0.

8-

0.2

0.1

C49.4

--

--

--

-0.

40.

40.

4-

--

-1.

0-

0.8

-0.

20.

1C4

9.50.

6-

--

-0.

40.

40.

4-

1.9

0.4

--

--

0.6

-1.

60.

30.

3C4

9.6-

--

--

0.4

--

--

-0.

40.

4-

--

--

0.1

0.1

C49.8

--

--

--

0.4

--

--

--

--

--

-0.

00.

0C4

9.9-

--

--

--

--

--

--

-1.

0-

--

0.1

0.0

C50

BREA

ST-

--

-1.

66.

828

.551

.484

.613

4.0

140.

717

5.0

218.

320

6.8

205.

219

0.4

176.

615

5.2

97.3

55.2

C50.0

--

--

-0.

41.

43.

73.

15.

37.

39.

610

.311

.310

.810

.65.

17.

84.

82.

7C5

0.1-

--

--

0.8

1.8

3.7

8.6

13.3

12.8

14.8

23.2

13.2

20.6

16.2

17.1

17.2

8.8

5.0

C50.2

--

--

0.8

1.9

3.2

2.2

9.4

7.2

14.2

12.4

21.7

18.6

20.1

19.5

14.5

6.3

8.6

4.9

C50.3

--

--

--

0.7

2.2

2.0

5.7

8.0

10.2

8.1

12.2

7.8

10.6

9.4

1.6

4.5

2.4

C50.4

--

--

0.4

3.0

15.1

26.1

44.6

65.3

70.9

83.8

95.6

96.6

84.7

79.1

74.2

53.3

44.7

26.1

C50.5

--

--

0.4

0.4

2.1

4.8

5.1

9.1

8.8

13.1

14.3

15.9

18.1

15.0

12.0

6.3

7.0

3.9

C50.6

--

--

--

0.4

-0.

40.

80.

40.

71.

5-

1.0

-0.

81.

60.

40.

2C5

0.8-

--

--

0.4

2.1

7.3

10.2

20.5

13.5

22.3

34.2

31.3

28.9

26.2

28.2

34.5

13.5

7.5

C50.9

--

--

--

1.8

1.5

1.2

6.8

4.8

8.1

9.6

7.7

13.2

13.4

15.4

26.6

5.0

2.5

C51

VULV

A-

--

--

0.4

--

-1.

11.

13.

55.

24.

510

.315

.016

.214

.13.

01.

1C5

1.0-

--

--

--

--

-0.

41.

41.

82.

35.

47.

27.

711

.01.

40.

5C5

1.1-

--

--

--

--

0.4

-1.

11.

50.

4-

0.6

0.8

1.6

0.3

0.2

C51.2

--

--

--

--

--

-0.

4-

-1.

0-

0.8

-0.

10.

0C5

1.8-

--

--

--

--

0.4

-0.

40.

4-

0.5

0.6

2.6

1.6

0.2

0.1

C51.9

--

--

-0.

4-

--

0.4

0.7

0.4

1.5

1.8

3.4

6.7

4.3

-1.

00.

4C5

2VA

GINA

--

-0.

5-

--

--

1.1

0.7

1.1

1.1

2.3

2.4

1.1

0.8

-0.

60.

4C5

3CE

RVIX

UTE

RI-

--

1.0

0.8

6.8

24.6

39.3

46.6

53.9

41.7

51.3

46.7

35.8

31.3

26.7

23.0

12.5

27.4

18.7

54 Part

7CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C53.0

--

--

0.8

2.6

7.7

11.4

13.3

17.8

13.2

16.6

14.3

13.2

12.2

8.4

2.6

3.1

8.7

5.9

C53.1

--

-1.

0-

2.6

11.6

20.2

22.7

23.2

18.6

21.9

18.0

15.0

12.2

9.5

15.4

6.3

12.1

8.4

C53.8

--

--

--

0.4

0.7

3.1

2.7

0.7

0.7

0.7

0.9

1.0

0.6

--

0.7

0.6

C53.9

--

--

-1.

54.

97.

07.

410

.29.

112

.013

.66.

85.

98.

45.

13.

15.

83.

8C5

4CO

RPUS

UTE

RI-

--

-0.

41.

50.

44.

014

.528

.553

.770

.780

.990

.387

.773

.546

.926

.632

.617

.3C5

4.0-

--

--

--

--

-0.

70.

4-

-0.

5-

--

0.1

0.1

C54.1

--

--

0.4

0.8

0.4

4.0

11.4

26.2

50.1

65.8

73.5

83.4

80.8

66.8

41.8

23.5

29.9

15.8

C54.2

--

--

-0.

8-

-2.

01.

1-

3.2

2.2

1.4

2.4

1.7

0.8

1.6

1.0

0.6

C54.3

--

--

--

--

--

--

0.7

0.9

--

--

0.1

0.1

C54.8

--

--

--

--

0.4

0.4

0.4

1.1

2.2

2.3

2.0

1.7

2.6

-0.

70.

3C5

4.9-

--

--

--

-0.

80.

82.

60.

42.

22.

32.

03.

31.

71.

60.

90.

5C5

5UT

ERUS

, NOS

--

--

--

-0.

7-

0.8

2.2

2.5

3.3

1.8

1.5

3.3

5.1

3.1

1.2

0.6

C56

OVAR

Y-

-0.

61.

42.

84.

67.

011

.718

.028

.841

.742

.847

.831

.845

.541

.837

.528

.222

.013

.0C5

7OT

HER

AND

UNSP

ECIF

IED

FEMA

LE G

ENITA

L OR

GANS

--

--

--

--

0.4

0.8

0.7

1.1

1.1

0.4

-1.

1-

1.6

0.4

0.2

C57.0

--

--

--

--

0.4

0.4

0.7

1.1

1.1

0.4

-1.

1-

-0.

30.

2C5

7.2-

--

--

--

--

0.4

--

--

--

--

0.0

0.0

C57.9

--

--

--

--

--

--

--

--

-1.

60.

00.

0C5

8PL

ACEN

TA-

--

--

0.4

--

0.4

--

--

--

--

-0.

10.

1C6

4KI

DNEY

2.8

--

--

-1.

81.

82.

76.

14.

811

.39.

215

.015

.211

.716

.29.

45.

63.

1C6

5RE

NAL

PELV

IS-

--

--

--

0.7

--

0.4

0.7

0.4

2.7

1.5

2.8

3.4

1.6

0.6

0.3

C66

URET

ER-

--

--

--

--

--

0.4

-0.

41.

51.

10.

8-

0.2

0.1

C67

BLAD

DER

--

--

-0.

41.

11.

84.

33.

46.

29.

615

.423

.622

.034

.030

.728

.28.

43.

8C6

7.0-

--

--

--

0.4

0.4

-1.

50.

4-

4.1

1.5

-3.

41.

60.

60.

3C6

7.1-

--

--

-0.

4-

--

-0.

40.

41.

4-

-0.

8-

0.2

0.1

C67.2

--

--

--

-0.

41.

20.

81.

12.

86.

24.

16.

912

.89.

47.

82.

41.

0C6

7.3-

--

--

-0.

4-

0.4

-0.

40.

40.

41.

42.

42.

21.

71.

60.

50.

2C6

7.4-

--

--

--

-0.

4-

1.1

1.4

1.5

2.7

2.0

6.1

0.8

3.1

0.9

0.4

C67.5

--

--

--

--

--

--

0.7

0.4

-0.

6-

1.6

0.1

0.1

C67.6

--

--

--

--

-0.

40.

41.

81.

83.

22.

43.

33.

41.

60.

90.

4C6

7.8-

--

--

--

-0.

41.

50.

71.

41.

81.

42.

92.

84.

36.

31.

00.

5C6

7.9-

--

--

0.4

0.4

1.1

1.6

0.8

1.1

1.1

2.6

5.0

3.9

6.1

6.8

4.7

1.7

0.8

C68

OTHE

R AN

D UN

SPEC

IFIE

D UR

INAR

Y OR

GANS

--

--

--

0.4

--

--

-0.

40.

40.

5-

-4.

70.

20.

1C6

8.0-

--

--

-0.

4-

---

--

0.4

0.4

--

-4.

70.

20.

1C6

8.9-

--

--

--

--

--

--

-0.

5-

--

0.0

0.0

C69

EYE

AND

ADNE

XA-

--

--

--

--

-1.

10.

41.

51.

82.

4-

3.4

-0.

50.

2C6

9.0-

--

--

--

--

--

--

0.4

1.0

--

-0.

10.

0C6

9.1-

--

--

--

--

--

--

-0.

5-

--

0.0

0.0

C69.3

--

--

--

--

--

0.4

-1.

10.

90.

5-

2.6

-0.

30.

1

55Part

8CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C69.4

--

--

--

--

--

0.4

--

--

--

-0.

00.

0C6

9.5-

--

--

--

--

--

-0.

4-

--

-0.

00.

0C6

9.6-

--

--

--

--

-0.

40.

40.

4-

--

--

0.1

0.1

C69.9

--

--

--

--

--

--

--

0.5

-0.

8-

0.1

0.0

C70

MENI

NGES

--

--

--

--

-0.

80.

70.

41.

53.

22.

02.

23.

43.

10.

80.

3C7

0.0-

--

--

--

--

0.8

0.7

0.4

1.1

2.3

1.0

0.6

--

0.4

0.2

C70.9

--

--

--

--

--

--

0.4

0.9

1.0

1.7

3.4

3.1

0.4

0.1

C71

BRAI

N1.

13.

73.

21.

91.

21.

91.

13.

32.

77.

28.

412

.712

.917

.216

.218

.918

.823

.57.

64.

8C7

1.0-

--

--

-0.

4-

--

0.4

-0.

40.

4-

2.2

0.8

-0.

20.

1C7

1.1-

0.6

--

--

-1.

50.

80.

8-

1.8

1.8

2.7

1.0

1.7

1.7

1.6

0.8

0.5

C71.2

--

0.6

-0.

4-

-1.

10.

81.

12.

22.

14.

05.

02.

42.

80.

8-

1.4

0.9

C71.3

-0.

6-

--

0.4

0.4

0.4

0.4

1.9

1.8

2.1

0.7

2.3

1.5

2.2

-3.

11.

00.

6C7

1.4-

-0.

60.

5-

--

--

--

--

0.4

1.5

0.6

0.8

-0.

20.

2C7

1.5-

-0.

6-

-0.

4-

-0.

4-

--

--

--

--

0.1

0.1

C71.6

1.1

0.6

0.6

--

0.8

--

-0.

40.

4-

0.4

0.9

--

0.8

-0.

30.

4C7

1.7-

0.6

--

0.4

--

--

0.8

0.7

0.4

--

--

--

0.2

0.2

C71.8

--

0.6

0.5

0.4

0.4

0.4

-0.

41.

92.

23.

22.

62.

32.

40.

60.

81.

61.

20.

8C7

1.9-

1.2

-1.

0-

--

0.4

-0.

40.

73.

22.

93.

27.

48.

912

.817

.22.

31.

0C7

2SP

INAL

COR

D, C

RANI

AL

NERV

ES, A

ND O

THER

PART

S OF

CE

NTRA

L NER

VOUS

SYS

TEM

--

--

-1.

1-

--

0.4

0.4

0.4

--

--

--

0.2

0.2

C72.0

--

--

-1.

1-

--

-0.

40.

4-

--

--

-0.

10.

1C7

2.1-

--

--

--

--

0.4

--

--

--

--

0.0

0.0

C73

THYR

OID

GLAN

D-

--

1.0

4.3

4.6

4.6

7.0

10.2

9.9

12.1

11.0

12.9

6.8

4.9

6.1

4.3

1.6

6.4

4.6

C74

ADRE

NAL

GLAN

D-

--

0.5

--

--

0.4

--

0.4

0.7

0.4

--

--

0.2

0.1

C74.1

--

--

--

--

--

-0.

40.

4-

--

--

0.1

0.0

C74.9

--

-0.

5-

--

-0.

4-

--

0.4

0.4

--

--

0.1

0.1

C75

OTHE

R EN

DOCR

INE

GLAN

DS

AND

RELA

TED

STRU

CTUR

ES-

--

--

--

-0.

4-

-0.

4-

--

--

-0.

10.

0C7

5.0-

--

--

--

-0.

4-

-0.

4-

--

--

-0.

10.

0C7

6OT

HER

AND

ILL-

DEFI

NED

SITE

S2.

2-

0.6

--

--

--

0.4

--

0.4

0.4

2.0

0.6

1.7

1.6

0.4

0.4

C76.0

0.6

--

--

--

--

--

--

-0.

5-

--

0.1

0.1

C76.1

--

--

--

--

--

--

-0.

4-

--

-0.

00.

0C7

6.21.

7-

--

--

--

-0.

4-

-0.

4-

1.0

0.6

1.7

1.6

0.3

0.3

C76.5

--

0.6

--

--

--

--

--

--

--

-0.

00.

1C7

6.7-

--

--

--

--

--

--

-0.

5-

--

0.0

0.0

C80

MALI

GNAN

T NE

OPLA

SM

WIT

HOUT

SPE

CIFI

CATI

ON O

F SI

TE-

--

-0.

40.

40.

71.

52.

46.

89.

115

.222

.828

.644

.632

.858

.945

.512

.15.

3C8

1HO

DGKI

N DI

SEAS

E-

1.2

0.6

2.9

2.4

2.3

1.8

2.2

0.8

-1.

52.

81.

12.

33.

92.

2-

1.6

1.7

1.5

56 Part

9CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C81.0

--

0.6

--

-0.

4-

--

--

-0.

40.

5-

--

0.1

0.1

C81.1

-0.

6-

2.4

2.0

1.5

0.7

0.7

0.4

-0.

41.

11.

10.

41.

00.

6-

-0.

80.

8C8

1.2-

--

0.5

0.4

0.8

0.7

1.5

0.4

-0.

41.

4-

0.4

1.5

1.7

--

0.6

0.4

C81.3

--

--

--

--

--

0.4

--

--

--

-0.

00.

0C8

1.9-

0.6

--

--

--

--

0.4

0.4

-0.

91.

0-

-1.

60.

20.

2C8

2FO

LLIC

ULAR

NON

-HOD

GKIN

LY

MPHO

MA-

--

--

--

0.4

1.2

0.8

1.1

0.4

1.5

0.9

1.5

2.8

0.8

3.1

0.7

0.4

C82.0

--

--

--

--

--

0.4

-0.

4-

--

--

0.1

0.0

C82.1

--

--

--

--

-0.

4-

--

-0.

50.

6-

-0.

10.

0C8

2.2-

--

--

--

--

-0.

7-

0.7

0.4

0.5

0.6

-1.

60.

20.

1C8

2.7-

--

--

--

--

--

--

--

-0.

8-

0.0

0.0

C82.9

--

--

--

-0.

41.

20.

4-

0.4

0.4

0.4

0.5

1.7

-1.

60.

30.

2C8

3DI

FFUS

E NO

N-HO

DGKI

N LY

MPHO

MA0.

60.

6-

-1.

21.

50.

41.

53.

12.

73.

65.

74.

011

.810

.36.

16.

03.

13.

42.

0C8

3.0-

--

--

-0.

4-

-0.

41.

11.

80.

74.

11.

01.

7-

1.6

0.7

0.4

C83.1

--

--

--

--

--

-0.

4-

0.9

1.0

--

-0.

10.

1C8

3.3-

--

-0.

81.

5-

1.5

2.0

2.3

1.8

1.8

2.9

3.6

5.4

3.3

1.7

1.6

1.7

1.1

C83.4

--

--

--

--

--

--

-0.

41.

0-

--

0.1

0.0

C83.5

-0.

6-

-0.

4-

--

0.4

--

-0.

40.

40.

5-

--

0.2

0.2

C83.6

--

--

--

--

--

--

--

-0.

6-

-0.

00.

0C8

3.7-

--

--

--

--

--

--

-0.

5-

--

0.0

0.0

C83.8

--

--

--

--

0.8

-0.

41.

4-

0.9

1.0

-4.

3-

0.4

0.2

C83.9

0.6

--

--

--

--

-0.

40.

4-

1.4

-0.

6-

-0.

20.

2C8

4PE

RIPH

ERAL

AND

CUT

ANEO

US

T-CE

LL LY

MPHO

MAS

--

--

--

--

-0.

41.

8-

-1.

40.

52.

2-

-0.

40.

2C8

4.0-

--

--

--

--

0.4

0.7

--

0.4

-0.

6-

-0.

10.

1C8

4.3-

--

--

--

--

--

--

0.4

--

--

0.0

0.0

C84.4

--

--

--

--

--

1.1

--

0.4

0.5

1.7

--

0.2

0.1

C85

OTHE

R AN

D UN

SPEC

IFIE

D TY

PES

OF N

ON-H

ODGK

IN

LYMP

HOMA

--

--

0.8

-0.

40.

40.

41.

91.

80.

71.

82.

75.

94.

43.

4-

1.3

0.7

C85.1

--

--

0.4

--

--

0.4

0.4

--

-0.

52.

8-

-0.

20.

1C8

5.7-

--

--

--

--

-0.

40.

4-

0.4

-0.

6-

-0.

10.

1C8

5.9-

--

-0.

4-

0.4

0.4

0.4

1.5

1.1

0.4

1.8

2.3

5.4

1.1

3.4

-1.

00.

5C8

8MA

LIGN

ANT

IMMU

NOPR

OLIF

ERAT

IVE

DISE

ASES

--

--

--

--

--

--

-0.

4-

--

-0.

00.

0C8

8.9-

--

--

--

--

--

--

0.4

--

--

0.0

0.0

C90

MULT

IPLE

MYE

LOMA

AND

MA

LIGN

ANT

PLAS

MA C

ELL

NEOP

LASM

S0.

6-

--

--

--

0.8

1.5

3.3

3.2

6.6

5.9

6.4

7.2

1.7

3.1

2.2

1.2

57Part

10CA

NCER

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y SI

TES

AND

AGE

AT D

IAGN

OSIS

IN B

ULGA

RIA

2009

- FE

MALE

S

CODE

ICD-

10SI

TEA

GE

AT D

IAG

NO

SIS

WO

RLD

STA

ND

.R

ATE

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

-79

80-8

485

+A

LLA

GES

C90.0

--

--

--

--

0.8

0.8

2.9

2.8

5.5

5.0

6.4

6.7

0.8

3.1

1.9

0.9

C90.1

0.6

--

--

--

--

--

--

--

--

-0.

00.

1C9

0.2-

--

--

--

--

0.8

0.4

0.4

1.1

0.9

-0.

60.

8-

0.3

0.2

C91

LYMP

HOID

LEU

KAEM

IA4.

54.

91.

91.

40.

8-

-0.

40.

41.

92.

94.

27.

05.

410

.87.

86.

84.

73.

32.

7C9

1.04.

54.

91.

91.

40.

8-

--

-0.

40.

70.

40.

40.

4-

0.6

1.7

-0.

81.

5C9

1.1-

--

--

--

0.4

0.4

1.5

1.8

3.2

5.5

4.5

9.3

5.0

4.3

4.7

2.1

1.0

C91.3

--

--

--

--

--

--

0.4

--

1.1

--

0.1

0.0

C91.4

--

--

--

--

--

-0.

40.

40.

41.

5-

--

0.2

0.1

C91.5

--

--

--

--

--

0.4

0.4

--

-0.

6-

-0.

10.

0C9

1.9-

--

--

--

--

--

-0.

4-

-0.

60.

8-

0.1

0.0

C92

MYEL

OID

LEUK

AEMI

A0.

60.

61.

90.

51.

20.

80.

70.

72.

02.

30.

72.

85.

97.

33.

46.

14.

33.

12.

41.

6C9

2.00.

60.

60.

60.

50.

40.

40.

4-

1.2

0.4

-1.

43.

70.

90.

52.

21.

71.

60.

90.

7C9

2.1-

-0.

6-

0.4

--

0.4

0.4

1.1

-1.

11.

54.

12.

02.

22.

6-

0.9

0.5

C92.4

--

--

--

--

--

--

0.4

--

--

-0.

00.

0C9

2.5-

--

-0.

40.

4-

-0.

4-

0.7

--

0.4

0.5

--

-0.

20.

2C9

2.9-

-0.

6-

--

0.4

0.4

-0.

8-

0.4

0.4

1.8

0.5

1.7

-1.

60.

40.

3C9

3MO

NOCY

TIC

LEUK

AEMI

A-

--

--

--

--

0.4

-0.

40.

4-

1.5

0.6

--

0.2

0.1

C93.0

--

--

--

--

-0.

4-

0.4

0.4

--

0.6

--

0.1

0.1

C93.1

--

--

--

--

--

--

--

0.5

--

-0.

00.

0C9

3.9-

--

--

--

--

--

--

-1.

0-

--

0.1

0.0

C94

OTHE

R LE

UKAE

MIAS

OF

SPEC

IFIE

D CE

LL T

YPE

--

-0.

5-

0.4

0.4

--

0.4

1.1

0.4

1.5

0.9

1.0

1.7

0.8

-0.

50.

3C9

4.0-

--

--

--

--

--

--

0.4

-0.

6-

-0.

10.

0C9

4.1-

--

--

0.4

0.4

--

0.4

0.7

-0.

70.

41.

00.

60.

8-

0.3

0.2

C94.5

--

--

--

--

--

0.4

0.4

0.4

--

--

-0.

10.

1C9

4.7-

--

0.5

--

--

--

--

0.4

--

0.6

--

0.1

0.1

C95

LEUK

AEMI

A, U

NSPE

CIFI

ED

CELL

TYP

E-

--

-0.

4-

--

0.4

0.8

0.7

0.7

0.4

0.4

0.5

2.2

4.3

1.6

0.5

0.2

C95.0

--

--

0.4

--

--

0.8

0.7

-0.

4-

-1.

10.

8-

0.2

0.1

C95.9

--

--

--

--

0.4

--

0.7

-0.

40.

51.

13.

41.

60.

30.

1C9

6OT

HER

AND

UNSP

ECIF

IED

NEOP

LASM

S OF

LYMP

HOID

, BL

OOD

FORM

ING

AND

RELA

TED

TISS

UES

--

--

-0.

4-

--

-0.

4-

-0.

4-

--

1.6

0.1

0.1

C96.1

--

--

-0.

4-

--

--

--

0.4

--

--

0.1

0.0

C96.2

--

--

--

--

--

0.4

--

--

--

1.6

0.1

0.0

D06

NOT

INCL

UDED

ABO

VE C

A IN

SI

TU O

F CE

RVIX

UTE

RI-

--

1.4

3.2

11.7

17.9

23.5

20.0

15.2

8.0

3.5

2.2

3.6

0.5

-0.

8-

7.6

6.7

58

C00 -

97AL

L SI

TES

184.

717

7.8

186.

618

7.6

189.

619

9.7

197.

420

8.0

197.

323

9.7

234.

423

5.2

233.

823

9.7

243.

225

4.5

257.

826

0.7

269.

827

8.2

280.

0C0

0LIP

7.6

6.3

5.6

4.8

4.4

4.4

4.1

3.4

3.3

3.7

3.6

3.1

2.5

2.6

2.4

2.5

2.4

2.0

2.2

2.0

2.2

C01-

02TO

NGUE

0.5

0.9

1.1

2.0

1.6

1.6

1.7

1.8

1.9

2.0

1.7

1.8

1.9

1.9

1.9

1.9

1.7

2.3

1.8

1.7

2.0

C03

GUM

0.3

0.3

0.2

0.6

0.5

0.4

0.4

0.4

0.6

0.6

0.4

0.5

0.3

0.4

0.5

0.4

0.3

0.4

0.6

0.6

0.6

C04

MOUT

H0.

10.

30.

60.

70.

50.

80.

60.

90.

70.

90.

80.

71.

00.

70.

80.

90.

80.

90.

90.

80.

8C0

5-06

OTHE

R AN

D UN

SPEC

IFIE

D PA

RTS

OF

MOUT

H0.

20.

30.

40.

50.

60.

50.

60.

50.

60.

50.

50.

80.

90.

70.

50.

50.

60.

60.

40.

80.

6C0

7-08

SALIV

ARY

GLAN

DS0.

70.

40.

50.

80.

70.

60.

60.

70.

60.

70.

40.

50.

80.

70.

80.

70.

91.

00.

70.

70.

7C0

9-10

OROP

HARY

NX0.

50.

70.

91.

21.

11.

31.

21.

51.

51.

91.

71.

81.

71.

81.

41.

22.

12.

12.

12.

32.

0C1

1NA

SOPH

ARYN

X0.

80.

90.

71.

00.

91.

10.

90.

90.

60.

90.

90.

90.

80.

81.

00.

80.

90.

91.

11.

11.

2C1

2-13

HYPO

PHAR

YNX

0.1

0.6

0.6

0.9

1.0

1.1

0.8

1.2

1.0

1.2

0.8

0.9

1.2

1.2

1.3

1.1

1.2

1.2

1.1

1.0

1.4

C14

PHAR

YNX

UNSP

ECIF

IED

0.1

0.1

0.0

0.1

0.1

-0.

00.

10.

10.

10.

20.

20.

20.

20.

10.

10.

30.

10.

30.

40.

4C1

5OE

SOPH

AGUS

1.5

1.0

1.7

1.5

1.7

1.6

1.6

2.2

1.6

2.5

2.5

2.2

2.1

1.8

2.4

2.4

2.3

2.7

2.5

2.7

2.7

C16

STOM

ACH

23.5

18.9

17.7

17.7

16.0

16.3

15.1

17.1

15.6

18.4

16.8

17.4

16.2

16.9

16.9

15.5

16.3

15.3

16.0

15.8

15.0

C17

SMAL

L IN

TEST

INE

0.2

0.1

0.1

0.1

0.2

0.2

0.2

0.1

0.2

0.4

0.2

0.3

0.4

0.4

0.3

0.4

0.5

0.4

0.5

0.4

0.4

C18

COLO

N7.

48.

49.

99.

410

.710

.510

.712

.011

.414

.614

.415

.816

.016

.717

.517

.618

.119

.120

.421

.621

.8C1

9-21

RECT

UM9.

59.

810

.810

.511

.812

.212

.512

.712

.714

.714

.215

.614

.314

.814

.215

.415

.716

.717

.116

.516

.7C2

2LIV

ER4.

93.

93.

84.

14.

54.

04.

04.

73.

86.

26.

95.

75.

05.

55.

25.

55.

86.

66.

05.

66.

6C2

3-24

GALL

BLAD

DER

ETC.

1.1

1.0

0.8

0.9

0.7

0.9

1.0

1.0

0.9

1.3

1.6

1.3

1.2

1.2

1.2

1.4

1.6

1.5

1.6

1.5

1.6

C25

PANC

REAS

5.6

5.5

6.2

6.4

6.6

6.6

6.3

6.6

6.8

9.1

8.4

9.0

8.4

8.0

8.7

9.7

8.2

9.5

9.2

9.9

10.1

C30-

31NO

SE, S

INUS

ES

ETC.

0.4

0.5

0.3

0.3

0.4

0.5

0.3

0.4

0.5

0.4

0.6

0.4

0.4

0.6

0.6

0.6

0.5

0.7

0.5

0.5

0.8

C32

LARY

NX6.

46.

57.

68.

48.

57.

37.

97.

97.

38.

28.

19.

09.

010

.010

.59.

99.

79.

810

.010

.410

.2C3

3-34

BRON

CHUS

, LU

NG39

.138

.840

.441

.842

.344

.743

.243

.841

.552

.847

.550

.348

.348

.351

.350

.250

.949

.451

.253

.452

.3C4

0-41

BONE

0.9

1.0

0.7

0.8

0.8

0.8

1.1

0.9

0.9

0.9

0.8

1.5

1.0

1.3

0.9

1.1

1.5

0.8

1.2

1.0

1.0

C43

MELA

NOMA

OF

SKIN

1.3

1.6

1.5

1.9

2.4

2.6

2.1

2.5

2.3

2.6

3.2

2.4

2.5

2.6

2.8

3.5

2.6

3.1

3.3

3.4

4.0

C44

OTHE

R SK

IN25

.824

.024

.122

.319

.722

.421

.022

.317

.720

.622

.020

.320

.321

.120

.323

.624

.024

.327

.327

.230

.3C4

7,C49

CONN

ECTI

VE

TISS

UE2.

31.

71.

62.

11.

41.

62.

21.

51.

61.

72.

12.

01.

71.

92.

22.

22.

11.

81.

81.

51.

6C5

0BR

EAST

0.2

0.4

0.4

0.4

0.5

0.6

0.6

0.6

0.6

0.5

0.4

0.5

0.5

0.6

0.6

0.6

0.6

0.8

0.6

0.6

0.8

AGE-

ADJU

STED

(WOR

LD S

TAND

ARD)

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y CA

NCER

SITE

S AND

YEA

R OF

DIA

GNOS

IS IN

BUL

GARI

A 19

81-20

09, M

ALES

CODE

IC

D-10

SITE

YEAR

OF

DIAG

NOSI

S19

8119

8519

9019

9119

9319

9419

9519

9619

9719

9819

9920

0020

0120

0220

0320

0420

0520

0620

0720

0820

09

Part

1

59

C61

PROS

TATE

9.0

8.9

10.0

10.0

11.6

12.1

12.3

13.3

14.7

16.7

16.0

16.5

17.1

18.1

18.2

20.5

20.6

18.8

20.1

21.7

21.2

C62

TEST

IS2.

43.

42.

83.

03.

03.

44.

03.

33.

53.

74.

53.

53.

23.

63.

84.

14.

54.

54.

65.

25.

5C6

0,C63

PENI

S ET

C.0.

40.

60.

60.

60.

40.

80.

60.

50.

70.

71.

00.

80.

80.

80.

80.

80.

70.

90.

71.

00.

8C6

7BL

ADDE

R7.

98.

79.

08.

99.

29.

410

.611

.29.

912

.212

.312

.413

.213

.913

.515

.315

.016

.816

.217

.917

.7C6

4-66

, C6

8KI

DNEY

ETC

.2.

32.

32.

83.

13.

54.

14.

04.

83.

85.

55.

76.

05.

86.

25.

87.

08.

27.

58.

68.

48.

7C6

9EY

E0.

30.

30.

40.

50.

40.

50.

50.

40.

40.

40.

70.

30.

50.

40.

40.

60.

40.

40.

40.

40.

6C7

1BR

AIN

3.2

3.0

3.3

3.5

3.5

3.6

4.3

4.2

3.8

5.5

6.0

4.9

6.3

5.5

6.0

6.6

6.5

7.0

6.7

7.5

6.0

C70,C

72OT

HER

PART

S OF

NER

VOUS

SY

STEM

0.3

0.3

0.1

0.1

0.1

0.2

0.3

0.1

0.3

0.6

0.3

0.3

0.4

0.5

0.3

0.4

0.5

0.5

0.4

0.5

0.6

C73

THYR

OID

0.8

0.7

0.7

0.7

0.5

0.8

0.7

0.8

0.8

0.8

0.8

0.9

0.9

0.9

0.8

0.8

1.1

0.8

0.8

0.9

1.3

C74-

75OT

HER

ENDO

CRIN

E GL

ANDS

0.1

0.1

0.1

0.1

0.2

0.3

0.2

0.2

0.1

0.3

0.4

0.3

0.4

0.2

0.2

0.5

0.4

0.4

0.6

0.3

0.4

C76

OTHE

R AN

D ILL

-DE

FINE

D SI

TES

0.3

0.1

0.2

0.2

0.3

0.3

0.3

0.2

0.4

0.2

0.4

0.2

0.1

0.3

0.2

0.2

0.2

0.4

0.2

0.2

0.2

C80

NEOP

LASM

W

ITHO

UT

SPEC

IFIC

ATIO

N OF

SIT

E3.

34.

46.

16.

36.

67.

67.

88.

59.

29.

79.

69.

610

.610

.711

.211

.413

.011

.612

.212

.312

.9C8

1HO

DGKI

N DI

SEAS

E1.

81.

61.

31.

61.

81.

81.

82.

42.

42.

82.

72.

22.

32.

52.

12.

61.

72.

01.

72.

22.

0C8

2-85

, C9

6NO

N-HO

DGKI

N’S

LYMP

HOMA

2.5

2.2

1.7

2.7

2.5

3.1

2.9

3.4

3.1

3.7

4.3

3.6

3.6

4.3

4.0

4.0

3.5

5.0

5.1

4.6

4.6

C88,C

90MU

LTIP

LE

MYEL

OMA

0.8

0.5

0.5

0.6

0.8

0.8

0.9

0.7

0.9

1.2

1.2

1.0

1.1

1.1

1.2

1.4

1.1

1.4

1.5

2.0

1.6

C91

LYMP

HOID

LE

UKAE

MIA

1.9

2.0

1.7

2.1

1.9

1.8

2.1

2.6

2.8

2.9

3.0

2.4

2.8

3.0

3.2

2.8

3.5

4.0

3.9

3.7

3.4

C92

MYEL

OID

LEUK

AEMI

A1.

20.

70.

80.

60.

91.

20.

91.

11.

41.

91.

81.

72.

52.

02.

22.

72.

12.

22.

02.

41.

6C9

3MO

NOCY

TIC

LEUK

AEMI

A0.

0-

0.0

0.0

0.0

0.1

0.0

0.2

0.1

0.2

0.1

0.1

0.2

0.1

0.2

0.1

0.1

0.0

0.1

0.1

0.1

C94

OTHE

R LE

UKAE

MIA

0.2

0.0

0.0

0.0

0.1

0.1

0.1

0.2

0.1

0.2

0.2

0.3

0.4

0.4

0.7

0.6

0.1

0.2

0.5

0.3

0.5

C95

LEUK

AEMI

A,

CELL

UN

SPEC

IFIE

D1.

11.

21.

10.

91.

11.

51.

00.

71.

41.

00.

80.

70.

60.

50.

40.

40.

70.

40.

50.

60.

4C2

6,C37

,C3

8,C39

,C4

5,C46

,C4

8

OTHE

RS A

ND

UNSP

ECIF

IED

SITE

S

1.0

0.4

0.6

0.7

1.2

1.4

1.2

1.4

1.4

2.0

1.8

2.4

2.0

2.1

1.9

1.8

2.4

1.6

2.4

2.3

2.1

Part

2AG

E-AD

JUST

ED (W

ORLD

STA

NDAR

D) IN

CIDE

NCE

RATE

S PE

R 10

0 000

BY

PRIM

ARY

CANC

ER S

ITES A

ND Y

EAR

OF D

IAGN

OSIS

IN B

ULGA

RIA

1981

-2009

, MAL

ESCO

DE

ICD-

10SI

TEYE

AR O

F DI

AGNO

SIS

1981

1985

1990

1991

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

60 Part

1

C00-

C97

ALL

SITE

S15

1.8

150.

015

2.6

154.

615

8.8

167.

116

7.2

175.

216

8.4

186.

719

0.4

183.

619

0.3

192.

919

9.1

205.

820

5.3

212.

721

7.4

222.

422

0.6

C00

LIP1.

21.

11.

10.

90.

90.

70.

70.

70.

90.

70.

80.

60.

50.

40.

50.

70.

50.

60.

50.

40.

6C0

1-02

TONG

UE0.

10.

20.

20.

30.

20.

10.

10.

20.

10.

20.

30.

20.

20.

40.

30.

50.

20.

50.

50.

40.

4C0

3GU

M0.

10.

10.

00.

10.

00.

10.

10.

10.

10.

10.

10.

10.

10.

00.

10.

00.

20.

20.

10.

10.

1C0

4MO

UTH

-0.

00.

00.

00.

00.

0-

0.0

0.0

-0.

10.

10.

10.

10.

10.

00.

00.

10.

10.

10.

0C0

5-06

OTHE

R AN

D UN

SPEC

IFIE

D PA

RTS

OF M

OUTH

0.1

0.1

0.0

0.0

0.1

0.1

0.1

0.1

0.1

0.1

0.2

0.2

0.2

0.2

0.1

0.1

0.2

0.1

0.2

0.1

0.2

C07-

08SA

LIVAR

Y GL

ANDS

0.4

0.4

0.5

0.3

0.6

0.4

0.4

0.2

0.4

0.4

0.2

0.4

0.3

0.4

0.5

0.3

0.4

0.5

0.6

0.6

0.4

C09-

10OR

OPHA

RYNX

0.2

0.1

0.1

0.2

0.1

0.2

0.1

0.1

0.2

0.2

0.2

0.1

0.1

0.2

0.1

0.1

0.2

0.2

0.3

0.3

0.3

C11

NASO

PHAR

YNX

0.4

0.4

0.4

0.4

0.3

0.4

0.2

0.3

0.4

0.4

0.3

0.4

0.2

0.5

0.2

0.4

0.4

0.3

0.5

0.3

0.5

C12-

13HY

POPH

ARYN

X0.

00.

00.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

20.

20.

10.

20.

10.

1C1

4PH

ARYN

X UN

SPEC

IFIE

D0.

10.

0-

0.0

--

0.0

0.0

-0.

00.

10.

00.

10.

10.

00.

00.

00.

10.

10.

00.

1C1

5OE

SOPH

AGUS

0.2

0.4

0.3

0.3

0.3

0.3

0.2

0.3

0.3

0.4

0.5

0.4

0.4

0.6

0.4

0.5

0.4

0.4

0.4

0.4

0.6

C16

STOM

ACH

13.2

10.3

9.0

8.4

8.2

7.9

7.5

7.9

7.2

8.8

8.3

8.4

7.2

8.3

7.2

7.6

7.0

7.3

7.1

7.6

6.5

C17

SMAL

L INT

ESTI

NE0.

10.

10.

00.

10.

10.

10.

10.

10.

20.

20.

10.

20.

30.

10.

20.

20.

20.

30.

20.

40.

2C1

8CO

LON

7.3

7.1

7.7

7.9

8.4

8.3

8.3

9.4

9.0

10.5

10.0

11.2

11.6

12.0

12.5

12.3

13.2

13.4

14.5

14.0

14.2

C19-

21RE

CTUM

6.6

6.6

6.3

7.2

7.0

8.1

7.6

8.4

7.6

8.2

8.8

8.2

8.4

7.9

8.4

8.7

9.0

9.3

8.6

9.2

8.8

C22

LIVER

2.8

1.7

2.0

2.0

1.8

2.1

2.3

2.1

2.2

2.8

3.1

2.8

2.0

2.1

2.2

2.1

2.4

2.4

2.4

2.2

2.0

C23-

24GA

LLBL

ADDE

R ET

C.2.

32.

21.

71.

81.

51.

51.

21.

61.

51.

91.

92.

01.

61.

82.

01.

61.

91.

81.

92.

11.

8C2

5PA

NCRE

AS2.

92.

83.

03.

43.

53.

23.

33.

33.

44.

44.

04.

84.

24.

04.

95.

14.

85.

05.

35.

45.

1C3

0-31

NOSE

, SIN

USES

ETC

.0.

30.

10.

20.

10.

20.

10.

30.

20.

20.

20.

20.

20.

20.

20.

10.

20.

30.

20.

30.

20.

2C3

2LA

RYNX

0.3

0.3

0.2

0.3

0.5

0.2

0.3

0.3

0.2

0.3

0.4

0.5

0.4

0.5

0.4

0.4

0.4

0.5

0.4

0.6

0.5

C33-

34BR

ONCH

US, L

UNG

4.4

5.4

4.3

5.8

5.6

5.3

5.5

5.9

5.2

7.3

7.2

6.8

6.7

7.0

7.4

7.5

7.6

7.8

8.3

8.5

8.6

C40-

41BO

NE0.

60.

40.

50.

50.

80.

60.

70.

70.

50.

90.

81.

00.

70.

80.

80.

60.

80.

90.

80.

70.

9C4

3ME

LANO

MA O

F SK

IN1.

71.

51.

52.

02.

22.

11.

92.

32.

42.

52.

71.

82.

32.

22.

12.

82.

12.

23.

23.

12.

9C4

4OT

HER

SKIN

20.1

19.5

18.9

16.3

15.3

16.2

15.6

15.8

12.9

14.1

16.2

13.4

15.0

13.5

14.7

17.0

17.9

16.5

18.8

19.0

21.6

C47,

C49

CONN

ECTI

VE T

ISSU

E3.

01.

01.

11.

21.

21.

31.

61.

31.

21.

01.

21.

21.

21.

31.

51.

31.

82.

11.

21.

81.

3C5

0BR

EAST

32.1

35.8

37.6

38.6

40.8

45.0

45.1

45.9

46.5

46.1

46.5

45.3

49.8

49.6

51.8

51.9

51.2

51.8

52.1

54.8

55.2

C51-

52OT

HER

FEMA

LE G

ENITA

L1.

01.

41.

51.

31.

21.

41.

31.

41.

51.

81.

61.

61.

51.

61.

51.

91.

71.

71.

71.

71.

5C5

5UT

ERUS

UNS

PECI

FIED

0.0

0.1

0.2

0.4

0.5

0.6

0.4

0.5

0.4

0.7

0.8

0.8

0.6

0.7

0.7

0.7

0.7

0.5

0.5

0.6

0.6

C53

CERV

IX U

TERI

10.3

10.1

12.3

14.0

14.0

14.8

14.8

16.7

15.6

17.0

17.3

17.1

18.8

19.4

19.3

19.5

18.9

21.2

20.1

20.6

18.7

C58

PLAC

ENTA

0.2

0.1

0.1

0.1

0.2

0.1

0.1

0.1

0.1

0.2

0.0

0.0

0.0

0.1

0.1

0.1

0.0

0.1

0.1

0.1

0.1

C54

CORP

US U

TERI

9.4

11.4

12.1

12.7

13.5

14.7

14.8

15.1

13.5

14.8

15.6

15.2

14.7

15.4

15.9

17.0

15.6

17.0

16.7

16.7

17.3

C56-

57OV

ARY

ETC.

8.7

8.4

9.7

9.4

10.6

11.1

10.6

11.5

10.3

11.6

11.2

10.7

11.4

12.3

12.0

13.3

12.4

12.7

13.6

13.2

13.2

AGE-

ADJU

STED

(WOR

LD S

TAND

ARD)

INCI

DENC

E RA

TES

PER

100 0

00 B

Y PR

IMAR

Y CA

NCER

SIT

ES A

ND Y

EAR

OF D

IAGN

OSIS

IN B

ULGA

RIA

1981

- 20

09, F

EMAL

ESCO

DE

ICD-

10SI

TEYE

AR O

F DI

AGNO

SIS

1981

1985

1990

1991

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

61

C67

BLAD

DER

1.5

1.7

1.5

1.5

1.8

1.6

1.9

2.1

1.9

2.0

2.3

2.3

2.6

2.4

2.8

3.0

3.3

4.0

3.6

3.7

3.8

C64-

66,

C68

KIDN

EY E

TC.

1.3

1.5

1.8

1.6

1.8

2.1

2.3

2.2

2.5

2.6

2.6

2.5

2.6

2.6

2.9

2.7

3.9

3.6

3.2

3.5

3.6

C69

EYE

0.1

0.2

0.2

0.2

0.2

0.2

0.4

0.2

0.4

0.3

0.5

0.3

0.5

0.4

0.3

0.4

0.5

0.4

0.6

0.4

0.2

C71

BRAI

N2.

62.

42.

42.

52.

52.

23.

12.

52.

24.

44.

03.

63.

64.

04.

04.

65.

44.

64.

54.

94.

8C7

0, C7

2OT

HER

PART

S OF

NE

RVOU

S SY

STEM

0.2

0.1

0.1

0.2

0.3

0.1

0.3

0.2

0.1

0.3

0.4

0.3

0.5

0.4

0.4

0.4

0.5

0.7

0.5

0.5

0.5

C73

THYR

OID

3.0

2.4

1.6

1.9

2.0

1.9

2.1

2.5

2.7

2.5

2.5

2.7

2.7

3.0

3.5

2.9

3.5

3.7

3.6

5.2

4.6

C74-

75OT

HER

ENDO

CRIN

E GL

ANDS

0.1

0.1

0.0

0.1

0.1

0.0

0.1

0.2

0.2

0.2

0.2

0.3

0.3

0.3

0.3

0.3

0.2

0.3

0.3

0.4

0.2

C76

OTHE

R AN

D ILL

-DEF

INED

SI

TES

0.4

0.3

0.2

0.4

0.2

0.4

0.2

0.4

0.5

0.3

0.2

0.2

0.3

0.3

0.2

0.2

0.1

0.2

0.2

0.2

0.4

C80

NEOP

LASM

WIT

HOUT

SP

ECIF

ICAT

ION

OF S

ITE

2.5

2.9

3.1

3.6

4.1

4.4

3.8

4.5

4.9

5.1

5.0

4.9

5.5

5.3

5.3

5.5

5.7

5.6

5.9

5.3

5.3

C81

HODG

KIN

DISE

ASE

1.0

1.0

1.0

1.2

1.4

1.1

1.0

1.1

2.0

1.8

2.0

1.4

1.3

1.6

1.7

1.3

1.5

1.4

1.9

1.9

1.5

C82-

85,

C96

N0N-

HODG

KIN

LYMP

HOMA

1.5

1.6

1.9

1.3

1.0

1.7

1.7

1.8

1.7

2.1

2.4

2.8

2.9

3.0

2.9

2.8

2.5

3.0

3.7

3.8

3.4

C88,

C90

MULT

IPLE

MYE

LOMA

0.6

0.4

0.5

0.6

0.5

0.7

0.7

0.4

0.7

0.9

1.0

0.8

0.9

1.1

1.0

1.4

1.1

1.1

1.3

1.3

1.2

C91

LYMP

HOID

LEUK

AEMI

A1.

40.

90.

91.

11.

21.

01.

41.

61.

72.

22.

52.

01.

71.

42.

41.

91.

92.

72.

62.

52.

7C9

2MY

ELOI

D LE

UKAE

MIA

1.0

0.5

0.4

0.7

0.8

0.8

0.8

0.8

1.0

1.4

1.6

1.5

1.8

1.4

1.4

1.4

1.0

1.7

2.3

1.6

1.6

C93

MONO

CYTI

C LE

UKAE

MIA

0.0

-0.

0-

0.0

0.1

0.0

0.1

0.0

0.1

0.1

0.1

0.1

0.2

0.1

0.1

0.0

0.1

0.1

0.2

0.1

C94

OTHE

R LE

UKAE

MIA

0.1

0.0

0.0

0.1

0.0

0.1

0.1

0.1

0.0

0.1

0.3

0.1

0.3

0.3

0.3

0.5

0.1

0.1

0.3

0.4

0.3

C95

LEUK

AEMI

A, C

ELL

UNSP

ECIF

IED

0.9

0.9

0.9

0.8

0.6

0.8

0.8

0.5

0.8

0.9

0.8

0.6

0.4

0.4

0.4

0.5

0.7

0.5

0.4

0.2

0.2

C26,C

37,

C38,C

39,

C45,C

46,

C48

OTHE

RS A

ND

UNSP

ECIF

IED

SITE

S

1.0

0.6

0.6

0.5

0.6

0.7

1.1

1.1

0.9

1.3

1.3

1.2

1.1

1.3

1.3

1.2

1.0

1.2

1.5

1.4

1.7

Part

2AG

E-AD

JUST

ED (W

ORLD

STA

NDAR

D) IN

CIDE

NCE

RATE

S PE

R 10

0 000

BY P

RIMA

RY C

ANCE

R SI

TES A

ND YE

AR O

F DIA

GNOS

IS IN

BUL

GARI

A 19

81 - 2

009,

FEMA

LES

CODE

IC

D-10

SITE

YEAR

OF

DIAG

NOSI

S19

8119

8519

9019

9119

9319

9419

9519

9619

9719

9819

9920

0020

0120

0220

0320

0420

0520

0620

0720

0820

09

62

ALL 1027 100.0 - 605 100.0 - 1632 100.0 -WITHOUT MORPHOLOGY 194 18.9 - 134 22.1 - 328 20.1 -WITH MORPHOLOGY 833 81.1 100.0 471 77.9 100.0 1304 79.9 100.0

80013 TUMOR CELLS. MALIGNANT 6 0.6 0.7 4 0.7 0.8 10 0.6 0.880103 CARCINOMA. NOS 11 1.1 1.3 4 0.7 0.8 15 0.9 1.280203 CARCINOMA.

UNDIFFERENTIATED. NOS 19 1.9 2.3 15 2.5 3.2 34 2.1 2.680213 CARCINOMA ANAPLASTIC. NOS 3 0.3 0.4 3 0.5 0.6 6 0.4 0.580413 ADENOCARCINOMA. NOS 2 0.2 0.2 1 0.2 0.2 3 0.2 0.280503 PAPILLARY CARCINOMA. NOS - - - 1 0.2 0.2 1 0.1 0.180703 SQUAMOUS CELL CARCINOMA.

NOS 5 0.5 0.6 1 0.2 0.2 6 0.4 0.580713 SQUAMOUS CELL CARCINOMA.

KERATINIZING. NOS 1 0.1 0.1 - - - 1 0.1 0.1

80723

SQUAMOUS CELL CARCINOMA. LARGE CELL. NONKERATINIZING 1 0.1 0.1 - - - 1 0.1 0.1

81403 ADENOCARCINOMA. NOS 557 54.2 66.9 290 47.9 61.6 847 51.9 65.081413 SCIRRHOUS

ADENOCARCINOMA 4 0.4 0.5 2 0.3 0.4 6 0.4 0.581423 LINITIS PLASTICA 1 0.1 0.1 2 0.3 0.4 3 0.2 0.281443 ADENOCARCINOMA.

INTESTINAL TYPE 29 2.8 3.5 17 2.8 3.6 46 2.8 3.581453 CARCINOMA. DIFFUSE TYPE 4 0.4 0.5 6 1.0 1.3 10 0.6 0.882103 ADENOCARCINOMA IN

ADENOMATOUS POLYP 2 0.2 0.2 - - - 2 0.1 0.282113 TUBULAR ADENOCARCINOMA 12 1.2 1.4 2 0.3 0.4 14 0.9 1.182463 NEUROENDOCRINE

CARCINOMA 2 0.2 0.2 2 0.3 0.4 4 0.2 0.382603 PAPILLARY

ADENOCARCINOMA. NOS 18 1.8 2.2 7 1.2 1.5 25 1.5 1.984803 MUCINOUS ADENOCARCINOMA 24 2.3 2.9 14 2.3 3.0 38 2.3 2.984813 MUCIN - PRODUCING

ADENOCARCINOMA 43 4.2 5.2 22 3.6 4.7 65 4.0 5.084903 SIGNET RING CELL

CARCINOMA 71 6.9 8.5 65 10.7 13.8 136 8.3 10.485103 MEDULLARY CARCINOMA. NOS - - - 1 0.2 0.2 1 0.1 0.185603 ADENOSQUAMOUS

CARCINOMA 4 0.4 0.5 4 0.7 0.8 8 0.5 0.688903 LEIOMYOSARCOMA. NOS 14 1.4 1.7 8 1.3 1.7 22 1.3 1.7

NUMBER AND PERCENTAGE OF NEW STOMACH CANCER CASES BY HISTOLOGICAL TYPES AND SEX IN BULGARIA 2009

CODE ICD-10 MORPHOLOGY

MALES FEMALES ALL

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

63


80013 TUMOR CELLS. MALIGNANT 1 0.1 0.1 2 0.2 0.2 3 0.1 0.180103 CARCINOMA. NOS 3 0.2 0.2 8 0.6 0.7 11 0.4 0.580203 CARCINOMA. UNDIFFERENTIATED.

NOS 2 0.1 0.2 3 0.2 0.3 5 0.2 0.280503 PAPILLARY CARCINOMA. NOS 1 0.1 0.1 1 0.1 0.1 2 0.1 0.180703 SQUAMOUS CELL CARCINOMA. NOS 2 0.1 0.2 - - - 2 0.1 0.181403 ADENOCARCINOMA. NOS 1034 69.7 78.3 836 66.4 75.9 1870 68.2 77.281413 SCIRRHOUS ADENOCARCINOMA - - - 1 0.1 0.1 1 0.0 0.081443 ADENOCARCINOMA. INTESTINAL

TYPE 11 0.7 0.8 12 1.0 1.1 23 0.8 0.982103 ADENOCARCINOMA IN

ADENOMATOUS POLYP 2 0.1 0.2 5 0.4 0.5 7 0.3 0.382113 TUBULAR ADENOCARCINOMA 1 0.1 0.1 - - - 1 0.0 0.0

82203ADENOCARCINOMA IN ADENOMATOUS POLYPOSIS COLI - - - 1 0.1 0.1 1 0.0 0.0

82403 CARCINOID TUMOR. NOS 7 0.5 0.5 3 0.2 0.3 10 0.4 0.482413 CARCINOID TUMOR. ARGENTAFFIN.

MALIGNANT 1 0.1 0.1 - - - 1 0.0 0.082443 COMPOSITE CARCINOID 1 0.1 0.1 - - - 1 0.0 0.082463 NEUROENDOCRINE CARCINOMA 1 0.1 0.1 6 0.5 0.5 7 0.3 0.382603 PAPILLARY ADENOCARCINOMA. NOS 33 2.2 2.5 22 1.7 2.0 55 2.0 2.382613 ADENOCARCINOMA IN VILLOUS

ADENOMA 2 0.1 0.2 1 0.1 0.1 3 0.1 0.182623 VILLOUS ADENOCARCINOMA 2 0.1 0.2 - - - 2 0.1 0.182633 ADENOCARCINOMA IN

TUBULOVILLOUS ADENOMA 13 0.9 1.0 3 0.2 0.3 16 0.6 0.784403 CYSTADENOCARCINOMA. NOS - - - 1 0.1 0.1 1 0.0 0.084803 MUCINOUS ADENOCARCINOMA 92 6.2 7.0 91 7.2 8.3 183 6.7 7.684813 MUCIN-PRODUCING

ADENOCARCINOMA 97 6.5 7.3 86 6.8 7.8 183 6.7 7.684903 SIGNET RING CELL CARCINOMA 10 0.7 0.8 14 1.1 1.3 24 0.9 1.085603 ADENOSQUAMOUS CARCINOMA 3 0.2 0.2 - - - 3 0.1 0.188903 LEIOMYOSARCOMA. NOS 1 0.1 0.1 3 0.2 0.3 4 0.1 0.289003 RHABDOMYOSARCOMA. NOS - - - 1 0.1 0.1 1 0.0 0.089803 CARCINOSARCOMA. NOS - - - 2 0.2 0.2 2 0.1 0.1

NUMBER AND PERCENTAGE OF NEW COLON CANCER CASES BY HISTOLOGICAL TYPES AND SEX IN BULGARIA 2009


MALES FEMALES ALL

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER%

FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED


ALL

NUMBER % FROM ALL % FROM MORPHO-LOGICALLY CONFIRMED

ALL 1072 100.0 -WITHOUT MORPHOLOGY 15 1.4 -WITH MORPHOLOGY 1057 98.6 100.0

80103 CARCINOMA. NOS 9 0.8 0.880203 CARCINOMA. UNDIFFERENTIATED. NOS 3 0.3 0.380513 VERRUCOUS CARCINOMA. NOS 5 0.5 0.580523 PAPILLARY SQUAMOUS CELL CARCINOMA 6 0.6 0.680703 SQUAMOUS CELL CARCINOMA. NOS 626 58.4 59.280713 SQUAMOUS CELL CARCINOMA. KERATINIZING. NOS 72 6.7 6.880723 SQUAMOUS CELL CARCINOMA. LARGE CELL. NONKERATINIZING 150 14.0 14.280733 SQUAMOUS CELL CARCINOMA. SMALL CELL. NONKERATINIZING 8 0.7 0.880753 ADENOID SQUAMOUS CELL CARCINOMA 1 0.1 0.180763 SQUAMOUS CELL CARCINOMA. MICROINVASIVE 50 4.7 4.781403 ADENOCARCINOMA. NOS 54 5.0 5.182463 NEUROENDOCRINE CARCINOMA 2 0.2 0.282603 PAPILLARY ADENOCARCINOMA. NOS 10 0.9 1.083103 CLEAR CELL ADENOCARCINOMA. NOS 7 0.7 0.783803 ENDOMETRIOID CARCINOMA 3 0.3 0.384303 MUCOEPIDERMOID CARCINOMA 2 0.2 0.284403 CYSTADENOCARCINOMA. NOS 2 0.2 0.284803 MUCINOUS ADENOCARCINOMA 10 0.9 1.084813 MUCIN-PRODUCING ADENOCARCINOMA 1 0.1 0.184903 SIGNET RING CELL CARCINOMA 1 0.1 0.185603 ADENOSQUAMOUS CARCINOMA 31 2.9 2.989803 CARCINOSARCOMA. NOS 3 0.3 0.391103 MESONEPHROMA. MALIGNANT 1 0.1 0.1

NUMBER AND PERCENTAGE OF NEW CERVIX UTERI CANCER CASES BY HISTOLOGICAL TYPES IN BULGARIA 2009

64


80013 TUMOR CELLS. MALIGNANT 1 0.1 0.1 2 0.3 0.3 3 0.2 0.280103 CARCINOMA. NOS 4 0.4 0.4 5 0.6 0.7 9 0.5 0.580203 CARCINOMA. UNDIFFERENTIATED. NOS 3 0.3 0.3 1 0.1 0.1 4 0.2 0.280503 PAPILLARY CARCINOMA. NOS 1 0.1 0.1 - - - 1 0.1 0.180703 SQUAMOUS CELL CARCINOMA. NOS 8 0.7 0.8 17 2.2 2.4 25 1.3 1.480713 SQUAMOUS CELL CARCINOMA.

KERATINIZING. NOS 2 0.2 0.2 2 0.3 0.3 4 0.2 0.2

80723SQUAMOUS CELL CARCINOMA. LARGE CELL. NONKERATINIZING - - - 1 0.1 0.1 1 0.1 0.1

81403 ADENOCARCINOMA. NOS 855 76.3 81.7 547 70.9 77.7 1402 74.1 80.181443 ADENOCARCINOMA. INTESTINAL TYPE 9 0.8 0.9 9 1.2 1.3 18 1.0 1.082103 ADENOCARCINOMA IN ADENOMATOUS

POLYP 2 0.2 0.2 1 0.1 0.1 3 0.2 0.282113 TUBULAR ADENOCARCINOMA 2 0.2 0.2 - - - 2 0.1 0.182403 CARCINOID TUMOR. NOS 1 0.1 0.1 1 0.1 0.1 2 0.1 0.182463 NEUROENDOCRINE CARCINOMA - - - 2 0.3 0.3 2 0.1 0.182603 PAPILLARY ADENOCARCINOMA. NOS 43 3.8 4.1 23 3.0 3.3 66 3.5 3.882613 ADENOCARCINOMA IN VILLOUS

ADENOMA 4 0.4 0.4 2 0.3 0.3 6 0.3 0.382623 VILLOUS ADENOCARCINOMA 3 0.3 0.3 4 0.5 0.6 7 0.4 0.482633 ADENOCARCINOMA IN TUBULOVILLOUS

ADENOMA 7 0.6 0.7 3 0.4 0.4 10 0.5 0.684803 MUCINOUS ADENOCARCINOMA 41 3.7 3.9 40 5.2 5.7 81 4.3 4.684813 MUCIN-PRODUCING

ADENOCARCINOMA 54 4.8 5.2 34 4.4 4.8 88 4.6 5.084903 SIGNET RING CELL CARCINOMA 5 0.4 0.5 4 0.5 0.6 9 0.5 0.585603 ADENOSQUAMOUS CARCINOMA 1 0.1 0.1 3 0.4 0.4 4 0.2 0.287203 MALIGNANT MELANOMA. NOS - - - 1 0.1 0.1 1 0.1 0.188103 FIBROSARCOMA. NOS - - - 1 0.1 0.1 1 0.1 0.188903 LEIOMYOSARCOMA. NOS 1 0.1 0.1 1 0.1 0.1 2 0.1 0.1

NUMBER AND PERCENTAGE OF NEW RECTUM AND ANUS CANCER CASES BY HISTOLOGICAL TYPES AND SEX IN BULGARIA 2009


MALES FEMALES ALL

NUMBER%

FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER%

FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED


ALL



80013 TUMOR CELLS. MALIGNANT 4 0.2 0.380103 CARCINOMA. NOS 18 1.1 1.280203 CARCINOMA. UNDIFFERENTIATED. NOS 6 0.4 0.480703 SQUAMOUS CELL CARCINOMA. NOS 3 0.2 0.280713 SQUAMOUS CELL CARCINOMA. KERATINIZING. NOS 1 0.1 0.181203 TRANSITIONAL CELL CARCINOMA 4 0.2 0.381303 PAPILLARY TRANSITIONAL CELL CARCINOMA 1 0.1 0.181403 ADENOCARCINOMA. NOS 1361 81.7 90.481903 TRABECULAR ADENOCARCINOMA 2 0.1 0.182013 CRIBRIFORM CARCINOMA 2 0.1 0.182603 PAPILLARY ADENOCARCINOMA. NOS 2 0.1 0.183103 CLEAR CELL ADENOCARCINOMA. NOS 14 0.8 0.984803 MUCINOUS ADENOCARCINOMA 2 0.1 0.184903 SIGNET RING CELL CARCINOMA 1 0.1 0.185103 MEDULLARY CARCINOMA. NOS 1 0.1 0.185503 ACINAR CELL CARCINOMA 81 4.9 5.485603 ADENOSQUAMOUS CARCINOMA 2 0.1 0.1

NUMBER AND PERCENTAGE OF NEW PROSTATE CANCER CASES BY HISTOLOGICAL TYPES IN BULGARIA 2009

65


80013 TUMOR CELLS. MALIGNANT 53 1.6 2.1 9 1.4 1.9 62 1.6 2.180023 MALIGNANT TUMOR. SMALL CELL TYPE 1 0.0 0.0 - - - 1 0.0 0.080103 CARCINOMA. NOS 76 2.3 3.0 13 2.0 2.7 89 2.3 3.080123 LARGE CELL CARCINOMA. NOS 14 0.4 0.6 2 0.3 0.4 16 0.4 0.580203 CARCINOMA. UNDIFFERENTIATED. NOS 30 0.9 1.2 8 1.2 1.7 38 1.0 1.380213 CARCINOMA. ANAPLASTIC. NOS 2 0.1 0.1 1 0.2 0.2 3 0.1 0.180223 PLEOMORPHIC CARCINOMA 11 0.3 0.4 3 0.5 0.6 14 0.4 0.580313 GIANT CELL CARCINOMA 20 0.6 0.8 4 0.6 0.8 24 0.6 0.880333 PSEUDOSARCMATOUS CARCINOMA 1 0.0 0.0 - - - 1 0.0 0.080413 SMALL CELL CARCINOMA. NOS 349 10.7 14.0 73 11.0 15.1 422 10.7 14.280423 OAT CELL CARCINOMA 21 0.6 0.8 4 0.6 0.8 25 0.6 0.880433 SMALL CELL CARCINOMA. FUSIFORM CELL 2 0.1 0.1 1 0.2 0.2 3 0.1 0.180443 SMALL CELL CARCINOMA. INTERMEDIATE CELL 3 0.1 0.1 - - - 3 0.1 0.180453 COMBINED SMALL CELL CARCINOMA 2 0.1 0.1 - - - 2 0.1 0.180503 PAPILLARY CARCINOMA. NOS 3 0.1 0.1 1 0.2 0.2 4 0.1 0.180523 PAPILLARY SQUAMOUS CELL CARCINOMA 2 0.1 0.1 1 0.2 0.2 3 0.1 0.180703 SQUAMOUS CELL CARCINOMA. NOS 1288 39.4 51.7 158 23.8 32.7 1446 36.8 48.680713 SQUAMOUS CELL CARCINOMA. KERATINIZING.

NOS 47 1.4 1.9 5 0.8 1.0 52 1.3 1.780723 SQUAMOUS CELL CARCINOMA. LARGE CELL.

NONKERATINIZING 80 2.4 3.2 4 0.6 0.8 84 2.1 2.880733 SQUAMOUS CELL CARCINOMA. SMALL CELL.

NONKERATINIZING 6 0.2 0.2 - - - 6 0.2 0.280743 SQUAMOUS CELL CARCINOMA. SPINDLE CELL 2 0.1 0.1 - - - 2 0.1 0.180753 ADENOID SQUAMOUS CELL CARCINOMA 1 0.0 0.0 - - - 1 0.0 0.081403 ADENOCARCINOMA. NOS 268 8.2 10.8 113 17.0 23.4 381 9.7 12.882003 ADENOID CYSTIC CARCINOMA 2 0.1 0.1 - - - 2 0.1 0.182403 CARCINOID TUMOR. NOS 9 0.3 0.4 9 1.4 1.9 18 0.5 0.682413 CARCINOID TUMOR. ARGETAFFIN. MALIGNANT 1 0.0 0.0 - - - 1 0.0 0.082463 NEUROENDOCRINE CARCINOMA 9 0.3 0.4 4 0.6 0.8 13 0.3 0.482503 BRONCHIOLO - ALVEOLAR ADENOCARCINOMA 39 1.2 1.6 17 2.6 3.5 56 1.4 1.982513 ALVEOLAR ADENOCARCINOMA 1 0.0 0.0 - - - 1 0.0 0.082603 PAPILLARY ADENOCARCINOMA. NOS 40 1.2 1.6 17 2.6 3.5 57 1.5 1.983103 CLEAR CELL ADENOCARCINOMA. NOS 9 0.3 0.4 1 0.2 0.2 10 0.3 0.384303 MUCOEPIDERMOID CARCINOMA 10 0.3 0.4 6 0.9 1.2 16 0.4 0.584803 MUCINOUS ADENOCARCINOMA 5 0.2 0.2 2 0.3 0.4 7 0.2 0.284813 MUCIN - PRODUCING ADENOCARCINOMA 14 0.4 0.6 6 0.9 1.2 20 0.5 0.784903 SIGNET RING CELL CARCINOMA 3 0.1 0.1 2 0.3 0.4 5 0.1 0.285503 ACINAR CELL CARCINOMA 9 0.3 0.4 8 1.2 1.7 17 0.4 0.685603 ADENOSQUAMOUS CARCINOMA 55 1.7 2.2 10 1.5 2.1 65 1.7 2.288543 PLEOMORPHIC LIPOSARCOMA 1 0.0 0.0 - - - 1 0.0 0.089803 CARCINOSARCOMA. NOS 1 0.0 0.0 - - - 1 0.0 0.090403 SYNOVIAL SARCOMA. NOS 1 0.0 0.0 - - - 1 0.0 0.091203 HEMANGIOSARCOMA 1 0.0 0.0 - - - 1 0.0 0.093643 PERIPHERAL NEUROECTODERMAL TUMOR - - - 1 0.2 0.2 1 0.0 0.0

NUMBER AND PERCENTAGE OF NEW LUNG (INCL. TRACHEA AND BRONCHUS) CANCER CASES BY HISTOLOGICAL TYPES AND SEX IN BULGARIA 2009


MALES FEMALES ALL

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER%

FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

66

ALL 50 100.0 - 3809 100.0 - 3859 100.0 -WITHOUT MORPHOLOGY - - - 142 3.7 - 142 3.7 -WITH MORPHOLOGY 50 100.0 100.0 3667 96.3 100.0 3717 96.3 100.0

80013 TUMOR CELLS. MALIGNANT 2 4.0 4.0 75 2.0 2.0 77 2.0 2.180103 CARCINOMA. NOS - - - 23 0.6 0.6 23 0.6 0.680113 EPITHELIOMA. MALIGNANT - - - 1 0.0 0.0 1 0.0 0.080203 CARCINOMA. UNDIFFERENTIATED. NOS - - - 14 0.4 0.4 14 0.4 0.480213 CARCINOMA. ANAPLASTIC. NOS - - - 5 0.1 0.1 5 0.1 0.180313 GIANT CELL CARCINOMA 1 2.0 2.0 - - - 1 0.0 0.080503 PAPILLARY CARCINOMA. NOS - - - 10 0.3 0.3 10 0.3 0.380703 SQUAMOUS CELL CARCINOMA. NOS - - - 3 0.1 0.1 3 0.1 0.180713 SQUAMOUS CELL CARCINOMA.

KERATINIZING. NOS - - - 2 0.1 0.1 2 0.1 0.181403 ADENOCARCINOMA. NOS 2 4.0 4.0 34 0.9 0.9 36 0.9 1.081413 SCIRRHOUS ADENOCARCINOMA - - - 7 0.2 0.2 7 0.2 0.282013 CRIBRIFORM CARCINOMA - - - 2 0.1 0.1 2 0.1 0.182113 TUBULAR ADENOCARCINOMA - - - 14 0.4 0.4 14 0.4 0.482463 NEUROENDOCRINE CARCINOMA. NOS - - - 1 0.0 0.0 1 0.0 0.082513 ALVEOLAR ADENOCARCINOMA - - - 1 0.0 0.0 1 0.0 0.082603 PAPILLARY ADENOCARCINOMA. NOS - - - 4 0.1 0.1 4 0.1 0.183143 LIPID-RICH CARCINOMA - - - 1 0.0 0.0 1 0.0 0.084013 APOCRINE ADENOCARCINOMA - - - 2 0.1 0.1 2 0.1 0.184403 CYSTADENOCARCINOMA. NOS - - - 1 0.0 0.0 1 0.0 0.084803 MUCINOUS ADENOCARCINOMA - - - 57 1.5 1.6 57 1.5 1.584813 MUCIN - PRODUCING ADENOCARCINOMA - - - 3 0.1 0.1 3 0.1 0.185003 INFILTRATING DUCT CARCINOMA 36 72.0 72.0 2484 65.2 67.7 2520 65.3 67.885013 COMEDOCARCINOMA. NOS - - - 40 1.1 1.1 40 1.0 1.185033 INTRADUCTAL PAPILLARY

ADENOCARCINOMA. WITH INVASION - - - 7 0.2 0.2 7 0.2 0.285043 INTRACYSTIC CARCINOMA. NOS - - - 2 0.1 0.1 2 0.1 0.185103 MEDULLARY CARCINOMA. NOS 3 6.0 6.0 44 1.2 1.2 47 1.2 1.385123 MEDULLARY CARCINOMA WITH LYMPHOID

STROMA - - - 2 0.1 0.1 2 0.1 0.185203 LOBULAR CARCINOMA. NOS 4 8.0 8.0 587 15.4 16.0 591 15.3 15.985213 INFILTRATING DUCTULAR CARCINOMA - - - 3 0.1 0.1 3 0.1 0.185223 INFILTRATING DUCT AND LOBULAR

CARCINOMA 1 2.0 2.0 192 5.0 5.2 193 5.0 5.285303 INFLAMMATORY CARCINOMA - - - 1 0.0 0.0 1 0.0 0.085403 PAGET DISEASE. MAMMARY - - - 21 0.6 0.6 21 0.5 0.685413 PAGET DISEASE AND INFILTRATING DUCT

CARCINOMA OF BREAST - - - 3 0.1 0.1 3 0.1 0.185433 PAGET DISEASE AND INTRADUCTAL

CARCINOMA OF BREAST - - - 2 0.1 0.1 2 0.1 0.185703 ADENOCARCINOMA WITH SQUAMOUS

METAPLASIA - - - 4 0.1 0.1 4 0.1 0.188003 SARCOMA. NOS 1 2.0 2.0 3 0.1 0.1 4 0.1 0.188103 FIBROSARCOMA. NOS - - - 1 0.0 0.0 1 0.0 0.088113 FIBROMYXOSARCOMA - - - 1 0.0 0.0 1 0.0 0.088303 FIBROUS HISTIOCYTOMA. MALIGNANT - - - 1 0.0 0.0 1 0.0 0.088903 LEIOMYOSARCOMA. NOS - - - 1 0.0 0.0 1 0.0 0.088953 MYOSACROMA - - - 1 0.0 0.0 1 0.0 0.089803 CARCINOSARCOMA. NOS - - - 1 0.0 0.0 1 0.0 0.090203 PHYLLODES TUMOR. MALIGNANT - - - 6 0.2 0.2 6 0.2 0.2

NUMBER AND PERCENTAGE OF NEW BREAST CANCER CASES BY HISTOLOGICAL TYPES AND SEX IN BULGARIA 2009


MALES FEMALES ALL

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

NUMBER % FROM ALL

% FROM MORPHO-

LOGICALLY CONFIRMED

67


ALL



80013 TUMOR CELLS, MALIGNANT 8 0.9 1.080103 CARCINOMA, NOS 5 0.6 0.680203 CARCINOMA, UNDIFFERENTIATED, NOS 14 1.6 1.880213 CARCINOMA, ANAPLASTIC, NOS 1 0.1 0.180503 PAPILLARY CARCINOMA, NOS 12 1.4 1.581403 ADENOCARCINOMA, NOS 98 11.4 12.582463 NEUROENDOCRINE CARCINOMA 1 0.1 0.182603 PAPILLARY ADENOCARCINOMA, NOS 77 8.9 9.883103 CLEAR CELL ADENOCARCINOMA, NOS 11 1.3 1.483203 GRANULAR CELL CARCINOMA 1 0.1 0.183803 ENDOMETRIOID CARCINOMA 37 4.3 4.784403 CYSTADENOCARCINOMA, NOS 43 5.0 5.584413 SEROUS CYSTADENOCARCINOMA, NOS 48 5.6 6.184423 SEROUS CYSTADENOCARCINOMA, BORDERLINE MALIGNANCY 2 0.2 0.384503 PAPILLARY CYSTADENOCARCINOMA, NOS 103 11.9 13.284513 PAPILLARY CYSTADENOMA, BORDERLINE MALIGNANCY 1 0.1 0.184603 PAPILLARY SEROUS CYSTADENOCARCINOMA 169 19.6 21.684623 PAPILLARY SEROUS CYSTADENOMA, BORDERLINE MALIGNANCY 4 0.5 0.584703 MUCINOUS CYSTADENOCARCINOMA, NOS 38 4.4 4.984713 PAPILLARY MUCINOUS CYSTADENOCARCINOMA 18 2.1 2.384723 MUCINOUS CYSTADENOMA, BORDERLINE MALIGNANCY 3 0.3 0.484733 PAPILLARY MUCINOUS CYSTADENOMA, BOREDERLINE MALIGNANCY 1 0.1 0.184803 MUCINOUS ADENOCARCINOMA 24 2.8 3.184813 MUCIN-PRODUCING ADENOCARCINOMA 9 1.0 1.284903 SIGNET RING CELL CARCINOMA 4 0.5 0.585603 ADENOSQUAMOUS CARCINOMA 7 0.8 0.986003 THECOMA, MALIGNANT 3 0.3 0.486203 GRANULOSA CELL TUMOR, MALIGNANT 26 3.0 3.386503 LEYDIG CELL TUMOR, MALGINANT 1 0.1 0.189503 MULLERIAN MIXED TUMOR 1 0.1 0.189513 MESODERMAL MIXED TUMOR 1 0.1 0.189803 CARCINOSARCOMA, NOS 1 0.1 0.189903 MESENCHYMOMA, MALIGNANT 1 0.1 0.190003 BRENNER TUMOR, MALIGNANT 4 0.5 0.590603 DYSGERMINOMA 2 0.2 0.390803 TERATOMA, MALIGNANT, NOS 2 0.2 0.391103 MESONEPHROMA, MALIGNANT 1 0.1 0.1

NUMBER AND PERCENTAGE OF NEW OVARY CANCER CASES BY HISTOLOGICAL TYPES IN BULGARIA 2009

68

C00-97 ALL SITES 2740 964 388 485 1134 462 446 645 328 880 337 465

C00 LIP 10 10 6 4 8 2 1 4 - 7 1 6

C01 BASE OF TONGUE 6 4 3 2 2 1 - 1 1 - 1 1C02 OTHER AND UNSPECIFIED

PARTS OF TONGUE 9 2 - 1 2 - 4 3 1 2 1 3

C03 GUM 4 1 - 2 4 1 1 2 - 4 - -

C04 FLOOR OF MOUTH 8 3 1 1 - 1 2 2 2 2 1 1

C05 PALATE 2 1 - - 3 - 1 1 - - 1 -C06 OTHER AND UNSPECIFIED

PARTS OF MOUTH 3 1 - - 1 - - - 1 - - 1

C07 PAROTID GLAND 4 1 - 1 1 2 1 1 - 3 - 2C08 OTHER AND UNSPECIFIED

MAJOR SALIVARY GLANDS 2 - 1 - - 1 - - 1 1 - -

C09 TONSIL 11 6 1 2 3 5 4 2 2 7 2 3

C10 OROPHARYNX 5 - 1 2 1 2 - 2 - 1 - 1

NUMBER OF NEW CANCER CASESCODEICD-10 SITE

DISTRICT

Sofi a city Bourgas Yambol Sliven Varna Dobrich Shoumen Veliko Tarnovo Gabrovo Pleven Lovech Vratsa

C11 NASOPHARYNX 9 4 1 2 3 3 2 2 4 6 - 1

C12 PYRIFORM SINUS 6 1 - - - - - - - 1 - -

C13 HYPOPHARYNX 4 2 2 1 4 - 7 3 2 7 3 3C14 OTHER AND ILL-DEFINED

SITES IN LIP, ORAL CAVITY AND PHARYNX 1 - - - 3 1 - - 1 - - -

C15 OESOPHAGUS 25 8 4 6 6 6 6 5 5 4 5 7

C16 STOMACH 107 64 35 24 54 46 19 38 22 42 23 20

C17 SMALL INTESTINE 6 - 1 1 4 1 2 1 - 1 - 1

C18 COLON 262 57 29 22 109 46 22 52 26 72 29 32

C19 RECTOSIGMOID JUNCTION 41 10 5 5 6 1 11 9 1 14 3 6

C20 RECTUM 113 41 21 23 77 27 17 37 20 37 16 27

C21 ANUS AND ANAL CANAL 5 - - - 1 - 2 - - - 1 1C22 LIVER AND INTRAHEPATIC

BILE DUCTS 64 39 7 6 31 14 16 6 4 6 4 18

C23 GALLBLADDER 8 4 3 1 1 4 - 6 1 7 - 4C24 OTHER AND UNSPECIFIED

PARTS OF BILIARY TRACT 9 2 1 1 4 1 3 1 1 4 1 5

C25 PANCREAS 107 34 10 21 42 23 12 18 15 43 15 22C26 OTHER AND ILL-DEFINED

DIGESTIVE ORGANS 1 - - - 1 - 1 - - - - -C30 NASAL CAVITY AND MIDDLE

EAR 2 - - - 3 - - 1 - 1 - -

C31 ACCESSORY SINUSES 3 2 2 1 1 - 1 3 - - 1 1

C32 LARYNX 91 27 14 25 24 25 13 18 4 22 12 13

C33 TRACHEA - - 1 - - - - - - 1 1 -

C34 BRONCHUS AND LUNG 423 163 92 100 174 83 103 118 52 164 44 81

C37 THYMUS - - - - 1 - 1 - 1 1 1 1C38 HEART, MEDIASTINUM, AND

PLEURA 4 - 1 2 2 - 3 - - 4 - 3C39 OTHER AND ILL-DEFINED

SITES WITHIN RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS - - - - - - - - - - - -

C40 BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS 5 4 1 1 3 - - 1 1 2 - -

C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES 2 1 - - - 1 1 - - - 1 -

C43 MELANOMA OF SKIN 62 14 7 4 13 5 1 9 8 10 2 7

69

213 364 1843 609 278 712 261 270 261 546 365 316 732 979 783 352

1 2 23 5 2 6 3 5 7 4 6 2 7 7 9 4

1 2 4 4 - 2 - 1 - 4 - - 4 - 2 2

1 3 6 3 1 1 3 2 1 2 - 2 8 3 - 1

- 2 3 2 - 1 1 - 2 1 - - - - - 1

- - 6 - - - - - 1 - 2 - 2 6 5 -

- - 4 - - 2 1 1 - - - 1 2 - 1 -

- - 2 - 1 - - 1 1 - - 1 1 - 1 -

- - 2 1 - 2 - 3 - 2 1 2 1 3 - -

1 - 2 2 - - - - - 1 - - - - - -

2 1 8 1 2 2 2 2 2 3 3 1 1 1 1 1

3 3 3 - 1 1 - - 1 1 - 2 2 1 - -

1 1 10 1 1 1 - - - 4 - - 3 1 2 -

- - - - - - - - - 3 2 1 - - - -

1 - 7 3 - - 1 4 2 3 2 2 2 1 1 2

1 1 3 4 2 - - - - - 2 1 2 - - -

1 - 9 2 5 6 5 3 1 7 7 4 9 12 8 -

10 14 104 32 22 37 18 19 20 38 19 14 67 49 42 28

- - 2 1 1 1 - 1 - - - - - - 3 -

19 25 144 56 18 73 13 23 17 57 35 39 52 91 41 22

1 6 16 5 2 7 1 1 2 3 7 1 - 10 2 -

11 25 97 37 15 42 12 12 23 32 21 11 35 50 36 12

- - 2 1 - 3 - - - - 1 - - - 1 -

2 10 48 21 4 16 6 5 5 5 9 5 12 28 16 14

1 1 3 1 1 2 1 2 1 - - 2 2 3 2 1

1 - 6 2 - 1 1 1 - 1 1 - 2 3 1 -

7 17 56 19 5 25 9 3 8 22 19 15 17 37 26 13

- - - - - - - - - - - - - - 1 -

- - 4 - - - 1 - 1 - - - - - 1 -

- 2 5 3 1 - 1 - - - 1 - 1 - 3 1

11 6 63 24 12 12 11 11 12 26 25 13 22 37 28 15

- - - - - - - - - - 1 - - - 1 1

36 54 345 123 63 134 65 48 46 91 57 66 123 175 171 67

- - - - - - - - 1 - - 1 - - - -

1 1 2 - - - 1 - - - 1 2 - 1 - -

- - - - - - - - - - - - 1 - - -

- - - - - 1 - - - - 1 1 - 1 1 -

- - 3 2 1 - - - 2 1 1 1 1 1 1 -

2 6 21 5 3 4 - 2 4 9 7 1 9 15 8 4

BY PRIMARY SITES AND DISTRICTS IN BULGARIA 2009 - MALESDISTRICT

Vidin Montana Plovdiv Pazardjik Smolyan Rousse Razgrad Silistra Targovi-shte

Sofi a district

Kyus-tendil Pernik Blagoev-

gradStara

Zagora Haskovo Kurdjali

Part 1

70


DISTRICT


C44 OTHER SKIN 350 138 40 67 139 27 64 70 28 101 29 49

C45 MESOTHELIOMA 8 - - 3 2 - 1 1 - 1 - 1

C46 KAPOSI’S SARCOMA - 1 1 - 3 - - - - - - -C47 PERIPHERAL NERVES AND

AUTONOMIC NERVOUS SYSTEM 2 - - - - - - - - - - -

C48 RETROPERITONEUM AND PERITONEUM 6 3 1 1 4 1 - 2 1 - 2 1

C49 CONNECTIVE AND OTHER SOFT TISSUES 11 2 3 1 6 4 - 5 2 7 1 1

C50 BREAST 13 2 1 - 2 2 2 4 - 3 1 2

C60 PENIS 4 4 2 3 3 - - 2 - 3 1 -

C61 PROSTATE GLAND 303 71 25 30 140 33 22 58 47 90 43 36

C62 TESTIS 36 7 2 7 13 8 6 14 7 7 3 15C63 OTHER AND UNSPECIFIED

MALE GENITAL ORGANS 2 - - - 1 - - - - - - -

C64 KIDNEY 66 32 8 10 25 12 10 16 10 25 15 10

C65 RENAL PELVIS 9 1 - 1 5 - - 3 2 1 3 1

C66 URETER 2 - - 2 1 1 - 1 - - 1 1

C67 BLADDER 194 84 22 36 69 20 24 36 23 60 35 34C68 OTHER AND UNSPECIFIED

URINARY ORGANS - - - - - - - - - - 1 -C69 EYE AND ADNEXA 2 1 - 2 1 1 1 1 1 2 1 -

C70 MENINGES 2 3 - 1 - - 1 1 - 1 - -

C71 BRAIN 43 24 6 7 21 17 10 8 6 10 1 8C72 SPINAL CORD, CRANIAL

NERVES, AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM - - - - - - - - - - - -

C73 THYROID GLAND 16 4 1 5 7 1 3 1 3 1 - 2

C74 ADRENAL GLAND 2 - - 1 1 1 - 2 - - 1 -C75 OTHER ENDOCRINE GLANDS

AND RELATED STRUCTURES - - - - - - - - - 1 - -C76 OTHER AND ILL-DEFINED

SITES - 1 - - 2 - 1 - - - - -C80 MALIGNANT NEOPLASM

WITHOUT SPECIFICATION OF SITE 110 37 13 29 38 15 26 44 8 54 20 22

C81 HODGKIN DISEASE 16 6 1 - 3 2 2 5 1 1 1 3C82 FOLLICULAR NON-HODGKIN

LYMPHOMA 6 7 2 1 2 - 2 - - - 2 1C83 DIFFUSE NON-HODGKIN

LYMPHOMA 33 4 2 2 12 7 1 8 2 5 2 -C84 PERIPHERAL AND CUTANEOUS

T-CELL LYMPHOMAS 3 - - - 2 - 1 1 1 - - 1C85 OTHER AND UNSPECIFIED

TYPES OF NON-HODGKIN LYMPHOMA 8 1 1 2 5 3 1 3 3 6 - 2

C88 MALIGNANT IMMUNOPROLIFERATIVE DISEASES - - - - - - - - - 1 - -

C90 MULTIPLE MYELOMA AND MALIGNANT PLASMA CELL NEOPLASMS 15 4 2 4 8 1 2 2 2 4 - -

C91 LYMPHOID LEUKAEMIA 30 8 3 3 17 1 2 6 2 12 2 2

C92 MYELOID LEUKAEMIA 14 8 1 5 8 3 3 2 2 6 1 1

C93 MONOCYTIC LEUKAEMIA 1 1 - - - - - 1 - - - 1C94 OTHER LEUKAEMIAS OF

SPECIFIED CELL TYPE 3 3 - 1 1 - 2 1 1 1 1 -C95 LEUKAEMIA, UNSPECIFIED

CELL TYPE 6 1 1 - 1 - - 1 - 1 1 -C96 OTHER AND UNSPECIFIED

NEOPLASMS OF LYMPHOID,BLOOD FORMING ANDRELATED TISSUES - - - - - - 2 - - - - -

71

Part 2

32 48 215 59 27 115 37 36 31 52 24 25 135 139 93 61

- - 3 4 - 1 - 2 1 - - 1 - - 3 -

- - - - - - - - - - - - - 1 1 -

- - - - - - - 1 - - - - - - - -

- - 5 2 - 4 1 - - 1 - 1 4 4 1 2

1 3 11 5 3 2 1 1 4 2 1 2 2 3 5 2

1 3 2 2 1 1 2 - 1 1 - - 2 1 1 -

2 1 4 1 - 3 - 1 - 3 2 - 4 3 2 -

15 34 183 44 17 60 13 17 13 51 43 37 64 84 66 27

3 6 20 9 5 9 3 3 2 5 3 6 13 11 8 4

- - 1 - - 1 - - - - - - - - - -

2 8 51 22 7 21 6 9 7 12 5 6 9 25 17 9

- - 10 2 1 - - - - 1 1 1 1 2 2 -

- - 2 - - - - - - - - - - - 3 1

16 32 121 45 20 38 12 20 17 29 19 12 33 52 53 19

- 2 - - - - - - - - - - - - - -

- 1 3 2 - - - 1 - 1 - - - 1 6 1

- 1 4 - - 1 1 - - - - - 1 1 3 3

3 3 30 13 4 12 2 7 3 13 7 4 13 16 14 4

- 1 2 1 - 1 - - 1 1 - - 1 - 1 -

- - 8 1 2 4 2 1 - - - - - 3 1 -

- - 1 - - 1 - - - 1 - - - - 1 -

- - - - - - - - - - - - - - 1 -

- - 1 - - - - - - 1 - - 1 - 1 -

10 17 80 21 11 30 13 14 9 29 20 16 45 41 46 17

2 2 14 2 1 2 4 1 1 2 - 1 1 4 4 4

1 - 1 - - 2 - - - - - - - - 2 -

2 4 10 3 4 2 3 - 2 8 3 2 8 6 7 5

- 1 2 - - - - 1 - 2 1 - - 2 - 1

- 6 2 3 3 3 - 1 1 - 1 2 - 4 6 -

- - - - - - - - - - - - - - - -

4 2 10 1 5 6 1 - 4 1 - 3 3 8 4 -

2 3 15 3 4 8 2 2 2 6 1 4 - 11 10 3

- 2 13 1 - 1 2 1 1 2 1 1 4 10 4 -

1 - 1 - - - - - - - - - - - 1 -

1 1 1 2 - 1 - 1 - - - 1 - 9 - -

- 1 4 - - 1 - - 1 2 2 - - 2 1 -

- - - 1 - - - - - - - - - - - -



Sofi a district


gradStara


72

C00-97 ALL SITES 2977 934 336 395 1076 412 401 538 301 628 327 438C00 LIP 2 4 4 2 5 1 1 1 - 1 2 2C01 BASE OF TONGUE 2 1 - - - 1 - - - - - -C02 OTHER AND UNSPECIFIED

PARTS OF TONGUE 4 1 - - 2 - 1 - - - - -C03 GUM 3 1 - - - - 1 - - - - -C04 FLOOR OF MOUTH - - - 1 - - - - - - - -C05 PALATE 1 - - - 1 - - - - - 1 -C06 OTHER AND UNSPECIFIED

PARTS OF MOUTH 1 1 - - - - - - - - - -C07 PAROTID GLAND 2 1 1 - - 1 - - 1 3 - 1C08 OTHER AND UNSPECIFIED

MAJOR SALIVARY GLANDS 2 - - 1 - 1 - - 1 - - 1C09 TONSIL 2 1 2 - 1 - 1 1 - - - 1C10 OROPHARYNX 2 - - 1 1 - - - - - - 1C11 NASOPHARYNX 3 1 - 1 1 1 2 - - 2 1 4C12 PYRIFORM SINUS - 1 - - - - - - - - - -C13 HYPOPHARYNX 1 - - - 1 - - - 1 - - -C14 OTHER AND ILL-DEFINED

SITES IN LIP, ORAL CAVITY AND PHARYNX 2 - - 1 - - - - - - - -

C15 OESOPHAGUS 10 3 1 2 2 - 1 1 - 1 1 2C16 STOMACH 79 38 17 11 46 17 15 16 12 26 9 13C17 SMALL INTESTINE 5 - - 1 - - - 1 - - 1 1C18 COLON 254 57 17 30 92 27 22 49 35 44 32 28C19 RECTOSIGMOID JUNCTION 33 8 4 3 2 3 5 8 - 5 8 6C20 RECTUM 92 33 15 12 43 17 13 28 13 26 17 22C21 ANUS AND ANAL CANAL 8 1 - - 4 - 1 - - - - -C22 LIVER AND INTRAHEPATIC

BILE DUCTS 30 17 9 7 12 8 2 7 4 3 2 2C23 GALLBLADDER 12 10 6 4 10 6 3 5 2 8 5 3C24 OTHER AND UNSPECIFIED

PARTS OF BILIARY TRACT 3 4 1 - 4 - 5 - 2 4 2 1C25 PANCREAS 91 22 17 13 29 15 13 12 5 21 7 13C26 OTHER AND ILL-DEFINED

DIGESTIVE ORGANS 5 1 - - 3 - 1 1 - - - -C30 NASAL CAVITY AND MIDDLE

EAR 3 - - - 1 - - - - - - -C31 ACCESSORY SINUSES 3 - - 1 1 1 - - - - - 1C32 LARYNX 8 1 1 1 4 3 - - 1 1 - -C33 TRACHEA 3 - - - - - - - - - - -C34 BRONCHUS AND LUNG 161 31 12 13 47 17 17 23 11 25 12 9C37 THYMUS 2 - - - - - - - - - - -C38 HEART, MEDIASTINUM, AND

PLEURA 4 1 - 1 - - 2 1 - - - 1C39 OTHER AND ILL-DEFINED

SITES WITHIN RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS 1 - - - - - - - - - - -

C40 BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS 5 - 2 - 2 - 2 - - - - -

C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES 3 2 - - - 3 - 1 - - 2 -

C43 MELANOMA OF SKIN 41 7 5 7 8 7 6 4 8 4 6 7C44 OTHER SKIN 303 114 28 40 131 22 55 51 28 78 31 61C45 MESOTHELIOMA 2 3 - 1 1 - - 2 - - - -C46 KAPOSI’S SARCOMA - - - - - 1 - 1 - - - -


DISTRICT


73

213 350 1626 569 248 669 210 248 224 510 327 323 611 814 560 2891 4 7 3 1 1 3 2 1 - 1 - 3 7 2 1

- - - - - 1 - - 1 - 1 - 2 1 - -

1 - 1 1 1 1 - - 1 1 - - 4 - - -

- - 2 1 - - - - - - - - - - 2 -

- - 1 - - - - - - - - - - - 1 -- - 1 1 - - - - - 1 - - - - - -

- - 3 - - - - - - - - - - - - -

1 - 1 2 - - - - - 1 1 1 1 1 - 1

- - - - 1 - - 1 1 1 - - 1 - - 1

- - 1 - - - - - - - - 1 - - - -

- - 2 - - - - - - - - - 1 1 1 -

1 - 4 - - 1 - 1 - 2 - 1 - - - -

- - - - - - - - - - - - - - - -

- 1 1 - - - 1 - - - - 1 - - - -

- - 1 - - - - - - - - - - - - -

- - 4 1 2 - - 2 - 5 1 - 5 1 3 2

3 12 66 27 14 9 6 11 11 26 17 17 30 27 17 13

1 - 4 - - - - - - - - - - 2 1 -

11 27 141 38 13 56 9 16 6 43 19 31 55 56 37 14

- 1 6 6 2 5 2 3 3 4 5 3 - 7 - -

10 17 63 16 8 18 3 5 2 21 14 9 23 37 22 8- 1 7 1 - 1 - 1 - - 1 3 2 2 - -

3 5 21 10 2 4 4 3 5 4 2 - 8 8 5 73 4 9 4 1 10 5 3 3 5 - - 6 4 2 5

- - 1 1 - 1 2 1 - 1 - 1 1 5 1 1

3 10 44 14 10 20 9 3 6 16 15 9 19 29 13 7

- 1 - - - 2 - 1 1 1 - - - 1 - -

- - 1 - - 1 - - - - - - - - - -- 2 1 1 - 1 - - - - - - - 1 - -

1 - 6 - 1 3 - - - - - 2 3 1 - -

- - - - - - - - - - - - - - - -5 7 71 22 15 18 4 7 8 25 12 13 13 27 27 8- - 1 1 - - - - - - 1 - - - - -

- - 2 - - - 1 1 - - - - - 1 1 1

- - - - - - - - - - - - - - - -

1 - 1 - - - - - 1 - - - - 1 - 1

- - 3 2 1 1 - - - 1 - 1 - 1 1 -

4 2 16 5 1 13 1 2 1 7 2 9 6 5 8 2

32 42 198 68 32 127 40 42 22 43 32 33 153 131 91 46

- 1 1 3 - 2 - - 1 - 1 - - 2 1 1

- - - - - - - - - - - - - - - -

Part 1BY PRIMARY SITES AND DISTRICTS IN BULGARIA 2009 - FEMALESDISTRICT


Sofi a district


gradStara


74

C47 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM - 1 - - - 1 - - - - - -

C48 RETROPERITONEUM AND PERITONEUM 12 2 - - 4 3 1 - 1 2 - 1

C49 CONNECTIVE AND OTHER SOFT TISSUES 4 5 4 4 6 - 3 4 2 2 1 -

C50 BREAST 830 225 80 89 244 93 75 105 74 140 56 77C51 VULVA 15 5 3 3 13 2 3 4 4 7 5 5C52 VAGINA 8 - - 1 2 - - - - 3 - -C53 CERVIX UTERI 169 59 16 40 59 39 32 41 14 59 36 48C54 CORPUS UTERI 202 93 21 28 80 39 28 53 27 52 20 36C55 UTERUS, NOS 3 6 1 - - 1 - 3 - 2 - 2C56 OVARY 146 52 20 21 47 15 28 27 23 19 18 25C57 OTHER AND UNSPECIFIED

FEMALE GENITAL ORGANS 1 1 1 - 1 3 2 - 1 - - 1C58 PLACENTA 1 - - - - - - - - - - -C64 KIDNEY 37 18 8 4 17 6 8 8 6 5 7 5C65 RENAL PELVIS 7 - - 2 - - - 3 1 - 1 1C66 URETER 3 - - - - - - - 1 - - 1C67 BLADDER 72 13 7 3 22 7 8 14 3 11 8 11C68 OTHER AND UNSPECIFIED

URINARY ORGANS 2 - - - - - - - - - - -C69 EYE AND ADNEXA 6 2 - 1 1 3 - - - 1 - -C70 MENINGES 5 1 - - 2 1 2 2 - 2 - -C71 BRAIN 51 15 9 10 21 19 7 9 5 10 5 7C72 SPINAL CORD, CRANIAL

NERVES, AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM 1 1 1 - - 1 - - - - - -

C73 THYROID GLAND 42 15 4 10 18 3 3 5 2 8 7 6C74 ADRENAL GLAND 2 - - - 1 - 1 - - - - -C75 OTHER ENDOCRINE GLANDS

AND RELATED STRUCTURES - 1 - - - - - - - - - -C76 OTHER AND ILL-DEFINED

SITES 3 2 1 - - - - - - 1 - 1C80 MALIGNANT NEOPLASM

WITHOUT SPECIFICATION OF SITE 64 17 4 12 30 12 16 21 6 39 11 14

C81 HODGKIN DISEASE 9 5 2 - 2 - 1 4 1 - 2 1C82 FOLLICULAR NON-HODGKIN

LYMPHOMA 4 3 2 1 4 2 - - 1 1 1 -C83 DIFFUSE NON-HODGKIN

LYMPHOMA 21 2 - 2 16 3 1 2 4 2 2 5C84 PERIPHERAL AND CUTANEOUS

T-CELL LYMPHOMAS 2 1 - - 1 - - - - - - 1C85 OTHER AND UNSPECIFIED

TYPES OF NON-HODGKIN LYMPHOMA 7 3 - 1 4 - 1 3 - 3 - 1

C88 MALIGNANT IMMUNOPROLIFERATIVE DISEASES - - - - - - 1 - - - - -

C90 MULTIPLE MYELOMA AND MALIGNANT PLASMA CELL NEOPLASMS 17 4 2 2 7 - - 7 - 3 3 4

C91 LYMPHOID LEUKAEMIA 18 6 6 5 14 4 1 3 - 1 2 3C92 MYELOID LEUKAEMIA 14 8 2 2 3 3 8 3 1 3 2 1C93 MONOCYTIC LEUKAEMIA - - - - 1 - 1 - - - - -C94 OTHER LEUKAEMIAS OF

SPECIFIED CELL TYPE 3 - - - 1 - 1 3 - - - -C95 LEUKAEMIA, UNSPECIFIED

CELL TYPE 7 1 - - 1 - - 1 - - 1 1C96 OTHER AND UNSPECIFIED

NEOPLASMS OF LYMPHOID, BLOOD FORMING AND RELATED TISSUES 1 2 - - - - - - - - - -


DISTRICT


75

- - 1 - - - - - - - - - - 1 - -

1 2 4 1 1 2 - 1 - 1 1 2 4 - 1 2

- 1 12 4 2 3 - - - 4 1 1 1 4 2 4

59 78 372 120 55 145 33 56 60 118 91 79 100 185 114 56- 6 10 4 1 5 2 1 - 1 1 1 2 6 5 3

- - 2 - - - 1 1 - - - 1 2 3 1 -23 34 59 33 10 49 12 23 22 24 25 26 37 54 21 8

13 34 125 56 23 40 21 17 23 43 33 30 24 52 43 22

- 1 4 2 1 - - - - 7 1 3 6 1 2 1

16 10 81 37 16 46 10 11 7 15 15 17 38 41 47 14

- - 2 - - 1 - - - - - - 1 - - -

- - - - - - - 1 - - - - - - - -

2 2 18 7 1 9 5 2 2 7 2 1 9 9 8 5

- - 5 - - 1 - - - 1 - 1 - 1 1 -- - - - - - - - - - - 1 - - 1 1

2 15 31 10 4 14 2 4 4 12 4 3 4 12 16 11

- - - - - - - 1 - - - - - 2 1 1

- - 2 1 - - 1 1 - - 1 - - 1 - -

- - 4 1 - - - - - 1 1 1 - - - 7

3 7 30 8 7 10 3 4 3 10 5 3 10 12 11 5

- - 1 - - - - - - 1 - - - - - -

- 4 51 7 6 10 7 2 3 5 2 2 8 9 4 7- - 1 - - - - - - - - - - - 1 -

- - - - - - - - - 1 - - - - - -

1 - - 1 - - - - - 2 - - - 1 2 1

3 9 52 18 5 23 9 7 10 23 12 4 8 12 24 8

1 2 6 6 2 1 1 1 1 4 - 2 4 5 3 1

- - 4 - - 2 - - 2 - - - - - - -

2 3 16 6 3 - 5 1 2 12 2 1 10 6 2 2

- - - 2 - 2 - - - 3 2 - - - - -

1 1 6 3 - 3 - - 4 3 - 3 - 4 - 1

- - - - - - - - - - - - - - - -

1 - 9 1 1 2 2 2 1 1 1 2 1 7 3 31 3 13 4 2 5 3 2 3 2 - 2 5 12 4 52 - 7 6 2 - 2 5 2 - 2 1 1 7 4 2- - 2 1 - - - - - - - - - - 2 -

- - 3 - - - 1 - 1 - - - - 7 - -

1 1 1 2 1 - - - - 1 - 1 - - 1 -

- - - - - - - - - - - - - 1 - -



Sofi a district


gradStara


76

C00-97 ALL SITES 290.4 284.6 297.0 292.4 311.1 268.6 290.5 261.9 253.0 314.2 219.0 258.5

C00 LIP 0.9 2.9 4.5 2.9 2.0 1.0 0.4 1.6 0.0 2.1 0.3 2.5

C01 BASE OF TONGUE 0.7 1.2 2.6 0.9 0.7 0.6 0.0 0.4 0.8 0.0 0.8 0.7C02 OTHER AND UNSPECIFIED

PARTS OF TONGUE 1.1 0.6 0.0 0.7 0.5 0.0 2.9 1.6 0.8 1.0 0.8 1.7

C03 GUM 0.5 0.3 0.0 1.4 1.2 0.8 0.6 0.9 0.0 2.1 0.0 0.0

C04 FLOOR OF MOUTH 0.9 0.9 0.8 0.6 0.0 0.7 1.4 1.0 1.7 0.8 0.8 0.6

C05 PALATE 0.2 0.3 0.0 0.0 0.9 0.0 0.6 0.5 0.0 0.0 0.8 0.0C06 OTHER AND UNSPECIFIED

PARTS OF MOUTH 0.4 0.3 0.0 0.0 0.3 0.0 0.0 0.0 0.8 0.0 0.0 0.5

C07 PAROTID GLAND 0.4 0.3 0.0 0.6 0.1 1.3 0.7 0.2 0.0 1.4 0.0 0.9C08 OTHER AND UNSPECIFIED

MAJOR SALIVARY GLANDS 0.2 0.0 0.9 0.0 0.0 0.6 0.0 0.0 0.7 0.4 0.0 0.0

C09 TONSIL 1.3 2.0 0.8 1.4 1.0 3.0 2.7 0.8 1.4 2.8 1.8 2.3

C10 OROPHARYNX 0.5 0.0 0.8 1.3 0.3 1.2 0.0 1.0 0.0 0.4 0.0 0.6

AGE-ADJUSTED (WORLD STANDARD) INCIDENCE RATES OF CANCER PER 100 000CODEICD-10 SITE

DISTRICT


C11 NASOPHARYNX 1.4 1.4 0.6 1.3 0.9 2.2 1.3 1.2 4.3 2.1 0.0 0.6

C12 PYRIFORM SINUS 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0

C13 HYPOPHARYNX 0.5 0.5 2.2 0.8 1.1 0.0 5.3 1.3 2.2 2.9 4.0 2.0C14 OTHER AND ILL-DEFINED

SITES IN LIP, ORAL CAVITY AND PHARYNX 0.1 0.0 0.0 0.0 1.0 0.6 0.0 0.0 1.4 0.0 0.0 0.0

C15 OESOPHAGUS 3.0 2.7 3.1 3.1 1.7 3.4 4.4 1.8 5.3 1.4 3.7 4.5

C16 STOMACH 11.0 18.2 23.1 11.1 14.9 25.1 11.6 13.7 13.7 13.2 15.4 10.3

C17 SMALL INTESTINE 0.6 0.0 0.4 0.8 1.0 0.8 1.2 0.4 0.0 0.6 0.0 0.5

C18 COLON 26.4 16.9 21.2 14.2 28.2 23.8 13.6 19.7 19.8 25.7 18.3 16.9

C19 RECTOSIGMOID JUNCTION 3.7 3.2 4.5 3.2 1.9 0.6 7.5 3.5 0.7 5.2 1.9 2.6

C20 RECTUM 12.1 12.2 15.5 12.4 19.9 14.7 9.6 14.8 15.3 13.0 9.8 14.8

C21 ANUS AND ANAL CANAL 0.6 0.0 0.0 0.0 0.3 0.0 1.3 0.0 0.0 0.0 0.8 0.7C22 LIVER AND INTRAHEPATIC

BILE DUCTS 7.2 10.3 3.7 3.7 8.4 8.7 9.9 2.4 4.6 2.6 2.1 10.4

C23 GALLBLADDER 0.6 1.2 1.9 0.6 0.2 1.4 0.0 1.9 0.8 2.6 0.0 1.9C24 OTHER AND UNSPECIFIED

PARTS OF BILIARY TRACT 1.0 0.6 0.4 0.3 1.1 0.6 1.8 0.7 0.8 1.0 0.8 1.9

C25 PANCREAS 11.6 9.8 7.7 12.4 11.4 14.8 8.2 7.8 10.9 13.2 8.5 10.8C26 OTHER AND ILL-DEFINED

DIGESTIVE ORGANS 0.1 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0C30 NASAL CAVITY AND MIDDLE

EAR 0.2 0.0 0.0 0.0 0.7 0.0 0.0 0.4 0.0 0.5 0.0 0.0

C31 ACCESSORY SINUSES 0.3 0.4 2.2 0.7 0.3 0.0 0.6 1.2 0.0 0.0 0.8 0.7

C32 LARYNX 10.4 8.1 11.1 16.6 7.5 15.4 8.9 7.9 4.2 7.8 7.8 8.5

C33 TRACHEA 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.0

C34 BRONCHUS AND LUNG 47.0 50.3 71.9 63.8 47.7 49.9 68.6 50.5 42.8 61.4 30.1 46.0

C37 THYMUS 0.0 0.0 0.0 0.0 0.3 0.0 0.9 0.0 0.3 0.6 0.8 0.6C38 HEART, MEDIASTINUM, AND

PLEURA 0.3 0.0 0.6 1.6 0.5 0.0 2.1 0.0 0.0 2.9 0.0 2.0C39 OTHER AND ILL-DEFINED

SITES WITHIN RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C40 BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS 0.9 1.2 1.2 0.7 1.2 0.0 0.0 0.8 2.6 1.0 0.0 0.0

C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES 0.4 1.0 0.0 0.0 0.0 0.6 1.4 0.0 0.0 0.0 0.5 0.0

C43 MELANOMA OF SKIN 6.5 3.5 5.5 2.4 4.6 2.9 1.2 4.1 7.6 3.0 1.3 3.8

77

193.0 233.1 307.9 248.8 263.4 312.2 242.7 235.1 251.8 235.2 264.2 237.5 285.5 312.3 336.0 286.3

0.7 1.2 3.3 2.1 1.7 2.8 2.6 4.4 5.6 1.9 3.8 1.0 3.0 1.4 4.8 3.2

0.9 1.5 0.8 1.9 0.0 0.7 0.0 0.9 0.0 2.1 0.0 0.0 1.5 0.0 0.7 2.1

1.0 2.8 1.3 1.2 0.8 0.5 3.2 2.0 1.1 1.1 0.0 2.2 3.6 1.2 0.0 0.9

0.0 1.7 0.6 0.9 0.0 0.6 0.9 0.0 2.2 0.6 0.0 0.0 0.0 0.0 0.0 1.1

0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 1.3 0.0 1.4 0.0 0.8 1.9 2.7 0.0

0.0 0.0 0.7 0.0 0.0 1.1 0.9 1.1 0.0 0.0 0.0 0.8 0.9 0.0 0.5 0.0

0.0 0.0 0.3 0.0 1.1 0.0 0.0 0.9 0.8 0.0 0.0 0.9 0.4 0.0 0.5 0.0

0.0 0.0 0.4 0.4 0.0 0.9 0.0 2.5 0.0 1.0 0.7 1.2 0.2 0.6 0.0 0.0

1.0 0.0 0.4 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0

2.0 0.7 1.5 0.5 2.2 0.9 2.0 2.1 2.4 1.4 2.8 0.3 0.4 0.4 0.4 1.1

2.4 2.6 0.5 0.0 1.1 0.5 0.0 0.0 1.0 0.5 0.0 1.4 0.8 0.5 0.0 0.0

1.0 0.7 1.8 0.8 1.1 0.8 0.0 0.0 0.0 2.0 0.0 0.0 1.6 0.5 1.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 2.1 0.8 0.0 0.0 0.0 0.01.0 0.0 1.2 1.1 0.0 0.0 1.0 3.6 2.0 1.4 1.6 1.8 0.9 0.3 0.5 2.0

1.0 1.1 0.4 1.9 1.9 0.0 0.0 0.0 0.0 0.0 1.6 0.9 0.8 0.0 0.0 0.0

0.9 0.0 1.4 1.0 5.0 2.7 4.6 2.5 1.0 3.1 4.8 2.6 3.6 4.3 3.8 0.0

7.3 8.4 17.2 13.0 18.7 13.4 15.1 15.2 17.1 14.3 14.2 8.9 25.4 14.6 17.4 23.8

0.0 0.0 0.4 0.2 0.8 0.4 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0

17.5 16.0 22.8 20.6 17.6 30.6 11.6 17.6 14.6 22.2 22.0 28.9 20.1 28.5 16.8 17.9

1.0 4.4 2.5 1.9 2.1 3.3 0.6 0.5 1.9 0.8 4.7 0.3 0.0 2.9 0.7 0.0

8.8 13.6 15.8 15.4 14.2 17.5 10.8 9.0 21.0 13.4 12.9 6.1 14.1 14.9 15.2 9.0

0.0 0.0 0.2 0.5 0.0 1.7 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.5 0.0

1.4 5.5 8.0 8.6 4.2 7.9 5.7 7.4 4.8 2.3 8.9 4.1 4.7 9.4 6.0 11.7

0.3 0.3 0.4 0.2 1.1 0.7 0.9 2.0 1.3 0.0 0.0 0.9 0.7 0.8 0.9 0.9

1.0 0.0 0.8 0.8 0.0 0.2 0.9 0.8 0.0 0.6 1.0 0.0 0.7 1.1 0.4 0.0

4.9 10.9 9.6 8.0 5.2 12.5 7.4 2.8 7.6 9.6 14.3 11.3 7.2 11.4 10.2 11.2

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0

0.0 0.0 0.6 0.0 0.0 0.0 1.2 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0

0.0 2.3 0.9 1.4 0.8 0.0 0.9 0.0 0.0 0.0 0.3 0.0 0.4 0.0 1.5 0.8

13.3 3.9 11.4 10.3 11.1 5.9 11.0 8.4 12.0 12.4 20.4 11.5 9.0 12.6 13.4 12.5

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.4 0.7

32.4 38.7 59.7 52.3 56.4 64.1 60.9 41.4 43.4 39.2 44.1 53.0 48.4 58.7 74.8 57.8

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 1.3 0.0 0.0 0.0 0.0

0.4 0.7 0.4 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.8 1.3 0.0 0.3 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 2.1 0.3 0.0 0.7 0.6 0.0

0.0 0.0 0.5 0.8 0.8 0.0 0.0 0.0 4.1 0.7 2.1 0.3 0.8 0.4 0.6 0.0

3.2 3.2 3.8 2.5 2.5 2.1 0.0 1.6 6.4 3.9 5.3 1.3 3.9 5.9 3.4 3.3



Sofi a district


gradStara


Part 1

78


DISTRICT


C44 OTHER SKIN 32.1 36.4 27.8 38.0 34.7 13.3 37.1 23.6 18.4 30.4 14.6 20.7

C45 MESOTHELIOMA 0.8 0.0 0.0 1.3 0.7 0.0 0.7 0.5 0.0 0.3 0.0 0.2

C46 KAPOSI’S SARCOMA 0.0 0.3 0.6 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0C47 PERIPHERAL NERVES AND

AUTONOMIC NERVOUS SYSTEM 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C48 RETROPERITONEUM AND PERITONEUM 0.6 1.0 0.9 0.7 1.2 0.6 0.0 0.7 0.3 0.0 2.3 0.8

C49 CONNECTIVE AND OTHER SOFT TISSUES 1.2 0.6 2.2 0.3 1.9 2.6 0.0 2.3 0.9 2.7 0.8 0.6

C50 BREAST 1.4 0.5 0.6 0.0 0.6 1.5 1.4 1.5 0.0 1.1 0.8 0.8

C60 PENIS 0.5 1.2 1.2 1.6 0.8 0.0 0.0 1.0 0.0 0.9 0.3 0.0

C61 PROSTATE GLAND 28.2 17.2 14.1 14.5 34.5 17.1 11.9 18.6 26.4 25.7 22.8 16.7

C62 TESTIS 4.7 2.4 2.7 6.4 4.0 6.7 5.5 9.4 10.3 5.3 4.0 15.7C63 OTHER AND UNSPECIFIED

MALE GENITAL ORGANS 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C64 KIDNEY 7.2 11.3 7.9 6.9 7.6 6.2 6.5 7.5 7.1 11.3 10.0 6.1

C65 RENAL PELVIS 1.0 0.3 0.0 0.5 1.5 0.0 0.0 0.8 1.5 0.4 1.4 0.6

C66 URETER 0.3 0.0 0.0 1.4 0.3 0.6 0.0 0.2 0.0 0.0 0.5 0.5

C67 BLADDER 20.7 24.9 17.3 19.9 19.5 11.6 14.2 14.5 18.3 21.7 23.1 17.8C68 OTHER AND UNSPECIFIED

URINARY ORGANS 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0C69 EYE AND ADNEXA 0.3 0.3 0.0 1.0 0.3 0.8 2.4 0.4 1.1 0.5 0.8 0.0

C70 MENINGES 0.2 1.0 0.0 1.1 0.0 0.0 0.6 0.8 0.0 0.4 0.0 0.0

C71 BRAIN 6.3 9.2 7.1 4.7 6.8 9.4 7.5 3.6 4.3 5.5 0.8 6.2C72 SPINAL CORD, CRANIAL

NERVES, AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C73 THYROID GLAND 1.9 1.3 1.0 3.3 2.7 0.5 2.4 0.7 2.8 0.4 0.0 2.0

C74 ADRENAL GLAND 0.2 0.0 0.0 1.6 0.4 2.4 0.0 0.9 0.0 0.0 1.1 0.0C75 OTHER ENDOCRINE GLANDS

AND RELATED STRUCTURES 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0C76 OTHER AND ILL-DEFINED

SITES 0.0 0.4 0.0 0.0 0.6 0.0 0.6 0.0 0.0 0.0 0.0 0.0C80 MALIGNANT NEOPLASM

WITHOUT SPECIFICATION OF SITE 11.7 10.6 10.8 17.9 10.8 9.2 16.2 16.8 6.2 19.4 14.3 12.2

C81 HODGKIN DISEASE 2.4 2.2 1.2 0.0 1.0 1.6 1.4 4.4 0.8 0.9 1.7 2.2C82 FOLLICULAR NON-HODGKIN

LYMPHOMA 0.7 2.3 1.5 1.3 0.5 0.0 0.9 0.0 0.0 0.0 0.6 0.6C83 DIFFUSE NON-HODGKIN

LYMPHOMA 3.8 1.4 2.1 1.2 5.1 4.2 0.8 3.3 2.2 1.7 1.1 0.0C84 PERIPHERAL AND CUTANEOUS

T-CELL LYMPHOMAS 0.3 0.0 0.0 0.0 0.4 0.0 0.6 0.7 0.4 0.0 0.0 0.8C85 OTHER AND UNSPECIFIED

TYPES OF NON-HODGKIN LYMPHOMA 1.0 0.3 0.4 1.0 2.5 2.3 0.7 2.1 2.5 2.1 0.0 2.8

C88 MALIGNANT IMMUNOPROLIFERATIVE DISEASES 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0

C90 MULTIPLE MYELOMA AND MALIGNANT PLASMA CELL NEOPLASMS 1.6 1.4 1.4 2.4 2.2 0.6 1.5 0.6 1.2 1.6 0.0 0.0

C91 LYMPHOID LEUKAEMIA 5.0 3.0 6.4 1.5 4.6 0.3 2.2 2.9 2.9 5.5 3.1 1.1

C92 MYELOID LEUKAEMIA 1.4 2.9 1.0 3.5 2.2 2.2 2.2 0.4 1.0 2.2 0.9 0.5

C93 MONOCYTIC LEUKAEMIA 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2C94 OTHER LEUKAEMIAS OF

SPECIFIED CELL TYPE 0.4 1.0 0.0 0.5 0.3 0.0 1.3 0.5 0.8 0.4 0.9 0.0C95 LEUKAEMIA, UNSPECIFIED

CELL TYPE 0.5 0.3 0.9 0.0 0.1 0.0 0.0 0.7 0.0 0.3 0.8 0.0C96 OTHER AND UNSPECIFIED

NEOPLASMS OF LYMPHOID,BLOOD FORMING ANDRELATED TISSUES 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0

79

Part 2

23.0 23.5 30.8 22.0 25.2 47.6 33.3 32.4 24.8 18.7 14.7 16.2 48.2 41.0 33.0 45.9

0.0 0.0 0.5 1.6 0.0 0.7 0.0 1.8 1.0 0.0 0.0 0.3 0.0 0.0 1.8 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.7 1.0 0.0 1.8 1.1 0.0 0.0 0.4 0.0 0.9 2.7 1.5 0.5 1.4

1.0 3.1 2.5 2.6 3.0 0.7 0.5 0.8 4.0 0.4 1.2 2.6 1.0 1.5 2.6 1.5

0.9 1.5 0.4 0.7 1.0 0.5 2.0 0.0 0.5 0.4 0.0 0.0 0.7 0.2 0.4 0.0

1.7 0.3 0.7 0.4 0.0 1.4 0.0 1.2 0.0 1.5 1.6 0.0 1.7 0.9 1.4 0.0

11.4 17.0 25.4 14.6 14.8 20.8 10.1 13.5 11.9 16.4 21.0 19.8 21.3 22.6 22.8 18.0

4.4 7.5 4.8 6.0 6.7 5.7 4.2 4.5 2.5 4.4 5.0 7.6 6.2 5.6 6.5 4.5

0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

1.9 5.7 9.4 9.8 6.9 10.4 5.5 8.1 6.9 5.3 3.4 5.1 4.7 8.4 8.5 9.7

0.0 0.0 1.7 1.1 1.0 0.0 0.0 0.0 0.0 0.2 0.8 0.3 0.4 0.5 0.9 0.0

0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 1.1

14.0 21.6 20.0 15.9 16.7 16.1 10.7 15.2 15.0 12.8 12.3 9.7 12.6 16.2 20.9 14.5

0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.7 0.9 2.1 0.0 0.0 0.0 0.9 0.0 0.7 0.0 0.0 0.0 0.5 2.9 1.0

0.0 0.7 0.6 0.0 0.0 0.5 1.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 1.5 1.8

4.2 2.1 6.2 5.6 3.8 5.5 2.1 7.1 3.7 11.2 9.7 6.8 5.1 5.9 8.5 3.8

0.0 0.7 0.4 0.5 0.0 0.5 0.0 0.0 3.0 0.4 0.0 0.0 0.4 0.0 0.2 0.0

0.0 0.0 1.3 0.5 3.1 2.5 2.0 1.3 0.0 0.0 0.0 0.0 0.0 1.1 0.7 0.0

0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 2.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0

0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 1.4 0.0 0.9 0.0

9.5 10.6 14.0 8.4 10.9 12.7 12.1 11.5 6.9 12.5 14.1 12.9 16.4 13.4 19.5 13.1

6.8 2.4 3.5 1.0 1.1 0.9 5.0 1.4 3.8 1.1 0.0 1.3 0.5 1.6 2.1 3.1

1.0 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0

1.9 3.3 1.7 1.3 3.6 0.9 3.7 0.0 3.3 3.7 1.4 2.2 3.6 1.9 2.9 3.6

0.0 0.5 0.4 0.0 0.0 0.0 0.0 0.9 0.0 1.3 1.1 0.0 0.0 0.3 0.0 1.0

0.0 4.0 0.4 1.2 2.9 1.2 0.0 0.8 1.0 0.0 0.8 2.1 0.0 1.4 2.4 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

3.9 1.2 1.8 0.5 4.9 3.2 1.1 0.0 4.2 0.4 0.0 2.4 1.4 2.4 2.1 0.0

1.4 2.2 4.6 1.1 7.6 2.9 2.9 3.8 3.8 2.6 1.1 2.1 0.0 4.3 4.5 2.4

0.0 1.8 2.4 0.2 0.0 0.5 2.2 1.2 1.0 0.8 1.0 0.9 2.9 2.8 2.2 0.0

1.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0

1.0 1.1 0.2 1.0 0.0 0.4 0.0 0.8 0.0 0.0 0.0 0.9 0.0 3.4 0.0 0.0

0.0 0.3 0.6 0.0 0.0 0.7 0.0 0.0 0.8 0.9 1.6 0.0 0.0 0.5 0.5 0.0

0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0



Sofi a district


gradStara


80

C00-97 ALL SITES 250.8 244.3 212.8 216.8 253.4 215.8 208.5 190.7 195.1 193.4 196.5 207.4C00 LIP 0.1 0.9 1.7 0.7 0.9 0.4 0.2 0.3 0.0 0.1 0.5 0.4

C01 BASE OF TONGUE 0.1 0.4 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0C02 OTHER AND UNSPECIFIED

PARTS OF TONGUE 0.5 0.3 0.0 0.0 0.4 0.0 0.8 0.0 0.0 0.0 0.0 0.0

C03 GUM 0.2 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0

C04 FLOOR OF MOUTH 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C05 PALATE 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0C06 OTHER AND UNSPECIFIED

PARTS OF MOUTH 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C07 PAROTID GLAND 0.2 0.4 0.2 0.0 0.0 0.4 0.0 0.0 0.7 1.6 0.0 0.9C08 OTHER AND UNSPECIFIED

MAJOR SALIVARY GLANDS 0.2 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.7

C09 TONSIL 0.2 0.4 2.1 0.0 0.2 0.0 0.9 0.4 0.0 0.0 0.0 0.2

C10 OROPHARYNX 0.2 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.9

C11 NASOPHARYNX 0.4 0.3 0.0 0.8 0.3 0.8 1.6 0.0 0.0 0.7 2.1 3.4

C12 PYRIFORM SINUS 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C13 HYPOPHARYNX 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0C14 OTHER AND ILL-DEFINED

SITES IN LIP, ORAL CAVITY AND PHARYNX 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C15 OESOPHAGUS 0.8 0.6 0.2 1.6 0.4 0.0 0.4 0.4 0.0 0.1 0.6 0.6

C16 STOMACH 5.6 7.7 7.3 5.1 9.0 7.0 7.1 4.4 6.8 6.7 5.0 4.4

C17 SMALL INTESTINE 0.4 0.0 0.0 0.8 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.5

C18 COLON 18.3 13.0 8.8 14.1 18.2 12.5 10.9 15.0 15.6 11.2 15.0 9.8

C19 RECTOSIGMOID JUNCTION 2.4 1.5 1.9 0.9 0.4 1.4 2.8 1.5 0.0 1.7 4.8 3.1

C20 RECTUM 6.6 7.8 6.3 4.6 8.3 7.6 5.6 9.3 7.0 6.9 7.6 10.1

C21 ANUS AND ANAL CANAL 0.6 0.3 0.0 0.0 1.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0C22 LIVER AND INTRAHEPATIC

BILE DUCTS 1.9 3.5 4.0 3.2 2.3 3.4 0.4 1.4 2.7 1.2 1.1 0.6

C23 GALLBLADDER 0.8 2.2 2.9 1.7 1.8 2.4 1.0 1.5 0.5 2.1 2.5 1.2C24 OTHER AND UNSPECIFIED

PARTS OF BILIARY TRACT 0.2 0.8 0.2 0.0 0.7 0.0 2.0 0.0 0.9 1.5 0.6 0.2

C25 PANCREAS 6.1 5.1 7.6 5.0 5.5 6.8 5.3 3.4 3.0 5.1 3.9 4.7C26 OTHER AND ILL-DEFINED

DIGESTIVE ORGANS 0.2 0.1 0.0 0.0 0.7 0.0 0.2 0.1 0.0 0.0 0.0 0.0C30 NASAL CAVITY AND MIDDLE

EAR 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C31 ACCESSORY SINUSES 0.3 0.0 0.0 0.5 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.1

C32 LARYNX 0.7 0.2 0.5 0.5 1.0 1.3 0.0 0.0 0.7 0.4 0.0 0.0

C33 TRACHEA 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C34 BRONCHUS AND LUNG 13.7 7.8 8.0 7.5 11.2 8.8 7.7 7.1 8.5 7.3 8.1 4.3

C37 THYMUS 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0C38 HEART, MEDIASTINUM AND

PLEURA 0.6 0.3 0.0 0.5 0.0 0.0 1.3 0.6 0.0 0.0 0.0 0.3C39 OTHER AND ILL-DEFINED

SITES WITHIN RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C40 BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS 1.2 0.0 1.4 0.0 0.6 0.0 0.8 0.0 0.0 0.0 0.0 0.0

C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES 0.9 0.8 0.0 0.0 0.0 3.0 0.0 0.6 0.0 0.0 1.4 0.0

C43 MELANOMA OF SKIN 3.6 2.3 4.4 4.0 2.2 3.5 3.4 2.0 7.5 1.2 2.2 2.7

C44 OTHER SKIN 19.6 24.0 13.3 15.6 25.5 9.9 24.0 13.3 14.6 17.9 12.6 18.6

C45 MESOTHELIOMA 0.2 1.0 0.0 0.5 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0

C46 KAPOSI’S SARCOMA 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.0 0.0


DISTRICT


81

190.2 204.6 232.9 214.9 201.6 259.4 168.0 201.6 197.3 187.0 211.2 209.2 204.4 226.1 199.7 216.20.2 2.1 0.8 0.8 0.4 0.3 2.2 1.0 0.9 0.0 0.2 0.0 0.5 1.1 0.5 0.5

0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.3 0.0 0.2 0.0 0.5 0.7 0.0 0.0

0.8 0.0 0.2 0.6 1.4 0.4 0.0 0.0 1.3 0.2 0.0 0.0 1.0 0.0 0.0 0.0

0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0

0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.00.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.8 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.4 0.2 0.1 0.0 0.7

0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.8 0.8 0.7 0.0 0.0 0.2 0.0 0.0 0.7

0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0

0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.4 0.0

1.4 0.0 0.8 0.0 0.0 0.6 0.0 0.6 0.0 1.4 0.0 1.3 0.0 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.7 0.2 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0

0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.5 0.4 1.8 0.0 0.0 1.7 0.0 2.0 0.9 0.0 1.5 0.3 1.0 1.2

1.6 4.9 7.3 8.2 8.2 2.7 4.5 8.1 10.4 6.5 6.7 6.9 9.8 5.6 4.0 9.1

0.8 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0

10.9 12.6 17.0 12.2 8.6 18.1 5.9 10.2 5.0 14.0 8.3 15.1 17.2 15.6 11.0 9.2

0.0 0.4 0.6 2.1 0.9 1.7 1.4 1.8 1.7 1.3 1.5 0.9 0.0 1.6 0.0 0.0

5.5 8.8 8.0 5.7 5.6 5.7 1.9 5.1 1.7 7.2 9.7 5.4 6.9 9.1 5.8 5.30.0 0.6 0.6 0.4 0.0 0.3 0.0 0.3 0.0 0.0 0.2 1.8 1.0 0.7 0.0 0.0

1.2 1.4 2.4 3.0 0.7 0.8 2.0 1.3 4.6 1.5 1.4 0.0 2.1 1.9 1.1 4.21.5 1.0 1.1 1.4 0.6 3.2 3.6 1.3 1.4 1.4 0.0 0.0 1.7 0.9 0.4 2.8

0.0 0.0 0.1 0.4 0.0 0.3 1.1 0.8 0.0 0.2 0.0 0.2 0.1 1.1 0.2 0.5

1.2 3.8 5.0 4.4 6.3 5.9 6.2 1.4 3.4 4.7 7.2 6.3 5.4 6.0 3.9 3.8

0.0 0.2 0.0 0.0 0.0 0.8 0.0 0.3 1.3 0.4 0.0 0.0 0.0 0.2 0.0 0.0

0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.00.0 1.4 0.2 0.6 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0

1.8 0.0 1.0 0.0 0.9 0.8 0.0 0.0 0.0 0.0 0.0 1.7 1.2 0.5 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.05.9 2.8 10.0 8.0 11.0 6.5 3.4 4.7 6.4 8.3 8.8 5.9 3.9 7.6 9.2 4.8

0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.1 0.0 0.0 0.0 0.8 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.3 1.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.8 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.7 0.0 2.6

0.0 0.0 0.3 1.0 0.9 0.6 0.0 0.0 0.0 0.7 0.0 0.2 0.0 0.3 1.2 0.0

3.3 0.8 3.0 1.9 0.9 8.0 1.3 1.9 1.3 2.7 2.6 6.6 2.2 1.9 3.2 0.6

21.3 13.4 22.8 18.0 24.5 46.2 27.6 30.7 13.2 10.9 15.0 16.4 42.0 25.9 24.7 27.7

0.0 1.1 0.2 1.1 0.0 0.8 0.0 0.0 0.8 0.0 1.2 0.0 0.0 0.5 0.3 1.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0



Sofi a district


gradStara


82

C47 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM 0.0 0.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0

C48 RETROPERITONEUM AND PERITONEUM 1.4 0.4 0.0 0.0 1.0 1.0 0.4 0.0 0.3 2.3 0.0 0.3

C49 CONNECTIVE AND OTHER SOFT TISSUES 0.4 1.6 2.5 3.6 1.2 0.0 2.3 2.1 1.7 0.7 0.6 0.0

C50 BREAST 75.3 61.5 54.7 53.2 60.4 51.5 43.7 40.4 55.8 45.4 40.7 37.2C51 VULVA 0.9 0.7 1.3 0.8 2.8 0.8 1.3 1.0 1.0 1.2 2.3 1.4

C52 VAGINA 0.7 0.0 0.0 0.5 0.4 0.0 0.0 0.0 0.0 1.2 0.0 0.0

C53 CERVIX UTERI 17.2 19.0 13.0 27.8 17.3 26.8 22.7 20.3 13.3 27.7 27.2 31.2

C54 CORPUS UTERI 17.1 23.8 13.0 17.0 20.8 19.9 13.9 19.6 17.5 14.7 11.6 19.8

C55 UTERUS, NOS 0.1 1.8 0.8 0.0 0.0 0.4 0.0 1.0 0.0 0.8 0.0 1.0

C56 OVARY 13.8 13.8 13.8 11.5 11.9 11.4 13.6 9.6 16.9 6.1 10.1 14.2C57 OTHER AND UNSPECIFIED

FEMALE GENITAL ORGANS 0.1 0.3 1.0 0.0 0.2 1.6 1.7 0.0 0.7 0.0 0.0 0.2

C58 PLACENTA 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C64 KIDNEY 3.1 5.1 4.2 1.6 5.9 3.6 4.3 2.0 3.4 1.5 3.9 2.6

C65 RENAL PELVIS 0.5 0.0 0.0 1.3 0.0 0.0 0.0 0.8 0.6 0.0 0.2 0.1

C66 URETER 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2

C67 BLADDER 5.7 3.3 4.2 0.9 4.5 3.5 3.4 4.1 1.1 3.0 5.3 3.8C68 OTHER AND UNSPECIFIED

URINARY ORGANS 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

C69 EYE AND ADNEXA 0.5 0.5 0.0 0.5 0.1 1.6 0.0 0.0 0.0 0.2 0.0 0.0

C70 MENINGES 0.4 0.2 0.0 0.0 0.6 0.2 1.0 0.7 0.0 0.5 0.0 0.0

C71 BRAIN 4.7 5.7 7.7 5.9 4.7 7.1 5.4 4.9 4.3 3.8 2.6 3.6C72 SPINAL CORD, CRANIAL

NERVES AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM 0.1 0.3 2.2 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0

C73 THYROID GLAND 4.2 5.4 3.4 8.0 6.0 2.0 2.6 3.0 0.9 4.5 6.0 5.2

C74 ADRENAL GLAND 0.4 0.0 0.0 0.0 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0C75 OTHER ENDOCRINE GLANDS

AND RELATED STRUCTURES 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0C76 OTHER AND ILL-DEFINED

SITES 0.9 1.3 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3C80 MALIGNANT NEOPLASM

WITHOUT SPECIFICATION OF SITE 4.7 4.2 2.4 6.2 6.9 5.2 6.5 7.0 2.2 9.9 4.5 5.9

C81 HODGKIN DISEASE 1.0 2.4 2.5 0.0 0.7 0.0 0.8 3.4 1.1 0.0 4.0 0.2C82 FOLLICULAR NON-HODGKIN

LYMPHOMA 0.4 0.6 1.2 0.9 1.2 1.2 0.0 0.0 0.5 0.6 0.2 0.0C83 DIFFUSE NON-HODGKIN

LYMPHOMA 1.8 0.5 0.0 2.3 4.0 2.2 0.2 0.9 3.1 0.6 1.8 3.6C84 PERIPHERAL AND CUTANEOUS

T-CELL LYMPHOMAS 0.1 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.585 OTHER AND UNSPECIFIED

TYPES OF NON-HODGKIN LYMPHOMA 0.6 0.7 0.0 0.6 1.0 0.0 0.2 1.2 0.0 1.2 0.0 0.5

C88 MALIGNANT IMMUNOPROLIFERATIVE DISEASES 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0

C90 MULTIPLE MYELOMA AND MALIGNANT PLASMA CELL NEOPLASMS 1.4 1.0 0.9 1.2 1.5 0.0 0.0 2.0 0.0 0.9 4.8 2.2

C91 LYMPHOID LEUKAEMIA 2.5 2.0 9.0 2.2 6.7 1.9 0.5 0.8 0.0 0.1 0.6 3.6

C92 MYELOID LEUKAEMIA 1.6 3.9 1.2 0.8 0.8 1.5 3.6 1.5 0.7 0.7 1.0 1.0

C93 MONOCYTIC LEUKAEMIA 0.0 0.0 0.0 0.0 0.2 0.0 0.9 0.0 0.0 0.0 0.0 0.0C94 OTHER LEUKAEMIAS OF

SPECIFIED CELL TYPE 0.3 0.0 0.0 0.0 0.2 0.0 0.6 1.6 0.0 0.0 0.0 0.0C95 LEUKAEMIA, UNSPECIFIED

CELL TYPE 0.5 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.9C96 OTHER AND UNSPECIFIED

NEOPLASMS OF LYMPHOID, BLOOD FORMING AND RELATED TISSUES 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

D06 NOT INCLUDED ABOVE CA IN SITU OF CERVIX UTERI 7.6 4.7 6.3 10.4 5.4 3.3 17.6 6.5 4.9 6.8 2.5 10.0


DISTRICT


83

0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0

0.8 1.3 0.7 0.5 1.4 1.1 0.0 1.1 0.0 0.1 2.0 1.4 1.2 0.0 0.3 1.9

0.0 1.4 1.9 2.0 1.4 1.0 0.0 0.0 0.0 2.2 4.2 0.2 0.5 1.5 0.5 3.955.9 48.8 59.1 48.8 48.8 61.2 28.6 51.0 55.7 48.6 64.5 60.0 35.9 57.1 46.6 45.0

0.0 2.8 1.3 0.8 0.6 1.4 1.4 0.6 0.0 0.2 0.7 0.4 0.8 0.8 0.9 2.6

0.0 0.0 0.6 0.0 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.9 0.7 1.1 0.4 0.026.1 30.7 11.5 16.7 9.1 25.4 12.8 22.4 25.1 12.2 21.6 25.2 15.3 21.2 10.4 7.8

13.1 19.6 17.6 21.3 20.1 15.7 16.8 13.8 18.9 15.8 22.5 20.3 8.3 14.2 15.6 16.3

0.0 1.1 0.6 0.5 0.9 0.0 0.0 0.0 0.0 2.5 0.9 1.2 1.5 0.3 0.5 0.7

18.2 6.4 14.4 15.1 15.4 18.0 9.6 9.4 7.0 7.2 10.3 13.0 15.1 13.7 22.5 12.3

0.0 0.0 0.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

3.3 2.3 2.4 2.6 0.9 3.3 4.5 1.6 1.6 2.2 1.4 0.2 4.5 2.1 3.3 5.7

0.0 0.0 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.1 0.7 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.7

1.3 5.1 3.6 2.4 2.3 4.2 2.0 3.1 2.9 2.7 1.7 1.4 1.4 2.9 5.3 9.2

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.6 0.7 0.5

0.0 0.0 0.1 0.4 0.0 0.0 1.0 0.6 0.0 0.0 0.7 0.0 0.0 0.3 0.0 0.0

0.0 0.0 0.6 0.6 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.0 0.0 0.0 3.6

2.2 8.9 4.1 6.1 7.0 4.5 1.8 3.1 5.0 5.4 3.6 1.0 4.2 4.6 5.5 3.8

0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.00.0 4.6 9.3 4.2 7.3 5.5 7.0 1.9 3.8 4.6 1.5 2.0 3.6 2.9 2.3 6.6

0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0

0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 1.5 0.4 0.5

1.4 6.2 6.6 5.6 2.8 6.5 5.6 4.9 7.0 6.5 5.0 2.1 2.0 3.0 7.0 5.8

0.8 2.4 1.3 4.4 2.0 0.7 0.8 0.6 0.6 3.4 0.0 1.7 2.7 2.4 0.9 0.7

0.0 0.0 0.4 0.0 0.0 1.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0

2.4 2.2 3.0 2.3 2.5 0.0 4.4 0.7 1.3 3.9 1.3 1.3 4.5 1.6 0.8 1.8

0.0 0.0 0.0 0.9 0.0 0.9 0.0 0.0 0.0 0.4 1.4 0.0 0.0 0.0 0.0 0.0

0.5 0.6 1.2 1.2 0.0 1.1 0.0 0.0 2.4 0.9 0.0 1.6 0.0 1.1 0.0 0.3

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.8 0.0 1.4 0.2 1.2 1.0 1.2 1.9 0.8 0.7 0.7 0.7 0.4 1.6 1.2 1.50.8 3.0 2.8 2.6 1.1 1.8 3.6 4.2 1.4 0.4 0.0 1.6 3.5 3.3 3.0 7.51.9 0.0 1.1 2.8 2.9 0.0 2.0 4.6 4.8 0.0 1.9 1.3 0.2 3.0 1.2 1.60.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0

0.0 0.0 0.3 0.0 0.0 0.0 1.3 0.0 2.2 0.0 0.0 0.0 0.0 1.9 0.0 0.0

1.4 1.1 0.3 0.9 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.1 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0

3.4 3.7 3.3 5.3 1.5 6.0 2.4 9.3 8.0 2.2 7.0 4.5 7.7 17.2 11.3 1.0



Sofi a district


gradStara


84

DISTRIBUTION OF THE NEWLY DIAGNOSED CANCER CASESBY PRIMARY SITES AND STAGES IN BULGARIA 2009

CODE ICD-10 SITE TOTAL NUMBER

I STAGE II STAGE III STAGE IV STAGE UNKNOWN STAGE

NUMBER % NUMBER % NUMBER % NUMBER % NUMBER %

C00-97 ALL SITES 34712 8665 25.0 7468 21.5 6601 19.0 7539 21.7 4439 12.8C00-97 BUT C44

ALL SITES BUT NON-MELANOMA SKIN 30407 5205 17.1 6744 22.2 6512 21.4 7532 24.8 4414 14.5

C00 LIP 214 151 70.6 47 22.0 12 5.6 3 1.4 1 0.5C01-02 TONGUE 142 14 18.3 33 23.2 38 26.8 46 32.4 11 7.7C03-06 MOUTH 138 8 26.3 28 20.3 34 24.6 63 45.7 5 3.6C07-08 SALIVARY GLANDS 77 5 11.7 25 32.5 25 32.5 17 22.1 5 6.5C09 TONSIL 92 - - 11 12.0 35 38.0 40 43.5 6 6.5C10 OTHER OROPHARYNX 43 3 7.0 8 18.6 9 20.9 21 48.8 2 4.7C11 NASOPHARYNX 88 2 2.3 9 10.2 35 39.8 38 43.2 4 4.5C12-13 HYPOPHARYNX 91 1 6.7 6 6.6 17 18.7 59 64.8 8 8.8C14 PHARYNX UNSPECIFIED 26 - - 1 3.8 3 11.5 18 69.2 4 15.4C15 OESOPHAGUS 216 8 3.7 40 18.5 56 25.9 59 27.3 53 24.5C16 STOMACH 1632 88 5.4 244 15.0 384 23.5 686 42.0 230 14.1C17 SMALL INTESTINE 44 3 6.8 11 25.0 4 9.1 12 27.3 14 31.8C18 COLON 2742 243 8.9 915 33.4 657 24.0 695 25.3 232 8.5C19-21 RECTUM AND ANUS 1893 258 35.0 667 35.2 450 23.8 400 21.1 118 6.2C22 LIVER 615 4 0.7 20 3.3 70 11.4 238 38.7 283 46.0C23-24 GALLBLADDER AND

EXTRAHEPATIC BILE DUCTS 295 29 16.7 43 14.6 55 18.6 122 41.4 46 15.6C25 PANCREAS 1145 13 1.1 73 6.4 207 18.1 665 58.1 187 16.3C30-31 NOSE, SINUSES 66 4 20.0 8 12.1 12 18.2 33 50.0 9 13.6C32 LARYNX 653 65 10.0 110 16.8 182 27.9 264 40.4 32 4.9C33-34 TRACHEA, BRONCHUS, LUNG 3930 134 3.4 337 8.6 1525 38.8 1505 38.3 429 10.9C37-38 OTHER THORACIC ORGANS 58 1 7.7 3 5.2 12 20.7 11 19.0 31 53.4C40-41 BONE 81 2 4.9 11 13.6 5 6.2 10 12.3 53 65.4C43 MELANOMA OF SKIN 436 82 18.8 113 25.9 118 27.1 46 10.6 77 17.7C44 OTHER SKIN 4305 3460 80.4 724 16.8 89 2.1 7 0.2 25 0.6C45 MESOTHELIOMA 54 6 11.1 4 7.4 17 31.5 12 22.2 15 27.8C46 KAPOSI’S SARCOMA 9 - - 3 33.3 - - - - 6 66.7C47,C49 CONNECTIVE AND SOFT TISSUE 172 17 10.3 39 22.7 16 9.3 14 8.1 86 50.0C50 BREAST 3859 1008 26.1 1727 44.8 762 19.7 258 6.7 104 2.7C51 VULVA 117 50 42.7 42 35.9 18 15.4 4 3.4 3 2.6C52 VAGINA 25 4 16.0 6 24.0 11 44.0 2 8.0 2 8.0C53 CERVIX UTERI 1072 446 41.6 257 24.0 264 24.6 52 4.9 53 4.9C54 CORPUS UTERI 1278 886 69.3 181 14.2 109 8.5 26 2.0 76 5.9C55 UTERUS UNSPECIFIED 47 13 27.7 5 10.6 5 10.6 6 12.8 18 38.3C56 OVARY 862 229 26.6 94 10.9 323 37.5 171 19.8 45 5.2C57 OTHER FEMALE GENITAL

ORGANS 15 4 26.7 3 20.0 3 20.0 2 13.3 3 20.0C58 PLACENTA 2 1 50.0 - - - - - - 1 50.0C60 PENIS 48 14 29.2 19 39.6 8 16.7 4 8.3 3 6.3C61 PROSTATE 1666 290 17.4 603 36.2 417 25.0 236 14.2 120 7.2C62 TESTIS 235 99 42.1 80 34.0 24 10.2 21 8.9 11 4.7C63 OTHER MALE GENITAL ORGANS 5 1 20.0 1 20.0 1 20.0 - - 2 40.0C64 KIDNEY 673 109 16.2 169 25.1 163 24.2 178 26.4 54 8.0C65 RENAL PELVIS 72 12 16.7 23 31.9 25 34.7 10 13.9 2 2.8C66 URETER 23 7 30.4 3 13.0 5 21.7 1 4.3 7 30.4C67 BLADDER 1502 631 42.0 522 34.8 198 13.2 79 5.3 72 4.8C68 OTHER URINARY ORGANS 10 3 30.0 4 40.0 1 10.0 - - 2 20.0C69 EYE 50 12 24.0 12 24.0 3 6.0 4 8.0 19 38.0C70-72 BRAIN, NERVOUS SYSTEM 677 3 0.4 9 1.3 27 4.0 16 2.6 622 91.9C73 THYROID GLAND 316 163 51.6 71 22.5 39 12.3 30 9.5 13 4.1C74 ADRENAL GLAND 18 - - 2 11.1 5 27.8 7 38.9 4 22.2C75 OTHER ENDOCRINE GLANDS 4 1 25.0 - - - - - - 3 75.0C81 HODGKIN DISEASE 153 10 6.5 27 17.6 15 9.8 13 8.5 88 57.5C82-85, C96 NON-HODGKIN LYMPHOMA 495 42 8.5 31 6.3 30 6.1 88 17.8 304 61.4C88 IMMUNOPROLIFERATIVE

DISEASES 2 - - - - - - - - 2 100.0C90 MULTIPLE MYELOMA 182 4 2.2 10 5.5 36 19.8 3 1.6 129 70.9C91 LYMPHOID LEUKAEMIA 293 11 3.8 17 5.8 15 5.1 9 3.1 241 82.3C92 MYELOID LEUKAEMIA 190 - - 1 0.5 4 2.1 4 2.1 181 95.3C93 MONOCYTIC LEUKAEMIA 14 - - - - - - - - 14 100.0C94 OTHER LEUKAEMIAS 51 - - - - - - 1 2.0 50 98.0C95 LEUKAEMIA UNSPECIFIED 47 - - - - 2 4.3 4 8.5 41 87.2C26,C39, C48, C76, C80

OTHERS AND UNSPECIFIED SITES

1452 11 0.8 16 1.1 21 1.4 1226 84.5 178 12.3

85

DISTRIBUTION OF THE NEWLY DIAGNOSED CANCER CASES BY SELECTED PRIMARY SITES, STAGES AND DISTRICTS IN BULGARIA 2009

DISTRICT

FEMALE BREAST CERVIX UTERI PROSTATETOTAL I+II

STAGEIII+IV

STAGEUNKNOWN

STAGETOTAL I+II

STAGEIII+IV

STAGEUNKNOWN

STAGETOTAL I+II

STAGEIII+IV

STAGEUNKNOWN

STAGENUMBER % % % NUMBER % % % NUMBER % % %

BLAGOEVGRAD 100 85.0 15.0 - 37 73.0 27.0 - 64 35.9 59.4 4.7

BOURGAS 225 61.8 36.9 1.3 59 71.2 28.8 - 71 40.8 59.2 -

YAMBOL 80 58.8 41.3 - 16 43.8 56.3 - 25 24.0 72.0 4.0

VARNA 244 82.8 14.3 2.9 59 71.2 23.7 5.1 140 73.6 18.6 7.9

DOBRICH 93 72.0 24.7 3.2 39 69.2 17.9 12.8 33 54.5 24.2 21.2VELIKO TURNOVO 105 67.6 32.4 - 41 82.9 17.1 - 58 79.3 20.7 -

GABROVO 74 58.1 41.9 - 14 50.0 35.7 14.3 47 70.2 27.7 2.1

VRATSA 79 64.6 25.3 10.1 50 40.0 26.0 34.0 37 51.4 16.2 32.4

VIDIN 59 62.7 27.1 10.2 23 52.2 30.4 17.4 15 66.7 20.0 13.3

MONTANA 78 60.3 34.6 5.1 34 55.9 20.6 23.5 34 58.8 20.6 20.6

PLEVEN 138 65.2 33.3 1.4 57 77.2 22.8 - 89 30.3 66.3 3.4

LOVECH 56 66.1 28.6 5.4 36 55.6 38.9 5.6 43 48.8 46.5 4.7

PLOVDIV 372 75.5 24.2 0.3 59 67.8 32.2 - 183 45.4 53.6 1.1

PAZARDJIK 120 65.0 33.3 1.7 33 84.8 15.2 - 44 38.6 61.4 -

SMOLYAN 55 63.6 36.4 - 10 60.0 40.0 - 17 47.1 47.1 5.9

ROUSSE 145 74.5 24.1 1.4 49 75.5 22.4 2.0 60 73.3 25.0 1.7

RAZGRAD 33 75.8 15.2 9.1 12 58.3 25.0 16.7 13 46.2 30.8 23.1

SILISTRA 56 69.6 25.0 5.4 23 69.6 30.4 - 17 64.7 29.4 5.9

SOFIA SITY 830 76.5 20.8 2.7 169 61.5 34.9 3.6 303 61.4 28.4 10.2

SOFIA DISTRICT 118 69.5 25.4 5.1 24 66.7 29.2 4.2 51 47.1 43.1 9.8

KYUSTENDIL 91 62.6 25.3 12.1 25 56.0 40.0 4.0 43 44.2 37.2 18.6

PERNIK 79 69.6 26.6 3.8 26 53.8 42.3 3.8 37 62.2 32.4 5.4

STARA ZAGORA 185 67.6 31.4 1.1 54 59.3 40.7 - 84 38.1 56.0 6.0

SLIVEN 89 68.5 30.3 1.1 40 67.5 32.5 - 30 30.0 70.0 -

HASKOVO 113 73.5 23.9 2.7 21 81.0 19.0 - 65 76.9 15.4 7.7

KURDJALI 57 75.4 24.6 - 8 87.5 12.5 - 28 57.1 39.3 3.6

SHOUMEN 75 57.3 40.0 2.7 32 71.9 28.1 - 22 31.8 40.9 27.3

TURGOVISHTE 60 68.3 23.3 8.3 22 63.6 36.4 - 13 23.1 76.9 -

86

CODEICD-10 SITE

MALES FEMALES TOTAL

NUMBER CRUDE DATA 100 000 % NUMBER CRUDE DATA

100 000 % NUMBER %

C00-97 ALL SITES 9987 272.1 100.0 7019 179.3 100.0 17006 100.0C00-97 BUT C44 ALL SITES BUT NON-MELANOMA SKIN 9931 8.9 99.4 6971 2.0 99.3 16902 99.4C00 LIP 15 0.4 0.2 3 0.1 0.0 18 0.1C01-02 TONGUE 62 1.7 0.6 14 0.4 0.2 76 0.4C03-06 MOUTH 51 1.4 0.5 15 0.4 0.2 66 0.4C07-08 SALIVARY GLANDS 28 0.8 0.3 16 0.4 0.2 44 0.3C09 TONSIL 44 1.2 0.4 1 0.0 0.0 45 0.3C10 OTHER OROPHARYNX 31 0.8 0.3 5 0.1 0.1 36 0.2C11 NASOPHARYNX 15 0.4 0.2 3 0.1 0.0 18 0.1C12-13 HYPOPHARYNX 43 1.2 0.4 11 0.3 0.2 54 0.3C14 PHARYNX UNSPECIFIED 38 1.0 0.4 9 0.2 0.1 47 0.3C15 OESOPHAGUS 153 4.2 1.5 42 1.1 0.6 195 1.1C16 STOMACH 850 23.2 8.5 490 12.5 7.0 1340 7.9C17 SMALL INTESTINE 35 1.0 0.4 24 0.6 0.3 59 0.3C18 COLON 844 23.0 8.5 711 18.2 10.1 1555 9.1C19-21 RECTUM AND ANUS 528 14.4 5.3 369 9.4 5.3 897 5.3C22 LIVER 514 14.0 5.1 286 7.3 4.1 800 4.7

C23-24GALLBLADDER AND EXTRAHEPATIC BILE DUCTS 62 1.7 0.6 108 2.8 1.5 170 1.0

C25 PANCREAS 551 15.0 5.5 433 11.1 6.2 984 5.8C30-31 NOSE, SINUSES 22 0.6 0.2 11 0.3 0.2 33 0.2C32 LARYNX 347 9.5 3.5 20 0.5 0.3 367 2.2C33-34 TRACHEA, BRONCHUS, LUNG 2697 73.5 27.0 586 15.0 8.3 3283 19.3C37-38 OTHER THORACIC ORGANS 30 0.8 0.3 26 0.7 0.4 56 0.3C40-41 BONE 87 2.4 0.9 58 1.5 0.8 145 0.9C43 MELANOMA OF SKIN 101 2.8 1.0 66 1.7 0.9 167 1.0C44 OTHER SKIN 56 1.5 0.6 48 1.2 0.7 104 0.6C45 MESOTHELIOMA 5 0.1 0.1 6 0.2 0.1 11 0.1C46 KAPOSI’S SARCOMA 2 0.1 0.0 - - - 2 0.0C47,C49 CONNECTIVE AND SOFT TISSUE 14 0.4 0.1 14 0.4 0.2 28 0.2C50 BREAST 27 0.7 0.3 1234 31.5 17.6 1261 7.4C51 VULVA - - - 39 1.0 0.6 39 0.2C52 VAGINA - - - 11 0.3 0.2 11 0.1C53 CERVIX UTERI - - - 356 9.1 5.1 356 2.1C54 CORPUS UTERI - - - 242 6.2 3.4 242 1.4C55 UTERUS UNSPECIFIED - - - 125 3.2 1.8 125 0.7C56 OVARY - - - 395 10.1 5.6 395 2.3C57 OTHER FEMALE GENITAL ORGANS - - - 15 0.4 0.2 15 0.1C58 PLACENTA - - - - - - - -C60 PENIS 21 0.6 0.2 - - - 21 0.1C61 PROSTATE 820 22.3 8.2 - - - 820 4.8C62 TESTIS 40 1.1 0.4 - - - 40 0.2C63 OTHER MALE GENITAL ORGANS 4 0.1 0.0 - - - 4 0.0C64 KIDNEY 234 6.4 2.3 86 2.2 1.2 320 1.9C65 RENAL PELVIS 5 0.1 0.1 - - - 5 0.0C66 URETER 7 0.2 0.1 7 0.2 0.1 14 0.1C67 BLADDER 371 10.1 3.7 112 2.9 1.6 483 2.8C68 OTHER URINARY ORGANS 3 0.1 0.0 - - - 3 0.0C69 EYE 8 0.2 0.1 8 0.2 0.1 16 0.1C70-72 BRAIN, NERVOUS SYSTEM 337 9.2 3.4 284 7.3 4.0 621 3.7C73 THYROID 20 0.5 0.2 27 0.7 0.4 47 0.3C74 ADRENAL GLAND 9 0.2 0.1 6 02 0.1 15 0.1C75 OTHER ENDOCRINE GLANDS 4 0.1 0.0 6 0.2 0.1 10 0.1C81 HODGKIN DISEASE 38 1.0 0.4 17 0.4 0.2 55 0.3C82-85, C96 NON-HODGKIN LYMPHOMA 149 4.1 1.5 130 3.3 1.9 279 1.6C88 IMMUNOPROLIFERATIVE DISEASES 1 0.0 0.0 1 0.0 0.0 2 0.0C90 MULTIPLE MYELOMA 35 1.0 0.4 44 1.1 0.6 79 0.5C91 LYMPHOID LEUKAEMIA 86 2.3 0.9 56 1.4 0.8 142 0.8C92 MYELOID LEUKAEMIA 87 2.4 0.9 71 1.8 1.0 158 0.9C93 MONOCYTIC LEUKAEMIA 6 0.2 0.1 8 0.2 0.1 14 0.1C94 OTHER LEUKAEMIAS 18 0.5 0.2 16 0.4 0.2 34 0.2C95 LEUKAEMIA UNSPECIFIED 52 1.4 0.5 40 1.0 0.6 92 0.5C26,C39, C48, C76-C80

OTHERS AND UNSPECIFIED SITES352 9.6 3.5 280 7.2 4.0 632 3.7

C97 MALIGNANT NEOPLASMS OF INDEPENDENT (PRIMARY) MULTIPLE SITES 28 0.8 0.3 28 0.7 0.4 56 0.3

CANCER MORTALITY IN BULGARIA 2009 DISTRIBUTION OF DEATHS BY PRIMARY SITES AND SEX

87

C00 -

97AL

L SI

TES

118.

013

4.5

139.

614

2.6

143.

315

0.1

146.

314

5.2

144.

414

3.6

141.

913

3.4

139.

114

0.8

140.

814

4.8

155.

615

5.6

156.

415

8.4

150.

2C0

0LIP

0.4

0.5

0.4

0.3

0.4

0.6

0.4

0.4

0.4

0.4

0.3

0.3

0.4

0.5

0.2

0.2

0.4

0.3

0.2

0.2

0.2

C01-

02TO

NGUE

0.3

0.6

0.8

0.9

1.1

1.1

1.0

1.2

1.0

1.4

1.1

1.0

1.1

1.1

0.8

0.9

1.3

2.2

1.8

1.2

1.1

C03

GUM

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.2

0.2

0.1

0.1

0.2

0.0

0.1

0.1

0.1

0.1

0.1

0.2

0.1

0.1

C04

MOUT

H0.

10.

10.

30.

30.

30.

40.

40.

20.

60.

60.

50.

40.

50.

60.

50.

60.

40.

30.

20.

30.

2C0

5-06

OTHE

R AN

D UN

SPEC

IFIED

PA

RTS

OF M

OUTH

0.1

0.2

0.2

0.1

0.3

0.2

0.4

0.4

0.2

0.5

0.4

0.3

0.5

0.5

0.3

0.3

0.5

0.5

0.4

0.4

0.5

C07-

08SA

LIVAR

Y GL

ANDS

0.2

0.1

0.1

0.1

0.1

0.1

0.2

0.3

0.3

0.3

0.2

0.1

0.2

0.2

0.2

0.2

0.3

0.5

0.5

0.4

0.4

C09-

10OR

OPHA

RYNX

0.1

0.5

0.5

0.6

0.9

0.9

0.6

0.4

0.6

0.7

0.4

0.4

0.6

0.5

0.6

0.5

0.7

0.8

0.8

1.1

1.2

C11

NASO

PHAR

YNX

0.1

0.2

0.1

0.2

0.1

0.2

0.2

0.2

0.2

0.5

0.3

0.1

0.3

0.2

0.2

0.3

0.5

0.4

0.5

0.3

0.3

C12-

13HY

POPH

ARYN

X0.

20.

50.

71.

10.

40.

60.

70.

60.

60.

70.

70.

70.

90.

60.

91.

00.

71.

00.

80.

70.

8C1

4PH

ARYN

X UN

SPEC

IFIE

D0.

50.

40.

30.

50.

40.

60.

60.

60.

60.

50.

70.

40.

60.

50.

40.

40.

50.

50.

60.

40.

6C1

5OE

SOPH

AGUS

1.0

1.3

3.2

5.0

3.9

2.7

3.6

3.0

3.2

3.0

2.7

2.2

1.9

2.0

2.0

2.0

2.6

2.5

2.2

2.5

2.4

C16

STOM

ACH

23.1

21.4

19.8

19.3

18.1

18.6

16.4

16.7

15.7

15.7

14.9

14.5

14.1

14.4

13.2

13.2

13.9

12.9

13.4

12.7

12.0

C17

SMAL

L IN

TEST

INE

0.4

0.4

0.8

0.7

0.8

0.6

0.5

0.6

0.5

0.4

0.3

0.4

0.5

0.4

0.4

0.5

0.2

0.5

0.4

0.4

0.5

C18

COLO

N4.

95.

35.

86.

86.

37.

46.

06.

85.

67.

67.

46.

68.

39.

210

.09.

810

.911

.112

.011

.611

.8C1

9-21

RECT

UM6.

28.

99.

18.

59.

79.

810

.511

.311

.410

.29.

510

.19.

08.

27.

67.

38.

58.

48.

17.

17.

4C2

2LIV

ER8.

29.

18.

27.

87.

58.

08.

57.

67.

97.

78.

36.

97.

97.

17.

07.

87.

88.

88.

17.

77.

8C2

3-24

GALL

BLAD

DER

ETC.

0.7

0.7

0.5

0.5

0.9

1.0

1.1

0.7

0.9

0.9

1.2

1.0

1.0

0.9

0.8

0.8

1.3

0.7

0.9

0.8

0.9

C25

PANC

REAS

4.9

6.1

6.6

7.1

7.1

7.4

6.9

6.4

6.8

7.1

7.1

6.7

7.2

7.5

7.6

8.0

8.0

7.7

8.7

8.7

8.4

C30-

31NO

SE, S

INUS

ES

ETC.

0.2

0.2

0.2

0.2

0.2

0.2

0.2

0.2

0.3

0.2

0.3

0.2

0.2

0.2

0.2

0.4

0.2

0.4

0.3

0.2

0.3

C32

LARY

NX3.

44.

14.

74.

34.

85.

65.

15.

45.

15.

14.

55.

65.

05.

45.

36.

26.

56.

06.

26.

65.

6C3

3-34

BRON

CHUS

, LU

NG33

.639

.841

.040

.642

.243

.742

.642

.040

.538

.839

.937

.438

.039

.741

.240

.644

.443

.843

.945

.242

.3C4

0-41

BONE

1.7

1.1

1.4

1.5

1.3

1.1

1.2

1.0

1.2

1.1

0.9

1.0

1.1

1.2

1.0

1.0

1.3

1.3

1.5

1.5

1.5

C43

MELA

NOMA

OF

SKIN

0.5

0.9

0.7

0.8

1.1

1.4

1.0

1.1

0.9

0.9

1.3

1.0

1.2

1.0

1.3

1.1

1.6

1.4

1.4

1.4

1.5

C44

OTHE

R SK

IN0.

70.

40.

70.

60.

70.

70.

70.

60.

50.

60.

50.

40.

70.

60.

70.

70.

81.

01.

11.

10.

7C4

7,C49

CONN

ECTI

VE

TISS

UE0.

20.

40.

20.

30.

30.

30.

40.

20.

20.

30.

30.

40.

40.

40.

20.

20.

40.

10.

20.

20.

2C5

0BR

EAST

0.2

0.2

0.2

0.2

0.0

0.2

0.1

0.2

0.1

0.2

0.2

0.2

0.1

0.2

0.2

0.2

0.4

0.4

0.2

0.4

0.4

AGE-

ADJU

STED

(WOR

LD S

TAND

ARD)

MOR

TALIT

Y RA

TES

PER

100 0

00 B

Y PR

IMAR

Y CA

NCER

SITE

S AND

YEA

R OF

DIA

GNOS

IS IN

BUL

GARI

A 19

80 - 2

009,

MAL

ESCO

DE

ICD-

10SI

TEYE

AR O

F DI

AGNO

SIS

1980

1985

1990

1991

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009Pa

rt 1

88

C61

PROS

TATE

6.4

7.0

8.6

7.8

8.6

8.5

8.2

8.9

9.7

9.0

8.9

8.6

9.5

9.7

9.2

9.5

10.0

9.9

9.9

11.0

10.0

C62

TEST

IS0.

91.

21.

20.

81.

01.

21.

20.

91.

20.

71.

00.

60.

70.

40.

81.

00.

91.

10.

90.

80.

8C6

0,C63

PENI

S ET

C.0.

20.

20.

30.

30.

40.

20.

20.

30.

10.

20.

20.

20.

20.

20.

40.

20.

50.

40.

30.

30.

4C6

7BL

ADDE

R4.

04.

44.

25.

04.

94.

95.

24.

85.

04.

74.

74.

44.

74.

64.

55.

05.

45.

45.

75.

24.

9C6

4-66

, C6

8KI

DNEY

ETC

.1.

61.

82.

12.

22.

12.

52.

32.

42.

62.

73.

02.

32.

43.

03.

03.

13.

63.

93.

83.

93.

8C6

9EY

E0.

20.

10.

20.

20.

10.

20.

10.

20.

10.

10.

00.

20.

10.

10.

10.

30.

20.

10.

10.

20.

1C7

1BR

AIN

2.0

5.0

4.8

5.0

4.3

4.8

4.7

4.6

5.2

4.4

4.8

3.9

4.4

5.4

5.1

5.1

5.8

5.8

5.8

7.2

5.3

C70,C

72OT

HER

PART

S OF

NER

VOUS

SY

STEM

0.2

0.4

0.3

0.4

0.3

0.5

0.3

0.3

0.5

0.4

0.3

0.3

0.5

0.4

0.2

0.4

0.4

0.7

0.5

0.6

0.7

C73

THYR

OID

0.3

0.5

0.2

0.4

0.2

0.5

0.3

0.3

0.4

0.3

0.4

0.4

0.4

0.3

0.3

0.4

0.3

0.3

0.3

0.4

0.3

C74-

75OT

HER

ENDO

CRIN

E GL

ANDS

0.1

0.2

0.2

0.3

0.1

0.2

0.2

0.3

0.1

0.3

0.2

0.1

0.2

0.3

0.3

0.2

0.4

0.2

0.3

0.4

0.3

C76

OTHE

R AN

D ILL

-DE

FINE

D SI

TES

0.1

0.1

0.2

0.1

0.2

0.2

0.2

0.3

0.6

1.1

0.6

0.5

0.5

0.3

0.6

0.6

0.6

0.5

0.5

0.7

0.8

C80

NEOP

LASM

W

ITHO

UT

SPEC

IFIC

ATIO

N OF

SIT

E1.

61.

31.

51.

92.

22.

63.

14.

04.

64.

44.

84.

04.

54.

94.

64.

93.

73.

83.

73.

83.

2C8

1HO

DGKI

N DI

SEAS

E0.

90.

81.

01.

21.

41.

21.

31.

41.

01.

10.

81.

00.

80.

80.

91.

00.

90.

90.

91.

00.

7C8

2-85

, C9

6NO

N-HO

DGKI

N LY

MPHO

MA1.

92.

22.

32.

21.

72.

21.

81.

71.

41.

81.

91.

61.

81.

61.

62.

02.

12.

02.

62.

62.

5C8

8,C90

MULT

IPLE

MY

ELOM

A0.

50.

50.

50.

50.

40.

60.

50.

30.

20.

60.

60.

60.

40.

40.

40.

50.

50.

70.

60.

90.

5C9

1LY

MPHO

ID

LEUK

AEMI

A1.

41.

51.

81.

71.

92.

31.

61.

41.

71.

81.

31.

01.

51.

21.

72.

01.

21.

71.

31.

41.

5C9

2MY

ELOI

D LE

UKAE

MIA

0.8

1.1

1.0

1.0

1.1

1.0

1.7

1.2

1.2

1.0

1.0

0.9

1.1

1.0

0.9

1.3

1.1

1.7

1.3

1.5

1.4

C93

MONO

CYTI

C LE

UKAE

MIA

0.0

0.0

0.0

0.2

0.0

0.0

0.0

0.0

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C94

OTHE

R LE

UKAE

MIA

0.9

0.5

0.4

0.6

0.6

0.3

0.3

0.3

0.3

0.5

0.5

0.6

0.5

0.6

0.8

0.4

0.3

0.2

0.4

0.5

0.3

C95

LEUK

AEMI

A,

CELL

UN

SPEC

IFIE

D1.

01.

31.

21.

11.

01.

32.

12.

01.

41.

00.

80.

80.

70.

60.

90.

80.

80.

60.

71.

01.

0C2

6,C37

,C3

8,C39

,C4

5,C46

,C4

8,C97

OTHE

RS A

ND

UNSP

ECIF

IED

SITE

S

1.0

1.0

1.2

1.2

1.5

1.4

1.7

1.6

1.3

2.1

1.9

2.8

2.2

1.7

1.8

1.8

2.6

2.1

2.2

2.0

2.1

Part

2AG

E-AD

JUST

ED (W

ORLD

STA

NDAR

D) M

ORTA

LITY

RATE

S PE

R 10

0 000

BY

PRIM

ARY

CANC

ER S

ITES A

ND Y

EAR

OF D

IAGN

OSIS

IN B

ULGA

RIA

1980

- 200

9, MA

LES

CODE

IC

D-10

SITE

YEAR

OF

DIAG

NOSI

S19

8019

8519

9019

9119

9319

9419

9519

9619

9719

9819

9920

0020

0120

0220

0320

0420

0520

0620

0720

0820

09

89Part

1

C00-

C97

ALL

SITE

S77

.087

.984

.187

.084

.986

.487

.086

.986

.983

.585

.581

.880

.782

.178

.781

.290

.286

.888

.388

.482

.1C0

0LIP

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.0

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.0

0.1

0.1

0.0

0.0

C01-

02TO

NGUE

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.2

0.1

0.1

0.1

0.1

0.1

0.1

0.2

0.1

0.2

0.7

0.5

0.2

0.2

C03

GUM

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.0

0.0

0.0

0.0

0.1

0.1

0.0

0.0

C04

MOUT

H0.

10.

10.

00.

00.

00.

00.

00.

00.

10.

00.

10.

10.

10.

10.

10.

10.

00.

00.

00.

10.

0C0

5-06

OTHE

R AN

D UN

SPEC

IFIE

D PA

RTS

OF M

OUTH

0.0

0.1

0.0

0.0

0.1

0.0

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.0

0.3

0.1

0.0

0.1

0.1

C07-

08SA

LIVAR

Y GL

ANDS

0.0

0.1

0.1

0.0

0.1

0.1

0.1

0.1

0.1

0.0

0.0

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.2

C09-

10OR

OPHA

RYNX

0.1

0.1

0.1

0.2

0.1

0.2

0.1

0.1

0.0

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

C11

NASO

PHAR

YNX

0.0

0.0

0.1

0.1

0.1

0.1

0.0

0.1

0.0

0.1

0.1

0.1

0.1

0.1

0.1

0.0

0.2

0.0

0.1

0.2

0.0

C12-

13HY

POPH

ARYN

X0.

00.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

10.

20.

20.

20.

20.

2C1

4PH

ARYN

X UN

SPEC

IFIE

D0.

10.

10.

10.

10.

10.

00.

00.

10.

10.

10.

10.

00.

10.

10.

10.

10.

20.

10.

10.

10.

1C1

5OE

SOPH

AGUS

0.2

0.5

0.9

2.0

1.4

0.7

0.9

0.8

1.0

0.6

0.5

0.4

0.4

0.6

0.4

0.6

0.4

0.4

0.4

0.3

0.5

C16

STOM

ACH

13.1

12.3

11.8

10.1

9.7

8.8

8.7

8.2

8.2

8.0

7.5

7.1

6.6

7.4

5.8

6.2

6.3

6.0

5.7

6.2

5.1

C17

SMAL

L INT

ESTI

NE0.

50.

40.

40.

60.

40.

40.

30.

40.

30.

30.

30.

30.

30.

30.

20.

20.

20.

10.

20.

20.

2C1

8CO

LON

3.8

3.8

4.8

5.4

4.7

4.7

4.1

4.9

4.8

4.7

5.1

5.0

5.4

5.9

5.6

5.8

6.8

6.4

7.4

7.7

7.0

C19-

21RE

CTUM

4.1

6.2

5.5

5.8

6.3

6.7

6.7

7.4

6.7

6.0

5.7

6.0

5.2

4.8

4.0

4.0

4.7

4.1

4.4

4.2

3.8

C22

LIVER

5.1

5.7

4.6

4.0

4.0

4.1

4.4

3.4

4.0

3.7

3.9

3.7

3.6

3.7

3.4

3.1

3.7

4.0

3.7

3.2

3.0

C23-

24GA

LLBL

ADDE

R ET

C.1.

41.

31.

21.

40.

81.

31.

31.

11.

21.

11.

21.

11.

11.

21.

10.

81.

10.

91.

11.

21.

1C2

5PA

NCRE

AS2.

63.

53.

43.

33.

13.

03.

23.

83.

53.

53.

53.

93.

73.

44.

04.

54.

34.

14.

44.

74.

4C3

0-31

NOSE

, SIN

USES

ETC

.0.

20.

20.

10.

20.

00.

10.

10.

10.

20.

10.

10.

10.

10.

10.

10.

00.

10.

10.

10.

10.

1C3

2LA

RYNX

0.4

0.3

0.2

0.2

0.3

0.4

0.4

0.3

0.3

0.3

0.1

0.3

0.3

0.4

0.2

0.4

0.3

0.2

0.3

0.3

0.2

C33-

34BR

ONCH

US, L

UNG

5.7

7.0

5.9

7.1

6.8

6.6

7.2

6.8

6.1

6.4

6.8

6.5

6.2

6.3

6.3

6.7

8.0

7.0

7.6

7.4

7.4

C40-

41BO

NE1.

00.

90.

50.

60.

71.

00.

40.

60.

70.

70.

60.

60.

60.

60.

60.

50.

80.

70.

60.

60.

9C4

7, C4

9CO

NNEC

TIVE

TIS

SUE

0.2

0.2

0.2

0.1

0.3

0.2

0.1

0.3

0.1

0.2

0.3

0.2

0.2

0.2

0.1

0.1

0.2

0.2

0.2

0.3

0.2

C43

MELA

NOMA

OF

SKIN

0.6

0.8

0.4

0.6

0.7

1.0

0.7

0.8

0.8

0.7

0.7

0.7

0.8

0.7

0.7

0.6

0.9

0.8

0.7

1.1

0.8

C44

OTHE

R SK

IN0.

50.

40.

50.

40.

40.

30.

40.

40.

30.

40.

30.

30.

40.

30.

30.

30.

60.

40.

40.

70.

4C5

0BR

EAST

12.1

16.0

15.5

16.0

14.8

15.8

16.2

16.3

16.7

14.3

15.3

15.6

14.3

14.4

14.7

14.7

16.7

15.7

15.5

16.3

14.8

C55

UTER

US U

NSPE

CIFI

ED2.

53.

03.

33.

63.

53.

43.

22.

73.

03.

33.

02.

72.

92.

62.

52.

71.

92.

31.

51.

61.

5C5

3CE

RVIX

UTE

RI2.

83.

84.

04.

04.

84.

95.

04.

94.

84.

96.

05.

25.

65.

65.

55.

75.

25.

26.

25.

35.

4C5

8PL

ACEN

TA0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C5

4CO

RPUS

UTE

RI1.

81.

82.

62.

92.

42.

31.

92.

12.

41.

81.

82.

21.

52.

22.

02.

03.

43.

43.

22.

82.

9C5

6-57

OVAR

Y ET

C.4.

44.

94.

13.

74.

65.

55.

04.

74.

84.

94.

84.

34.

05.

05.

05.

65.

96.

35.

66.

05.

2C5

1-52

OTHE

R FE

MALE

GEN

ITAL

0.6

0.6

0.4

0.4

0.4

0.4

0.6

0.5

0.6

0.7

0.6

0.7

0.7

0.6

0.6

0.5

0.6

0.7

0.4

0.7

0.4

AGE-

ADJU

STED

(WOR

LD S

TAND

ARD)

MOR

TALIT

Y RAT

ES P

ER 10

0 000

BY P

RIMA

RY C

ANCE

R SI

TES A

ND YE

AR O

F DIA

GNOS

IS IN

BUL

GARI

A 19

80 - 2

009,

FEMA

LES

CODE

IC

D-10

SITE

YEAR

OF

DIAG

NOSI

S19

8019

8519

9019

9119

9319

9419

9519

9619

9719

9819

9920

0020

0120

0220

0320

0420

0520

0620

0720

0820

09

90

C67

BLAD

DER

0.8

0.8

1.0

0.9

1.1

1.0

0.8

1.2

1.0

1.0

1.0

1.0

1.1

0.9

1.1

1.1

1.0

1.2

1.1

1.1

1.1

C64-

66,

C68

KIDN

EY E

TC.

0.9

0.9

1.0

1.0

1.0

1.4

1.1

1.2

1.1

1.3

1.0

1.1

0.9

1.0

1.0

1.1

1.4

1.4

1.4

1.4

1.1

C69

EYE

0.2

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.1

0.2

0.2

0.1

C71

BRAI

N1.

83.

43.

23.

63.

43.

44.

13.

33.

23.

43.

52.

63.

13.

33.

73.

74.

43.

73.

93.

83.

7C7

0, C7

2OT

HER

PART

S OF

NE

RVOU

S SY

STEM

0.2

0.3

0.3

0.5

0.2

0.2

0.2

0.3

0.3

0.2

0.3

0.1

0.3

0.4

0.2

0.1

0.3

0.4

0.4

0.4

0.4

C73

THYR

OID

0.6

0.7

0.3

0.6

0.4

0.5

0.4

0.4

0.5

0.6

0.5

0.3

0.4

0.6

0.4

0.3

0.3

0.3

0.4

0.3

0.3

C74-

75OT

HER

ENDO

CRIN

E GL

ANDS

0.2

0.1

0.1

0.1

0.2

0.0

0.1

0.1

0.1

0.1

0.1

0.2

0.3

0.2

0.2

0.1

0.3

0.3

0.2

0.2

0.1

C76

OTHE

R AN

D ILL

-DEF

INED

SI

TES

0.1

0.2

0.1

0.1

0.1

0.1

0.2

0.3

0.5

0.6

0.5

0.3

0.4

0.4

0.2

0.4

0.5

0.3

0.2

0.2

0.5

C80

NEOP

LASM

WIT

HOUT

SP

ECIF

ICAT

ION

OF S

ITE

1.2

1.1

1.1

1.5

1.7

1.5

2.0

2.8

3.0

2.8

2.8

2.3

3.1

2.7

2.7

2.9

1.9

2.4

2.4

1.9

1.7

C81

HODG

KIN

DISE

ASE

0.5

0.5

0.3

0.6

0.8

0.4

0.5

0.6

0.4

0.6

0.8

0.6

0.4

0.5

0.4

0.3

0.3

0.4

0.4

0.4

0.3

C82-

85,

C96

N0N-

HODG

KIN

LYMP

HOMA

1.1

0.9

1.2

1.3

1.0

1.0

0.7

0.8

0.7

1.0

1.2

1.0

0.9

0.8

0.9

0.9

1.2

1.3

1.4

1.4

1.8

C88,

C90

MULT

IPLE

MYE

LOMA

0.5

0.2

0.3

0.2

0.4

0.5

0.3

0.3

0.3

0.4

0.4

0.4

0.3

0.5

0.4

0.3

0.5

0.5

0.5

0.5

0.6

C91

LYMP

HOID

LEUK

AEMI

A0.

91.

51.

10.

71.

01.

21.

10.

60.

91.

21.

00.

80.

91.

00.

81.

11.

00.

80.

80.

80.

8C9

2MY

ELOI

D LE

UKAE

MIA

0.9

1.0

0.8

0.6

0.5

0.8

1.1

0.9

1.0

0.9

1.0

1.0

0.9

0.6

0.5

1.0

1.0

0.9

1.1

1.3

1.0

C93

MONO

CYTI

C LE

UKAE

MIA

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.1

C94

OTHE

R LE

UKAE

MIA

1.0

0.4

0.3

0.3

0.3

0.3

0.2

0.4

0.2

0.3

0.6

0.4

0.4

0.4

0.2

0.4

0.2

0.3

0.3

0.3

0.2

C95

LEUK

AEMI

A, C

ELL

UNSP

ECIF

IED

0.8

0.8

0.6

0.8

0.8

0.7

1.3

1.4

1.3

0.8

0.6

0.4

0.5

0.4

0.4

0.6

0.9

0.4

0.7

0.6

0.5

C26,C

37,

C38,C

39,

C45,C

46,

C48,

C97

OTHE

RS A

ND

UNSP

ECIF

IED

SITE

S

1.1

1.0

1.2

0.9

1.1

1.2

1.2

0.8

1.2

1.2

1.3

1.5

1.6

1.2

1.3

1.0

1.6

1.6

1.7

1.7

1.4

AGE-

ADJU

STED

(WOR

LD S

TAND

ARD)

MOR

TALIT

Y RAT

ES P

ER 10

0 000

BY P

RIMA

RY C

ANCE

R SI

TES A

ND YE

AR O

F DIA

GNOS

IS IN

BUL

GARI

A 19

80 - 2

009,

FEMA

LES

CODE

IC

D-10

SITE

YEAR

OF

DIAG

NOSI

S19

8019

8519

9019

9119

9319

9419

9519

9619

9719

9819

9920

0020

0120

0220

0320

0420

0520

0620

0720

0820

09Part

2

91

CODE ICD-10 SITE

MALE FEMALE TOTAL

NUMBER CRUDE DATA 100 000 % NUMBER CRUDE DATA

100 000 % NUMBER %

C00-C97 ALL SITES 103847 2829.4 100.0 158127 4039.2 100.0 261974 100.0

C00-C14 LIP, ORAL CAVITY AND PHARYNX 6091 166.0 5.9 2418 61.8 1.5 8509 3.2

C00 LIP 3794 103.4 3.7 1025 26.2 0.6 4819 1.8

C15-C26 DIGESTIVE ORGANS 20534 559.5 19.8 19018 485.8 12.0 39552 15.1

C15 ESOPHAGUS 333 9.1 0.3 165 4.2 0.1 498 0.2

C16 STOMACH 3304 90.0 3.2 2681 68.5 1.7 5985 2.3

C18 COLON 7948 216.5 7.7 8150 208.2 5.2 16098 6.1

C19-C21 RECTUM AND ANUS 6350 173.0 6.1 5694 145.4 3.6 12044 4.6

C22 LIVER AND INTRAHEPATIC BILE DUCTS 660 18.0 0.6 516 13.2 0.3 1176 0.4

C25 PANCREAS 1293 35.2 1.2 1141 29.2 0.7 2434 0.9C30-C39 RESPIRATORY SYSTEM AND

INTRATHORACIC ORGANS 13097 356.8 12.6 3705 94.6 2.3 16802 6.4

C32 LARYNX 4703 128.1 4.5 520 13.3 0.3 5223 2.0

C33,C34 TRACHEA, BRONCHUS AND LUNG 7934 216.2 7.6 2910 74.3 1.8 10844 4.1C40-C41 BONES, JOINTS AND ARTICULAR

CARTILAGE OF LIMBS 405 11.0 0.4 426 10.9 0.3 831 0.3

C43-C44 SKIN 27238 742.1 26.2 28463 727.0 18.0 55701 21.3

C43 MELANOMA OF SKIN 1631 44.4 1.6 2035 52.0 1.3 3666 1.4C45-C49 MESOTHELIAL, CONNECTIVE AND

OTHER SOFT TISSUES 1292 35.2 1.2 1514 38.7 1.0 2806 1.1

C50 BREAST 494 13.5 0.5 45565 1163.9 28.8 46059 17.6

C51-C58 FEMALE GENITAL ORGANS 0 0.0 0.0 40210 1027.1 25.4 40210 15.3

C53 CERVIX UTERI 0 0.0 0.0 13903 355.1 8.8 13903 5.3

C54 CORPUS UTERI 0 0.0 0.0 17131 437.6 10.8 17131 6.5

C55 UTERUS, NOS 0 0.0 0.0 277 7.1 0.2 277 0.1

C56 OVARY 0 0.0 0.0 7093 181.2 4.5 7093 2.7

C60-C63 MALE GENITAL ORGANS 13788 375.7 13.3 0 0.0 0.0 13788 5.3

C61 PROSTATE GLAND 10112 275.5 9.7 0 0.0 0.0 10112 3.9

C64-C68 URINARY TRACT 11085 302.0 10.7 4925 125.8 3.1 16010 6.1

C67 BLADDER 8337 227.1 8.0 2816 71.9 1.8 11153 4.3C69-C72 EYE, BRAIN AND OTHER PARTS OF

CENTRAL NERVOUS SYSTEM 1715 46.7 1.7 1702 43.5 1.1 3417 1.3

C69 EYE AND ADNEXA 296 8.1 0.3 298 7.6 0.2 594 0.2

C71 BRAIN 1235 33.6 1.2 1187 30.3 0.8 2422 0.9C73-C75 THYROID AND OTHER ENDOCRINE

GLANDS 806 22.0 0.8 3562 91.0 2.3 4368 1.7

C73 THYROID GLAND 720 19.6 0.7 3458 88.3 2.2 4178 1.6

C76-C80 OTHER AND ILL-DEFINED SITES 1874 51.1 1.8 1591 40.6 1.0 3465 1.3C81-C96 LYMPHATIC AND BLOOD-FORMING

TISSUES 5428 147.9 5.2 5028 128.4 3.2 10456 4.0

C81 HODGKIN DISEASE 1220 33.2 1.2 1103 28.2 0.7 2323 0.9

C82-C85 NON-HODGKIN LYMPHOMAS 1593 43.4 1.5 1541 39.4 1.0 3134 1.2

C91-C95 LEUKAEMIA 1992 54.3 1.9 1851 47.3 1.2 3843 1.5

C91 LYMPHOID LEUKAEMIA 1113 30.3 1.1 941 24.0 0.6 2054 0.8

C92 MYELOID LEUKAEMIA 595 16.2 0.6 637 16.3 0.4 1232 0.5

CANCER PREVALENCE IN BULGARIA 2009DISTRIBUTION BY PRIMARY SITES AND SEX

92

КРАТКОСРОЧНИ ПРОГНОЗИ НА БРОЯ ЗАБОЛЯВАНИЯ ОТ ЗЛОКАЧЕСТВЕНИ НОВООБРАЗУВАНИЯ В БЪЛГАРИЯ

Данните за броя заболявания от злокачествени ново-образувания за минали години се съхраняват във вид на динамични (времеви) редове. Времевият ред описва промяната на броя заболявания във времето. Така на-пример данните за броя заболявания от рак на белите дробове изглеждат по следния начин:

Years 1999 2000 2001 2002 2003 2004 2005 2006 2007Cancer cases 3421 3178 3464 3458 3589 3846 3672 3826 3580

0

500

1000

New

can

cer c

ases

1500

2000

2500

3000

3500

4000

4500

1998 2000 2002Years

2004 2006 2008

Number 1 2 3 4 5 6 7 8 9Cancer cases 3421 3178 3464 3458 3589 3846 3672 3826 3580

SHORT-TERM ESTIMATES OF NEW CANCER CASES

IN BULGARIA

The data on past annual cancer incidence caces is stored in the form of time series. These time series give an account of the change in incidence over time. For example, the data on the number of lung cancer cases looks like this:

Графично изменението във времето се представя по следния начин:

The change over time is graphically represented as follows:

Ако в горната таблица годините се заместят с техния пореден номер, тя ще изглежда така:

Това представяне има някои предимства и ще го из-ползваме по-нататък. По подобен начин изглеждат динамичните редове за броя заболявания за другите локализации. От табли-цата и графиката се вижда как се развива изучаваното явление ретроспективно във времето. Стойностите на динамичния ред се формират под въз-действието на три групи фактори: 1. Неуправляеми (би-ологични, природно-климатични и др.); 2. Управляеми и частично управляеми (социални, демографски, здрав-ни); 3. Неизвестни или случайно действащи. Въз основа на ретроспективните данни се прави заклю-

In the table above, the years can be replaced by their consecutive numbers. In this case it would look like this:

This representation has its advantages and will be used later on. The time series for the number of cancer cases with other primary sites look similar. The graph and the table show retrospectively how the examined phenomenon has been developing over time. The values of the time series are formed under the infl uence of three groups of factors: 1. Uncontrollable (biological, environmental etc.); 2. Controllable and semi-controllable (social, demographic, healthcare); 3. Unknown or random. After analysing the retrospective data a conclusion is reached on whether or not development patterns exist in

93

чение за съществуването на модели за развитие на съответния динамичен ред. И ако има някаква законо-мерност, се приема, че тя ще продължи да действа и в близко бъдеще. Тогава въз основа на данните може да бъде направена една прогноза. Такава прогноза е възможна благодарение на факта, че социално-иконо-мическите процеси и другите фактори проявяват опре-делена инерция (устойчивост) във времето. Този под-ход може успешно да се прилага само за краткосрочно прогнозиране. Възможно е прогнозиране и за по-дълъг срок, но в този случай надеждността на прогнози на-малява. Нещо повече, колкото по-дълъг е прогнозният период (по-далеч във времето от текущия момент), по-голяма е вероятността установената тенденция (зако-номерност) да се промени.По принцип динамичните редове могат да бъдат пред-ставени, както следва: , където е детер-минирана (закономерна) компонента на времевия ред, а е случайна компонента, която се формира от действието на голям брой случайни фактори. Детер-минираната компонента описва основните тенденции на развитие на изучаваното явление (или обект).Следва да се отбележи, че целта на прогнозирането не е изграждането на модел, който най-точно описва това явление в миналото, а на модел, който най-точно предсказва развитието на явлението в бъдеще.За означаване на основните тенденции (детерминирана-та компонента) на динамичните редове се използва по-нятието тренд. От графиката на горния пример се вижда, че през 2007 год. (9-а поредна година) броят на регистри-раните заболявания е по-голям от този през 1999 год. (първа или начална година). Това нарастване не върви последователно. През някои години броят на заболява-нията намалява, през други години се увеличава. Неза-висимо от това от показаната по-долу графика може да се каже, че има определена тенденция за нарастване на

y = 56,4x + 3277,3R2 = 0,5434

0

500

1000

1500

2000

2500

3000

3500

4000

4500

0 2 4

Consecutive number

6 8 10

New

can

cer c

ases

the respective time series. If any regularity is found, it is expected to continue in the near future. This allows you to make estimates based on the data. Such estimates are made possible by the fact that the social-economical processes and the other factors tend to be rather consistent over time. This approach can only be successfully applied for short-term predictions. It is possible to make estimates for a longer period of time, but in this case the reliability of the predictions drops. Moreover, the longer the prognostic period – the higher the possibility the established regularity may change.

Generally, the time series can be represented as follows: , where is a determined component of the

time series and is a random component, formed under the infl uence of a great number of random factors. The determined component represents the major tendencies in the development of the examined phenomenon (or object).It should be noted that the purpose of the predictions is not to establish a model which best describes this phenomenon over time, but a model which can most accurately estimate the development of the phenomenon in the future.The major tendencies (the determined component) of the time series will be represented by the term ‘trend’. From the graph in the example above you can see that in 2007 (the ninth consecutive year) the number of registered cases is higher than that in 1999 (the fi rst or initial year). This growth is not consistent. In some years the number of cases decreases while in others it increases. Regardless, when looking at the graph below, you could say that there is a certain tendency towards an increase in the number of cases. This tendency is linear. The trend line is shown as a straight continuous line.

94

броя заболявания. Тази тенденция е линейна. Линията на тренда е показана в права непрекъсната линия.Линейният тренд е най-грубо приближение, описващо изменението на стойностите на динамичния ред. При малък ретроспективен набор от данни установяването на по-сложна тенденция на развитие е невъзможно и трудно може да бъде обяснено. Ето защо за кратко-срочно прогнозиране в настоящото издание е използ-ван линеен модел. На горната графика е показан видът на линейния мо-дел, чрез който може да се прогнозира очаквания брой заболявания от рак на белите дробове за две години напред (за 2009 год.). Достатъчно е в уравнението y = 56.4* x + 3277.3 x да се замести с 11. Получе-ният очакван брой заболявания през 2009 година е 3897,73333 или приблизително 3898. Това число се нарича точкова оценка на очаквания брой заболявания за 2009 год. На практика е много малко вероятно точ-но тази стойност на прогнозата да се сбъдне. Това е така, защото точковата прогноза се изчислява, като се използва само детерминираната компонента (уравне-нието в горната графика – уравнението на тренда) на динамичния ред. Реалните стойности на динамичния ред се формират не само от тази компонента, но се влияят от действието на случайните фактори. По тази причина не се използва само точковата оценка, а тя се придружава от така наречения 95% доверителен интервал на прогнозата. Той показва в какви граници се очаква да бъде реалната стойност на прогнозата с 95% степен на достоверност. Прогнозата за 2 години напред е 3897.73333, или 3898 с 95% доверителен ин-тервал 3430 – 4366. Долната граница на този довери-телен интервал (3430) се нарича оптимистична прог-ноза, а горната граница (4366) песимистична прогноза. Познаването на този интервал е основа за планиране на необходимите ресурси за борба със съответното злокачествено заболяване (в посочения пример това е ракът на белия дроб).

The linear trend is a rough approximation describing the changes in the time series values. With a small retrospective database determining a more complex development tendency is impossible and hard to explain. Therefore a linear model is used in this edition of the Registry for the short-term estimation. The graph above shows the linear model with the help of which we can estimate the expected number of lung cancer cases two years ahead (for 2009). All that is necessary to substitute x with 11 in the following equation: y = 56.4* x + 3277.3. The resulting estimate for the number of cases for 2009 is 3897.73333 or approximately 3898. This number is called the point estimation of the expected number of cases for 2009. In fact it is highly improbable that the estimated number will be exact. That is because the point prediction is calculated using only the determined component (the equation in the above graph – the equation of the tendency) of the time series. The actual values of the time series are formed not only by this component, but are also infl uenced by random factors. For this reason we use not only point prediction, but also a 95% confi dence interval of the prognosis. This interval outlines the expected limits for the real value with a 95% degree of reliability. The estimate for two years ahead is 3897.73333 or 3898 with a 95% confi dence interval 3430 – 4366. The lower limit of this confi dence interval (3430) is called an ‘optimistic prediction’, while the upper limit (4366) is called a ‘pessimistic prediction’. Knowing this interval is grounds for planning the necessary resources to fi ght the respective type of cancer (in the example given – lung cancer).

95

CODE ICD-10 SITE NUMBER

OBSERVED NUMBER

EXPECTED95% LOWER

LIMIT EXPECTED95% UPPER

LIMIT EXPECTED DIFFERENCE

C00-C97 ALL SITES 34712 34595 33246 35944 117

C00-C14LIP, ORAL CAVITY AND PHARYNX 911 882 713 1052 29

C15-C26 DIGESTIVE ORGANS 8604 8641 7770 9513 -37C16 STOMACH 1632 1701 1445 1957 -69C18 COLON 2742 2686 2558 2815 56C19-C21 RECTUM AND ANUS 1893 1942 1633 2251 -49C30-C39 RESPIRATORY SYSTEM AND

INTRATHORACIC ORGANS 4709 4526 4094 4959 183C32 LARYNX 653 633 498 768 20C33-C34 TRACHEA, BRONCHUS AND

LUNG 3930 3807 3426 4187 123C40-C41 BONES, JOINTS AND

ARTICULAR CARTILAGE OF LIMBS 81 72 11 133 9

C50 BREAST 3859 3884 3499 4269 -25C51-C58 FEMALE GENITAL ORGANS 3418 3713 3422 4004 -295C53 CERVIX UTERI 1072 1228 1063 1393 -156C54 CORPUS UTERI 1278 1299 1154 1443 -21C55 UTERUS, NOS 47 46 20 73 1C56 OVARY 862 935 786 1084 -73C60-C63 MALE GENITAL ORGANS 1954 1979 1633 2325 -25C61 PROSTATE GLAND 1666 1721 1354 2087 -55C62 TESTIS 235 209 187 230 26C64-C68 URINARY TRACT 2280 2422 2178 2665 -142C67 BLADDER 1502 1593 1437 1748 -91C69-C72 EYE, BRAIN AND OTHER

PARTS OF CENTRAL NERVOUS SYSTEM 727 844 740 947 -117

C71 BRAIN 608 733 666 800 -125C73-C75 THYROID AND OTHER

ENDOCRINE GLANDS 338 313 268 358 25C73 THYROID GLAND 316 276 217 335 40C76-C80 OTHER AND ILL-DEFINED

SITES 1331 1484 1288 1681 -153C81-C96 LYMPHATIC AND BLOOD-

FORMING TISSUES 1427 1643 1330 1956 -216C81 HODGKIN DISEASE 153 136 91 180 17C82-C85 NON-HODGKIN LYMPHOMAS 488 451 351 551 37C91-C95 LEUKAEMIA 595 563 437 689 32C91 LYMPHOID LEUKAEMIA 293 286 218 353 8C92 MYELOID LEUKAEMIA 190 208 129 287 -18

NUMBER OF OBSERVED AND EXPECTED NEW CASES OF SELECTED CANCER SITES FOR 2009 WITH 95% CONFIDENCE INTERVAL

96

CODE ICD-10 SITE NUMBER

EXPECTED95% LOWER LIMIT

EXPECTED 95% UPPER LIMIT

EXPECTED

C00-C97 ALL SITES 37337 36267 38407C00-C14 LIP, ORAL CAVITY AND PHARYNX 929 823 1035C00 LIP 187 134 240C15-C26 DIGESTIVE ORGANS 9246 8586 9905C15 ESOPHAGUS 228 195 261C16 STOMACH 1647 1456 1838C18 COLON 3065 2882 3247C19-C21 RECTUM AND ANUS 2027 1814 2240C22 LIVER AND INTRAHEPATIC BILE DUCTS 636 497 774C25 PANCREAS 1234 1081 1387C30-C39 RESPIRATORY SYSTEM AND INTRATHORACIC

ORGANS 4858 4538 5178C32 LARYNX 673 592 754C33,C34 TRACHEA, BRONCHUS AND LUNG 4077 3796 4357C40-C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF

LIMBS 74 44 105C43-C44 SKIN 5064 4493 5635C43 MELANOMA OF SKIN 480 375 584C44 NON-MELANOMA SKIN 4584 4062 5106C45-C49 MESOTHELIAL, CONNECTIVE AND OTHER SOFT

TISSUES 358 313 404C50 BREAST 4046 3787 4306C51-C58 FEMALE GENITAL ORGANS 3699 3403 3994C53 CERVIX UTERI 1191 1025 1357C54 CORPUS UTERI 1335 1228 1441C55 UTERUS, NOS 43 19 67C56 OVARY 943 843 1043C60-C63 MALE GENITAL ORGANS 2131 1913 2349C61 PROSTATE GLAND 1820 1590 2049C62 TESTS 253 229 277C64-C68 URINARY TRACT 2616 2414 2817C67 BLADDER 1711 1578 1844C69-C72 EYE, BRAIN AND OTHER PARTS OF CENTRAL

NERVOUS SYSTEM 868 744 991C69 EYE AND ADNEXA 53 31 76C71 BRAIN 744 622 866C73-C75 THYROID AND OTHER ENDOCRINE GLANDS 374 320 428C73 THYROID GLAND 342 276 407C76-C80 OTHER AND ILL-DEFINED SITES 1459 1292 1627C81-C96 LYMPHATIC AND BLOOD-FORMING TISSUES 1615 1364 1866C81 HODGKIN DISEASE 146 105 187C82-C85 NON-HODGKIN LYMPHOMAS 560 475 645C91-C95 LEUKAEMIA 662 549 776C91 LYMPHOID LEUKAEMIA 332 273 392C92 MYELOID LEUKAEMIA 211 157 284

EXPECTED NUMBER OF NEW CANCER CASES BY PRIMARY SITES FOR 2012 WITH 95% CONFIDENCE INTERVAL

Documents

ЗАБОЛЯЕМОСТ ОТ РАК В БЪЛГАРИЯ, 2009 CANCER …€¦ · Head of BNCR Maria S. Danova Minka M. Nenova Tinka P. Kuneva Iovka K. Petkova Minka R. Yordanova Lilyana